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Chapter 1 
GENERAL INTRODUCTION 

RHEUMATOID ARTHRITIS (RA) is a chronic multi-systemic and articular in-
flammatory disorder of unknown origin. The association between RA and the human 
leucocyte antigen (HLA) DR4 suggests an inherited susceptibility (1,2). Women are 
affected two to three times more often than men (3). Rheumatoid arthritis may occur at 
any age, but it is generally agreed that its prevalence increases with advancing age (3). 
1.1 CRITERIA AND COURSE OF DISEASE 
The criteria for the classification of RA have recently been revised (4). A patient is 
said to have RA if at least four of seven criteria at least during 6 weeks are met (Table 
1). Besides joint symptoms and systemic features (such as fatigue, fever, anemia and 
weight loss), extra-articular features e.g. subcutaneous nodules, pleuropulmonary lesions 
and signs of vasculitis are relatively common manifestations of RA. 
There are roughly three patterns of articular course in RA. Firstly the monocyclic 
disease course in approximately 20% of patients. Secondly the intermittent, polycyclic 
course present in about 70% of patients and characterized by exacerbations and 
remissions. Thirdly the progressive form in about 10% of cases (2). This latter disease 
course is characterized by the development of destructive polyarthritis and frequent 
presence of extra-articular manifestations leading to considerable disability. 
Several factors are considered to be associated with a less favorable clinical outcome: 
appearance of subcutaneous nodules, impaired functional capacity after one year of 
disease, presence of rheumatoid factor, antiperinuclear factor in rheumatoid factor-
negative patients, persistently increased erythrocyte sedimentation rate (ESR) or C-
reactive protein (CRP), persistently low haemoglobin (Hb), and HLA-DR4 (5,6,7,8). 
1.2 PATHOGENESIS 
Despite extensive research, the cause of RA is still unknown. It is generally accepted 
that the presentation of an unknown antigen (stimulus) to a genetically susceptible 
individual can trigger RA (9). The responsible arthritogenic stimulus is unknown. 
Recently there is renewed interest in some infectious agents such as the Epstein-Barr 
virus and the mycobacteria (9). 
The sequence of pathological processes in RA can be divided into five stages (9): The 
first stage is characterized by antigen presenting (via macrophages or dendritic cells) to 
the T-lymphocytes. The second by proliferation of T- and B-lymphocytes and the 
development of new blood vessels (neo-angiogenesis) in the synovial membrane. In this 
stage B-lymphocytes are stimulated, via soluble mediators (=cytokines, produced by 
activated macrophages and lymphocytes) to secrete immunoglobulins and rheumatoid 
factor. This rheumatoid factor forms large immune complexes, which activate the 
complement system leading to a cascade of inflammatory events. Retained immune 
complexes localized in cartilage and intra-articular ligaments (10), may play an important 
role in the chronicity of the rheumatoid inflammation (11,12). In the third stage 
neutrophils accumulate in the synovial fluid and synovial cells proliferate markedly. In 
the fourth stage vascular and granulation tissue (pannus) arise from the synovial membra-
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Table 1. Criteria for the classification of Rheumatoid Arthritis (see also 
reference 4) 
1. Morning stiffness lasting at least one hour 
2. Arthritis of three or more joint areas * 
3. Arthritis of hand joints It 
4. Symmetric arthritis $ 
5. Rheumatoid nodules 
6. Presence of rheumatoid factor ** 
7. Radiographical changes @ 
* The 14 possible areas are: right or left proximal interphalangeal (PIP) joints, meta-
carpophalangeal (MCP) joints, wrist, elbow, knee, ankle, and metatarsophalangeal (MTP) joints. 
# Wrists, PIPs, or MCPs. 
$ Regarding the joint areas mentioned in the second criterium. 
** By any method of which the result has been positive in < 5% of normal control subjects. 
@ These must include erosions or periarticular decalcification on hand or wrist radiographs. 
ne and invade the cartilage starting from the margin. In the fifth stage there is more 
invasion and destruction of cartilage, while intra-articular ligaments and subchondral bone 
are also affected. Several enzymes such as collagenase (13) and cytokines such as 
interleukin-1 play a part in cartilage and bone destruction (14,15,16). From stage 2 to 
stage 5 symptoms and clinical findings increase. Radiographically, erosions and narro-
wing of joint space are found in stage 5. 
The important role of T-lymphocytes (17,18) in the pathogenesis of RA is reflected by 
several observations: Firstly, the immunohistological examination of the synovium in RA 
has demonstrated vast infiltration of lymphocytes. The majority of these cells are T-
helper (CD4) cells (19,20). Secondly, activation of T-lymphocytes is thought to occur 
after binding to the antigen presenting cell, which bears certain major histocompatibility 
(MHC) class 2 molecules associated with susceptibility to RA (9). Thirdly, several 
therapies used to diminish T-lymphocytes such as lymphapheresis (21,22), thoracic duct 
drainage (23,24), and total lymphoid irradiation (17,25,26,27), have been reported to be 
effective in RA. 
Clinically, B-cell proliferation in RA is reflected by the presence of rheumatoid factor 
and (polyclonal) elevated immunoglobulins. Decreased levels of C3 and C4 intra-articu-
larly indicate complement activation. 
In the next section of this chapter we shall discuss the question in which way cytotoxic 
drugs as azathiopnne (AZA) and methotrexate (MTX) may interfere in the above 
mentioned processes of rheumatoid inflammation. 
1.3 CYTOTOXIC DRUGS AND RHEUMATOID ARTHRITIS 
As mentioned before, RA consists of a complex process of immune and inflammatory 
events. Cytotoxic drugs as AZA and MTX are supposed to have (non-specific) anti-
inflammatory and immunosuppressive properties (28). It is generally accepted to treat RA 
patients with these drugs when there are features of progressive disease course such as a) 
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persistently active synovitis despite treatment with so-called first line antirheumatic drugs 
(=non-steroidal anti-inflammatory drugs (NSAIDs) combined with second-line drugs as 
hydroxychloroquine, parenteral gold and/or D-penicillamine, b) development of (severe) 
radiologic progression, c) development of extra-articular manifestations as vasculitis (29). 
The anti-inflammatory properties of AZA and MTX have been established in animal 
(30,31,32) and human studies (28,33,34,35). From the late sixties, AZA has been used 
by many investigators on the assumption that the drug suppressed immunological 
processes (36). However, despite apparent clinical benefit in autoimmune diseases, clear 
immunosuppression could not be demonstrated (36,37). To our knowledge studies in RA 
patients such as recently performed for MTX about its effect on, e.g. Chemotaxis, 
cytokines, neoangiogenesis etc., are lacking for AZA. In one open study of AZA versus 
cyclosporin in RA no significant changes in subsets of T-cells (CD4:CD8 ratio) were 
found after 24 weeks of AZA therapy (38). Furthermore there are conflicting data about 
the effect of AZA on rheumatoid factor and immunoglobulins (Chapter 2). Many data on 
an anti-inflammatory effect of AZA derive from animal experiments. 
Table 2. Animal studies and the influence of low-dose methotrexate 
Effect 
Suppression of adjuvant 
(A A)/ streptococcal 
cell wall 
arthritis (SCW) 
Retardation of joint 
destruction 
Suppression of influx 
of macrophages into 
synovium 
Inhibition of Chemo-
taxis (induced by LB4) ** 
Decrease of IL-1 syn-
thesis 
Suppression of proli-
feration and maturation 
of B-lymphocytes 
Animal 
rat (AA) 
rat (AA) 
rat (SCW) 
rat (AA) 
rat (AA) 
rat 
rat 
mice 
rat 
rat 
mice 
Dosage MTX 
(mg/kg/day) 
0 . 1 0 - 5 . 0 * 
0.15 -0.6 
0.13-0.03 
0.30 
0.13-0.06 
0.13-0.03 
0.13 -0.25 
0.25 
0.13-0.25 
0.30 
IO'7 to 10* 
Mol # 
Author 
Ward 
Welles 
Ridge 
Johnson 
Ridge 
Ridge 
Hu 
Suarez 
Hu 
Johnson 
Rosenthal 
(Rel) 
(30) 
(41) 
(42) 
(43) 
(44) 
(44) 
(45) 
(46) 
(45) 
(43) 
(47) 
0.125 mg/kg/day methotrexate (MTX) ¡η mice or rats is analogous to 8.75 mg MTX weekly in 
humans. 
LB4 means leukotriene B4 
A solution of 10"7 to IO4 Mol MTX was added to mouse cell cultures (in-vitro study). A 
concentration of 10' Mol is analogous to the serum MTX levels in RA patients 24 hours after 
ingestion of 7.5-15 mg MTX. 
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Table 3. Effects of low-dose methotrexate (MTX) in human studies (RA patients) 
Effect 
Inhibition of LB4 
synthesis 
Decrease of chemotactic 
migration of leucocytes 
Decrease of IgM-Rf 
synthesis 
Decrease of IL-1 * 
activity 
Antiproliferative 
effect: endothelial 
cells more inhibited 
than synovial fibro-
blasts # 
Decrease of immuno-
globulins 
Decrease of enzymes $ 
(collagenase > elastase) 
In vivo 
In vitro 
in vitro 
in vitro 
in vitro 
in vivo 
in vitro/ 
in VIVO 
in vitro 
in vivo 
in vivo 
in vitro 
Dosage MTX 
(mg/week 
orally or i.m) 
5.0 - 15.0 
10.0 
7.5 - 12.5 
7.5 - 15.0 
10.0 - 15.0 
10' to 10 •' 
Mol 
7.5- 15.0 
7.5 - 25.0 
7.5 - 12.5 
Author 
Sperling 
O'Callagh. 
Olsen 
Alarcón 
Segal 
Hirata 
Boerbooms 
Andersen 
Martel 
(Ref) 
(48) 
(49) 
(50) 
(50 
(52) 
(53) 
(54) 
(55) 
(13) 
IL-1 means interleukin-l; IL-1 synthesis was not inhibited. 
The effect of MTX in various concentrations added to cell cultures was studied. Inhibition of 
DNA synthesis of human umbilical vein endothelial cells in vitro and rabbit corneal 
neovascularization was studied. DNA synthesis of fibroblasts obtained from RA synovium was 
also measured. Neovascularization plays an important part in the formation of pannus in RA. 
Neutral protease activity was measured in cartilage and synovial membrane obtained from RA 
patients. These enzymes are involved in the process of cartilage matrix degradation. 
Probably due to the great interest in treatment of RA patients with low-dose MTX the 
last decade, many studies were published about possible mechanisms of action of MTX 
in RA. As Tables 2 and 3 show, the effects of MTX possibly implicated in the treatment 
of RA, are highly divergent. In addition, high-dose intravenous MTX (500 mg/m2) 
followed by leucovorin rescue, given in 5 RA patients, was associated with a distinct 
reduction of circulating activated T-lymphocytes i.e. decrease in surface DR expression 
on lymphocytes (39). Whether the observed change should be ascribed to a direct effect 
on T-cells or may reflect a recirculation pattern rather than total body alteration is 
unknown. Since the many cell types involved, interact with one another in a complex 
manner, there is intertwining of anti-inflammatory and immunosuppressive events. 
Therefore, it may be difficult to characterize a certain effect of a drug i.c of AZA or 
MTX as merely anti-inflammatory or immunosuppressive (40). Probably it would be 
better to call drugs such as MTX and AZA "immunoregulatory drugs" rather than 
"immunosuppressive" or cytotoxic drugs (40). 
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In summary, animal and human in vivo and in vitro studies suggest that low-dose 
MTX has anti-inflammatory, subtle immunomodulating and antiproliferative properties 
(Table 2 and 3). The exact mechanism of action of this drug remains however unclear. 
This thesis is mainly concerned with clinical aspects rather than with mechanism of 
action of therapy with AZA or MTX. 
1.4 AIM OF THE THESIS 
The m^jor objective of this thesis was to determine the place of methotrexate in the 
therapy of rheumatoid arthritis. In order to justify its increasing use in RA, a comparison 
was made with another immunoregulatory drug, azathioprine. As a variant on the 
treatment pyramid (56) for RA, in Figure 1 a scheme is presented in which the 
successive treatment steps in RA are illustrated. Onset of clinical response, short- and 
long-term efficacy, toxicity profile, and long-term safety are important factors in 
determining a place for the different antirheumatic drugs. Apart from these factors, 
degree of disease activity in a RA patient, presence and/or development of radiologic 
abnormalities, and other reasons as known drug allergy (e.g. to sulfonamides) may 
influence the final choice for a specific antirheumatic drug. 
Chapters 2, 3 and 4 are review articles: In Chapter 2 general data (pharmacology, 
clinical trials in RA, adverse reactions etc.) about azathioprine and in Chapter 3 general 
data about methotrexate are reviewed. In Chapter 4 the use of methotrexate in connective 
tissue diseases is described. 
Thereafter results from an open trial (Chapter 5) and a double-blind trial (Chapter 6, 7, 
8, 9) will be discussed. The following topics and questions will be dealt with: 
- Is methotrexate effective in refractory RA, i.e. in RA patients with therapeutic failure 
or intolerance to the next anti-rheumatic drugs: hydroxychloroquine, parenteral gold, 
D-penicillamine and azathioprine? (Chapter 5) 
- Are there differences in clinical results between RA patients treated with MTX or 
azathioprine, who were unresponsive to or react with toxicity to parenteral gold, D-
penicillamine or both drugs? The efficacy, toxicity and influence on sero-
immunological parameters are described in a double-blind comparative trial of 64 RA 
patients (Chapter 6) 
- Are there differences between radiographic results of RA patients who start on AZA 
or on MTX after one year of therapy? Is there difference in slowing of radiographic 
progression? (Chapter 7) 
- What kind of pulmonary abnormalities are found in a patient group with refractory 
RA? Are there changes in chest radiographs or results of pulmonary function tests 
during therapy with AZA or MTX? Is serial pulmonary function testing useful for 
monitoring MTX pulmonary toxicity? (Chapter 8) 
In Chapter 9 four rare, but dangerous side effects of AZA and MTX are described in 
more detail. Three of these four adverse reactions occurred during the double-blind trial: 
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pancytopenia due to AZA, severe hypersensitivity reactions due to AZA, and eruption of 
nodulosis related to MTX. Pancytopenia due to the combined use of MTX and other anti­
folate drugs is described in a fourth article of this chapter. Chapter 10 comprises final 
conclusions and the summary of this study. 
Figure 1. Scheme of the different steps in the treatment of rheumatoid arthritis. 
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Chapter 2 
AZATHIOPRINE 

2.1 CHEMISTRY, ABSORPTION, DISTRIBUTION, METABOLISM, 
EXCRETION 
Azathioprine (ImuranR) is a nitro-imidazole derivative of 6-mercaptopurine (6-MP) 
(la,lb). Its structural formula is 6-(l methyI-4-nitro 5-imidazolyl) thiopurine (Figure 1). 
Azathioprine (AZA) is well absorbed from the gastrointestinal tract. After oral admini­
stration, AZA rapidly disappears from the circulation and is extensively metabolized (see 
further). There is a relatively short elimination half-life (t'A) of 0.2-1 hour (3). Within 
24 hours about 50% of an oral dose AZA is excreted in the urine mainly as thiouric acid 
(2,3). Small amounts (10%) of unchanged AZA and 6-MP are eliminated in the urine. 
Approximately 12% of a dose is eliminated in the faeces. The plasma protein binding of 
AZA is about 30% (2). Its apparent volume of distribution (Vd) is 0.8 liter/kilogram (4). 
In renal transplant patients with a mean creatinine clearance of 57 ml/min given 100-
150 mg AZA intravenously, the average tV4 was 12.5 ± 3.9 minutes (5). In this study it 
was also demonstrated that a lower creatinine clearance [mean 13 ml/min (range 5-23)], 
did not influence the t'/z of AZA. However, these authors point out that their results do 
not exclude the possibility that active AZA metabolites (i.c 6-MP ribonucleotides) may be 
responsible for the commonly observed intolerance to or toxicity of AZA in patients with 
poor renal function (5). Because of possibly reduced AZA clearance in patients with a 
glomerular filtration rate of less than 10 ml/min, it is recommended to extend the dosage 
interval of AZA from 24 to 36 hours, or to reduce the dosage to 75% (3). 
Pharmacokinetic data of 6-MP and AZA in RA patients are lacking. Since AZA and 6-
MP have to be converted to their ribonucleotides before exerting their pharmacologic 
action, determination of plasma levels of AZA and 6-MP is of no direct clinical value 
with respect to effectiveness or toxicity of AZA (6). When AZA crosses the placenta, 
much of the drug has been deactivated. Low foetal 6-MP levels, however, are detectable 
(7,8). 
The first step in metabolism of AZA is thiolysis by glutathione, a substance present in 
the liver and erythrocytes (9). The thiolysis leads to formation of gluthationyl imidazole 
and releases 6-MP. Thereafter methylation of the sulfhydryl group and oxidation of the 
Figure 1. Structural formulas of azathioprine and 6-Mercaptopurine. 
S- г N-СНз 5Ή 
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Figure 2. Metabolism of Azathioprine (AZA) and б-Mercaptopurine (6-MP) and 
their influence on purine de-novo synthesis. 
AZA 
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/ 
-*TGDP 
\ 
TdGTP—»DNA 
TGTP RNA 
6-thiouric acid 
1 = Hypoxanthine guanine phosphoribosyltransferase (HGPRT) 
2 = Thiopurine methyltransferase (TPMT) 
3 = Xanthine oxydase 
4 = GMP reductase 
5 = Purine 5 nucleotidase (PNT) 
6 = Purine nucleoside Phosphorylase (PNP) 
* = Inhibition of phosphonbosyl pyrophosphate (PRPP) amidotransferase and other enzymes of 
purine metabolism by 6-MP nucleotides (see also Figure 3). 
methylated derivatives occur. The metabolism of 6-MP follows three major enzymatical 
routes (10,11) (Fig 2), of which the first route is the most important one. 
a. Conversion by the enzyme hypoxanthine guanine phosphonbosyl transferase 
(HGPRT), present in a.o erythrocytes. This conversion leads to thioinosinic mono­
phosphate (TIMP), a known inhibitor of several enzymes in the purine de-novo 
synthesis such as inosinic monophosphate (IMP) dehydrogenase (10,11,12). Finally -
via several enzymatic routes - incorporation into DNA and RNA synthesis occurs, 
which is a major mechanism of action of AZA (12). Drug resistance to AZA occurs in 
patients suffering from the Lesh Nyhan syndrome, an inborn error of metabolism due 
to deficiency of HGPRT (13,14). Formation of TIMP requires phosphonbosyl 
pyrophosphate (PRPP) as a cofactor (10). Since methyl thiopurines are inhibitors of 
PRPP amidotransferase and the natural nucleotides adenosine monophosphate (AMP) 
and guanine monophosphate (GMP) cause feedback inhibition of the same enzyme, the 
resultant decrease in AMP and GMP is called pseudo feedback inhibition (11) (Fig 3). 
b.Oxidation by xanthine oxydase, an enzyme mainly present in the liver. Oxidation 
leads to formation of 6 thiouric acid, the major urinary metabolite of AZA. Other 
urinary metabolites are inorganic sulfate, nitromethyl thio-imidazole, 6 methylpurine 
derivatives and small quantities of 6-MP and 8 OH-AZA. Concurrent use of allopuri-
nol, a xanthine oxydase inhibitor, and AZA induces increased toxicity of AZA. In such 
a situation the dosage of AZA must be reduced by 75 percent (11,15). 
с Formation of 6 methyl MP derivatives, catalyzed by thiopurine methyltransferase 
(TPMT). These metabolites also cause pseudo feedback inhibition (see above). 
Inherited low TPMT activity with subsequent raised 6-thioguanine (TGN) levels is pro-
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Figure 3. Purine de-novo synthesis and inhibition by 6-Mercaptopurine nucleotides 
(= Pseudofeedback inhibition *) . 
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2 — Phosphonbosyl pyrophosphate (PRPP)amidotransferase 
3 = Glycinamide nbonucleotide (GAR) synthetase 
4 = GAR formyltransferase 
5 = Ammo imidazolecarboxamide nbonucleotide (AICAR) formyltransferase 
6 = Inosinic monophosphate (IMP) dehydrogenase 
7 — Adenylosuccinate synthetase 
8 = Adenylosuccinate lyase 
* = Since the natural nucleotides AMP and GMP cause feedback inhibition (—1|-*) of PRPP 
amidotransferase (2), the feedback by 6-MP nucleotides* is called pseudofeedback inhibition 
# = Thioinosinic monophosphate (TIMP) also inhibits the enzymes (6), (7), (8) 
bably a major risk for developing AZA induced myelosuppression (12,16). 6-TGN is 
converted by HGPRT and leads to incorporation into DNA and RNA Very low TPMT 
activity occurs in 1 of 300 subjects and a low ( = intermediate) activity in 11% of the 
population (12,15) 
2.2 MECHANISM OF DRUG RESISTANCE 
Drug resistance to AZA may occur due to HGPRT deficiency. It may also be caused 
by other mechanisms decreased drug transport, mutant form of HGPRT, loss of, or 
altered adenosine phosphonbosyl transferase (APRT) (11) and increase of alkaline 
phosphatase activity in leucocytes (11,17). Because only a minonty of leukemia patients 
with clinical 6-MP resistance showed low HGPRT activity (10,18), other, yet unknown 
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factors are probably involved in thiopurine resistance. A recent finding is that children 
with very high TPMT activity tolerate long periods of full doses of 6-MP. The authors 
suggested that conventional doses of 6-MP in these children represent undertreatment 
(19). 
Hypothetically, a similar drug resistance to AZA in RA patients with very high TPMT 
activity may play a part in unresponsiveness to AZA. To our knowledge, thiopurine 
resistance in RA patients has not yet been investigated. 
Some authors suggest that altered purine metabolism might play a part in the patho-
genesis of RA. Therefore they measured some enzymes involved in purine metabolism 
(20). Of the three enzymes measured [purine-5-nucleotidase(PNT); purine nucleoside 
Phosphorylase (PNP) and adenosine deaminase (ADA)], ADA and PNT had significantly 
lower levels than in a control group. The consequence of these findings is not yet clear. 
2.3 MECHANISM OF ACTION 
Both azathioprine (AZA) and 6-MP are purine analogues and pro drugs, that is, they 
must be converted to their ribonucleotides before they can exert cytotoxic activity 
(lb, 10,11). Both drugs inhibit DNA and RNA synthesis early in the de-novo purine 
synthesis and at purine nucleotide interconversions (la, 11). 
The anti-inflammatory (21,22) and immunosuppressive effects of thiopurines in animals, 
such as suppression of adjuvant arthritis, selective effect on T-cells in mice and decrea-
sed delayed type hypersensitivity in rabbits are well documented (22-24). However, 
extrapolation of these results to man is difficult in view of species variability and suscep-
tibility to the drug. 
Inhibition of the local inflammatory response by 6-MP in man, was shown by two 
authors (25,26). Studying experimental inflammatory sites (skin window technique), 6-
MP inhibited the mononuclear cell exudation (25). In another study the polymorphonu-
clear cell function (Chemotaxis, phagocytosis) did not change significantly in renal 
transplant recipients receiving AZA (2.5 mg/kg/d) compared with a control group (27). 
A recent study in 30 RA patients (28) demonstrated an inhibitory effect of AZA on the 
natural killer (NK) cell function, as also shown in renal transplant recipients (29). 
However, only the 4 hour, not the 24 hour NK cell function was suppressed (28). Since 
the role of NK cells in RA (immunoregulation?) is still unclear, the significance of this 
observation is unknown. 
Studies focused on immunosuppressive properties of AZA in man have indicated con-
flicting results on the humoral immune response, possibly due to differences in nature 
and dose of test antigens used (29). The effect of AZA on the cellular immune response 
is weak and not convincing (29-32). No significant changes in CD4:CD8 ratio were 
found in RA patients treated with AZA (2.5 mg/kg/d) (32). Finally, there are conflicting 
results about the effect of AZA on immunoglobulin synthesis and rheumatoid factor (31-
37). 
In summary, data on immunosuppressive and anti-inflammatory effects of AZA in man 
are controversial. Despite established clinical effect in controlled clinical trials, the 
mechanism of action of AZA in RA remains unclear. 
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2.4 DRUG INTERACTIONS 
The increased toxicity following concurrent use of AZA and allopurinol, has been 
mentioned before. In renal allograft recipients the antifolate action of trimethoprim-sul-
famethoxazole on the bone marrow did increase the myelosuppressive effect of AZA 
(38,39). The inhibitory effect of AZA on non-depolarizing neuromuscular blocking drugs 
is probably caused by inhibition of the enzyme phosphodiesterase at the motor nerve ter-
minal (39,40). However, there is doubt about the clinical relevance of this interaction 
(40). 
2.5 DOSAGE OF AZA 
AZA is on the market in film coated tablets of 50 mg. Recently tablets containing 25 
mg AZA became also available. The usual dosage for RA ranges from 1.5 mg/kg to 
maximally 2.5 mg/kg body weight, but dosages as low as 1 mg/kg can be effective (41). 
Vials containing 50 mg AZA are used for intravenous administration. Dose adjustment in 
patients with renal insufficiency was mentioned before. To avoid neonatal cytopenia it is 
recommended to halve the maternal dose of AZA during the third trimester of pregnancy 
(42). 
2.6 CONTROLLED CLINICAL TRIALS OF AZA (see also Tables 1 and 2) 
Double-blind trials of AZA compared with either placebo or other second-line drugs in 
some 800 RA patients have demonstrated the clinical efficacy of AZA. A significant 
steroid sparing effect of AZA was reported on in the first placebo controlled trial of 
AZA (43,44). In other placebo controlled studies (AZA: 1.5-3.0 mg/kg) significant 
improvement of articular indices and grip strength was present and manifest from the 
sixth week (45-47). After cross-over, relapse of RA during placebo period developed 
(46). Full dose AZA (2.5 mg/kg body weight daily) versus half dose (1.25 mg/kg daily) 
was nearly equally effective (41), but in another study full dose was more effective (48). 
ESR remained unchanged in nearly all the trials of AZA mentioned. The number of 
withdrawals due to side effects ranged from 0 to 47%. Radiologic results were too 
incomplete for interpretation. 
Double-blind studies in which AZA was compared with other second-line drugs 
[cyclophosphamide (49,50), parenteral gold (49,52), chloroquine (52), D-penicillamine 
(51,53,54), methotrexate (34a,34b)], did not reveal intergroup differences regarding 
clinical disease variables such as articular index, grip strength and morning stiffness. The 
rate of withdrawal due to side effects of AZA in these studies varied considerably (10-
35%). ESR fell in some studies, but remained unchanged in other studies. Radiologic 
results were the same on both drugs. However, radiologic data were often too limited for 
general conclusions regarding influence of these drugs on radiologic progression in RA. 
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Table 1. Placebo controlled clinical trials of azathioprine in rheumatoid arthritis 
Author Number of Follow-up Dosage 
(ref) patients (wk) (mg/kg/d) 
Comments 
Mason 
(43) 
Levy 
(45) 
Urowitz 
(46) 
Urowitz 
(41) 
Goebel 
(47) 
Woodland 
(48) 
49 
18 
17 
31 
30 
42 
48 
2 x 2 4 
2 x 16 
24 
2 χ 12 
24 
2.5 
3.0 
2-2.5 
1-1.25 
vs 2-2.5 
1.5-2.0 
1.25 
vs 2.5 
Signif. steroid sparing effect [all patients used steroids (5-20 mg/ 
d)]; clinical data at 48 wk not mentioned; At 120 wk no benefit in 
30% and withdr. due to side effects in 30% of patients. * 
Crossover at 24 wk; Marked or moderate clinical improv. in 83%; 
Withdr. side effects in 11%. $ 
Crossover at 16 wk; signif. improv. in 4 disease variables; Side 
effects in 23% (no withdr.); ESR, Latex unchanged, signif. deer. 
IgA/IgG; Radiographs (10 patients) no differences in placebo or 
drug periods. $ 
Both drug groups signif. improv. in 3 disease variables; Withdr. 
side effects in 20%; ESR, Latex unchanged, IgA signif. decrease. 
In 2 patients radiographic progression after 24 wk. $ 
Signif. improv. in 2 disease variables; Side effects in 13% (no 
withdr.); signif. fall Iggs. $ 
Full dose more effective than half dose; signif. improv. 3 diseases 
variables in full dose group; Withdr. side effects in 47% (full dose) 
vs placebo and 29% (half dose); ESR no signif. change. $ 
* Long-term data from Harris et al. (44) 
# No placebo group in this study 
$ Deer. = decrease; ESR = erythrocyte sedimentation rate; improv. = improvement; Iggs = immunoglobulins; 
Latex = rheumatoid factor; signif. = significant; withdr. = withdrawal 
Table 2. Double-blind trials of azathioprine compared with other second-line drugs in rheumatoid arthritis 
Author Number of Follow- Dosage 
(ref) patients up (wk) and drug 
Comments 
Currey 
(49) 
Levy 
(50) 
Berry 
(51) 
Dwosh 
(52) 
Paulus 
(53) 
121 72 2.5 mg/kg/d 
AZAvs 1.5 
mg/kg/d CPA 
vs 50 mg/wk AU * 
42 24 CPA vs AZA 
vs placebo 
(unknown dosage) 
65 48 2.5 mg/kg/d 
AZA vs 1000 
mg/d D-P * 
33 24 1-2 mg/kg/d 
AZA vs 250 
mg/d C1Q 
vs 50 mg/wk AU * 
206 24 1.25-1.5 mg/kg/d 
AZA vs 10-12 
mg/kg D-P * 
No signif. intergroup differences except tender joint in CPA; CPA 
and AZA steroid sparing effects; Withdr. side effects CPA (51%), 
AZA (32%), AU (50%); More patients on AU marked radiologic 
deterioration. $ 
Crossover after 24 wk; AZA and CPA equally effective (signif. 
decrease in 3 disease variables). $ 
AZA and D-P equally effective; ESR signif. more decrease in 
D-P; signif. fall Latex; Withdr. side effects AZA (30%); D-P 
(30%); No radiologic differences. $ 
No signif. differences in change of disease variables between the 
drugs; Signif. fall ESR only in AU group; Withdr. side effects 
AZA (20%), C1Q (10%) and AU (0%); No radiologic differen­
ces. $ 
Improv. nearly all (10) disease variables. No signif. intergroup 
differences except for ESR and HB (in D-P more change); 
Withdr. side effects AZA (20%), D-P (28%). $ 
* Long-term data from Harris et al. (44) 
# No placebo group in this study 
$ Deer. = decrease; ESR = erythrocyte sedimentation rate; improv. = improvement; Iggs = immunoglobulins; 
Latex = rheumatoid factor; signif. = significant; withdr. = withdrawal 
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t-J Table 2. continued 
Author Number of Follow- Dosage 
(ref) patients up (wk) and drug 
Comments 
Halberg 
(54) 
Hamdy 
(34a) 
Bell 
(34b) 
74 
42 
34 
96 
52 
20 
2.5 mg/kg/d 
AZA vs 600 
mg/d D-P 
vs 150 mg/d Lev. * 
100-150 mg/d 
AZA vs 
10-15 mg/wk 
MTX 
100-150 mg/d 
AZA vs 
10-15 mg/wk 
MTX 
After 8 wk Lev. withdrawn due to agranulocytosis in 4 patients; 
No signif. differences in change of disease variables between 
AZA and D-P; Withdr. side effects AZA (15%), D-P (11%); 
After 96 wk only 1/3 of the patients completed therapy (primary 
treatment failure or relapse RA in 48% AZA and 29% D-P). No 
signif. differences in radiologic results at 96 wk. $ 
Signif. decrease 9 disease variables in both groups. No intergroup 
differences except for ESR (MTX signif. decrease ESR, Latex). 
Trend toward more marked and rapid improv. in MTX; Withdr. 
side effects AZA (10%), MTX (10%); No differences in radio-
logic results after 24 and 52 wk. $ 
Both drugs equally effective except more improv. grip strength in 
MTX; Withdr. side effects AZA (35%), MTX (6%); Withdr. 
other reasons in 11%. $ 
* AU = parenteral gold; AZA = azathioprine; CIQ = chloroquine; CPA = cyclophosphamide; D-P = D-penicillamine; 
Lev = levamisole; MTX = methotrexate 
$ ESR = erythrocyte sedimentation rate; HB = hemoglobin; improv. = improvement; Latex = rheumatoid factor; signif. = significant; 
withdr. = withdrawal 
2.7 LONG-TERM EXPERIENCE 
In three retrospective long-term studies of AZA a sustained clinical improvement of 
about 40-50% was found after 2-3 years (55-57). Discontinuation due to adverse 
reactions occurred in about 20% of the patients and due to lack of effect in 14 to 44%. 
In a large scale retrospective study of 325 patients the probability of continuing the 
same second-line drug (a.o. AZA) after 3 years was only 10% (58). In a recent prospec-
tive study of 393 patients treated with AZA, discontinuation due to side effects (mainly 
gastrointestinal), occurred in 17.4% of the patients. Unfortunately the exact follow-up 
period and the number of patients withdrawn due to lack of effect were not mentioned 
(59). 
In four prospective long-term studies of 21 (34a), 27 (44), 20 (54), and 17 (60) 
patients respectively, after follow-up periods of about 2 years, 30 to 50% of patients 
were still taking AZA. Discontinuation due to side effects occurred in 10 to 30% and due 
to lack of effect in 25 to 30% of patients. Radiologic evaluation disclosed progression in 
many patients. In one study radiologic as well as clinical results were similar for AZA 
and MTX (34a). However, the small number of patients at the end of that study, did not 
allow any conclusion about the ultimate influence of these drugs on radiologic pro-
gression in RA. 
2.8 ADVERSE REACTIONS 
The two most frequently encountered side effects of AZA are gastrointestinal com-
plaints in about 20% and leucopenia in about 15% of patients (14,61). The spectrum of 
adverse reactions is listed in Table 3. 
Gastrointestinal complaints comprise nausea, vomiting and abdominal discomfort. 
Sometimes diarrhoea or mouth ulcers develop (61). 
Hematological side effects such as leucopenia, pancytopenia (62), thrombocytopenia 
and pure red cell aplasia are mentioned in Chapter 9. A further case report of pan-
cytopenia due to AZA was published as well (63). The hematological side effects induced 
by low TPMT activity were pointed out before. 
Hepatotoxicity associated with AZA manifests itself with signs of cholestasis and 
hepatocellular damage. Underlying mechanisms are toxic, allergic or obstructive (64). 
There are several case reports of veno-occlusive disease and peliosis hepatis, due to non-
thrombotic blockade of the venous outflow tract observed in recipients of renal trans-
plants (65-67), systemic lupus erythematosus (68) and recently also in RA (69). The 
disorder is characterized clinically by hepatomegaly, ascites and variable liver enzyme 
elevations. Progressive liver failure with fatal outcome has been reported (70). The triad 
of severe liver function abnormalities, rash, and fever with chills is described in more 
detail in Chapter 9. 
Pancreatitis attributed to AZA was found in several patients with Crohn's disease (71) 
and in one RA patient (72). 
Azathioprine hypersensitivity has many manifestations ranging from fever (isolated or 
with rigors), to symptoms of a musculoskeletal (arthralgia, myalgia), cutaneous (urticaria, 
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Table 3. Adverse Reactions to Azathioprine 
Frequent (±15%) Less frequent (0-5 % ) Rare ( < 1 % ) 
gastrointestinal thrombocytopenia hypersensitivity 
leucopenia liver dysfunction - fever 
mucosal ulcers - arthralgia, 
myalgia 
- cholestasis 
- rash 
- shock 
- pancreatitis 
hematologic 
- pancytopenia 
- pure red cell aplasia 
- anemia 
erythema nodosum-like), neurologic (headache, neuritis), cardiovascular (shock, hypoten-
sion), gastrointestinal (nausea, gastroenteritis, liverinjury, pancreatitis) or respiratory 
nature (pneumonitis) (73). Fever, diarrhoea, nausea, mimicking gastroenteritis, were 
found in some patients (74). There are numerous reports of life-threatening shock accom-
panied by other manifestations of hypersensitivity (75-79). Rechallenge with azathioprine 
in such cases is dangerous and should only be done under careful observation (77). 
Azathioprine induced interstitial pneumonitis is another infrequent side effect. The 
clinical features comprise hypoxemia, low grade fever, abnormal chest radiographs and 
lung function tests (80-84). Histologically there is diffuse alveolar damage and in some 
patients interstitial fibrosis was found. Immune depositions in the lung were not demon-
strated. Clinical improvement with normalization of radiographs mostly occurs within 2 
weeks to 2 months. However, several patients died from superimposed infections (83). 
Whether the risk of infections in RA patients treated with AZA is increased, is debatable 
(14,85). It is also a matter of debate whether AZA causes alopecia (85). 
2.9 FERTILITY, PREGNANCY, LACTATION 
In spite of exposure to immunosuppressive drugs, about 70% of 308 pregnancies of 
renal transplant recipients resulted in full-term infants (86). However, the possibility of 
neonatal immunosuppression and growth retardation of infants due to AZA cannot be 
excluded (87). The clinical relevance of the clastogenic effects of AZA on chromosomes 
of RA patients is unclear, since this abnormality disappeared on discontinuation of the 
drug (88,89). Chromosomal abnormalities in 11 of 16 infants bom of transplant reci-
pients returned to normal at 1 year of age (86). 
The concentration of AZA in the breast milk (measured as 6-MP) is 1.2% of the 
maternal concentration (3). Since maximum infant plasma concentrations of 6-MP are 
less than 10% of maternal plasma concentrations, breast feeding of infants older than 34 
24 
weeks is probably safe (3). 
Studies of RA patients concerning male fertility during AZA therapy are scarce. In 23 
patients with connective tissue diseases, AZA did not decrease sperm counts (90,49). It 
is recommended to practice adequate contraception in women and men during the 
treatment period of AZA and for at least 3 months after the drug has been discontinued 
(2,8). 
2.10 NEOPLASMS 
Much concern exists about a substantial excess of neoplasms (mainly non Hodgkin 
lymphoma and skin cancer) in renal transplant recipients who have received immunosup-
pressive drugs (85). However, in dialysis patients not receiving these drugs a similar 
increase of neoplasms was observed (91), so that the contribution of AZA to this increase 
remains unclear. A similar situation exists for RA patients. Although some authors did 
not find an excess of neoplasms in RA patients (92-94), there is much more evidence of 
an increased risk of lymphoproliferative malignancies in RA (95-100). The mean interval 
between the onset of RA and the diagnosis of neoplasms ranges from 11.8 to 17 years 
(95). 
Hypotheses to explain the excess of neoplasms in auto-immune diseases are polyclonal 
B-cell proliferation - which triggers malignant transformation of cells - and activation of 
silent oncogenes by unknown antigen (96). An accelerated excess of neoplasms in RA 
patients treated with currently used AZA dosages (100-150 mg daily) has not been 
demonstrated at this moment (101,102,55,59). In a study of 202 RA patients treated with 
high dosage (300 mg AZA daily) and followed up for 20 years, an increased number of 
lymphomas (tenfold compared with fivefold in RA control group) was found (100). 
Further prospective studies with larger numbers of patients and longer follow-up periods 
(> 10 years) are necessary to elucidate the contribution of AZA to neoplasm induction in 
RA patients. 
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Chapter 3 
METHOTREXATE 

3.1 CHEMISTRY, TRANSPORT, POLYGLUT AMA TION 
The structural formula of methotrexate (MTX) is 4-amino-4 deoxy-N10-methylpteroyl-
glutamic acid (Figure 1). This formula resembles that of folic acid (1,2) 
MTX is transported via an active camer-mediated system into the hepatic cells (1,2) 
The drug is mainly converted to MTX Polyglutamates (P-Glu), catalyzed by folylgluta-
mate synthetase (Figure 2) Polyglutamation is an important process leading to intracel-
lular retention and accumulation of MTX, mainly in the liver and to a less extent in 
erythrocytes The enzyme dihydrofolate reductase (DHFR), however, is the target of 
action of MTX (see mechanism of action). Polyglutamate chain length increases with 
higher concentrations of MTX and longer duration of exposure to MTX (1) Low-dose 
MTX therapy in RA does not cause progressive accumulation of MTX-P-Glu in either 
the liver or the erythrocytes, not even after several years of therapy (3,4,5). Depleted 
(decrease of about 80%) hepatic folate levels were found in RA patients treated with low-
dose MTX (3) 
3.2 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
Several studies have indicated that MTX absorption was rapid and complete after 
dosages of less than 30 mg/m2 (1,2) Other, recent studies have demonstrated that the 
extent of absorption may be well under 50% for doses of 10-15 mg/m2 MTX (6) Food 
(especially dairy products), intestinal bactena and non-absorbable antibiotics can influence 
Figure 1. Structural formulas of methotrexate, folic acid and leucovorin. 
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Figure 2. Influence of methotrexate (MTX) and its metabolites (MTX) polyglutama-
tes) on purine de-novo (RNA/DNA) and pyrimidine (DNA) synthesis. 
NMormyl F H i « - ^ — • N Mormyl FHMGlu) 
(leucovorm) s 
N -Methyl FH¿ 
• purine 
synthesis 
FH4(Glu] « 
N5 ,0-10-MeFH4(Glu) 
ι 
dTMP 
ГМТХ|—-»MTXPGlu =^Z__ 
't 
MTX 
PRPP 
AICAR 
5 
IMP 
/ \ 
DNA RNA 
Active transport of MTX across cell membrane 
Dihydrofolatereductase (DIIFR) most important target enzyme of MTX action 
(—II—•= inhibition) 
Folylglutamatesynthetase 
Thymidinesynthetaie 
GAR formyltransferase 
AICAR formyltransferase 
Methiomne synthetase 
Methotrexate polyglutamates 
Methylene tetrahydrofolate 
Dihydrofolate 
a = 
1 
2 
3 
4 
5 
6 
MTXPGlu = 
MeFH4 
FH2 
Other abbreviations are mentioned m the list of Abbreviations 
the absorption of MTX (6,7,8). Alteration in plasma protein binding affects the amount 
of free extracellular MTX, which can result in increased toxicity. Fifty to seventy per­
cent of MTX is bound to protein, mainly albumin. 
The mean bioavailability (i.e. degree of absorption of a drug into the general circula­
tion) for commercial MTX tablets ranges from 25-100% (mean 73%) (9) The volume of 
distribution (Vd) of MTX is about 1 L/kg. The Vd of 7-OH MTX is much smaller (10). 
High values of Vd ( > 1 L/kg) mean high tissue concentrations compared with plasma and 
vice versa 
Distribution. Recent pharmacokinetic studies of low-dose MTX (7.5-15 mg/wk) therapy 
in RA and psoriasis patients have demonstrated a biphasic disappearance of MTX 
(5,6,9,11). The mean initial (distribution) half-life (tl/2) was found to range between 0 1 
and 1 2 hour, the mean terminal (elimination) t 1/2 between 4 5 and 6 5 hours (5,6,11). 
In one study (9) different mean initial and terminal t 1/2 values (3.3 and 14 9 hours 
respectively) were found. Perhaps decreased renal function in several patients in this 
study may explain the different results compared with the three other studies 
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Distribution and accumulation of MTX in tissues and organs depend on factors such as 
blood flow to the organs, permeation of MTX into tissues, the amount of intracellular P-
Glu and the level of DHFR (2). Proximal tubules of kidney, liver and intestinal 
epithelium preferentially contain MTX (7,12). 
The recovery of DNA synthesis of duodenal cells in mice was found to occur only when 
plasma MTX concentrations were 1x10' M or less (13). In view of this observation, a 
safe, critical 24 hour MTX plasma level of about 10' mol/1 in RA patients has been 
recommended (14). In several pharmacokinetic studies of RA and psoriasis patients 
treated with low-dose MTX (7.5-15 mg/wk), 24 hour MTX levels of less than 4x10' 
mol/1 were found (3,6,9,11). The critical MTX level recommended for patients with 
malignancies is much higher (15a, 15b). 
In the presence of pleural or peritoneal effusions, MTX may be trapped in these 
socalled 'third spaces'. These spaces may act as reservoirs and may result in prolonged 
plasma disappearance of MTX, which can lead to increase of toxicity (1,2). Entry of 
MTX across the blood-brain barrier occurs slowly and is limited. With doses of 5-100 
mg/m2 MTX, the cerebrospinal fluid MTX levels are about 1% of the plasma concen-
tration (2). MTX synovial fluid levels obtained from RA patients were similar (5) or 
higher (16) than MTX serum levels. Ratios of MTX in synovial fluid: MTX in serum of 
0.9-1.2 (5) to 1.6-7.0 (16) were found. 
Metabolism. At low doses of MTX there is relatively little metabolism (2). However 
with increasing doses (mainly high-dose MTX), 7-OH MTX, the major metabolite of 
MTX, becomes more important. The 7-OH compound is formed by aldehyde oxidase in 
the liver. Like MTX, 7-OH MTX is polyglutamated (2). Due to its high protein binding 
(91-93%), it is suggested that 7-OH MTX is, at least in part, involved in drug interaction 
between (high-dose) MTX and nonsteroidal anti-inflammatory drugs (NSAIDs) (10). In 
low-dose MTX used in rheumatic diseases, the 7-OH compound is probably not clinically 
important (17a). 
Excretion. Renal excretion is the major (80-90%) route of MTX elimination (1,2). At 
low plasma MTX concentrations, there is renal reabsorption. At higher concentrations the 
clearance of MTX exceeds that of inulin, indicating active tubular secretion as well as 
glomerular filtration (1,2) 
Methotrexate kinetics were studied in 14 RA patients treated with 15 mg MTX weekly. 
Mean kinetic variables did not differ significantly when patients were treated with or 
without NSAIDs. However in three patients with decreased renal clearance (<50 
ml/min), elimination half-life and area under serum concentration versus time curve 
(AUC) of MTX increased markedly. This urges caution in prescribing MTX therapy in 
RA patients with diminished (<50 ml/min) renal function (9). The biliary secretion of 
MTX is less important than the renal excretion. Most of the MTX, excreted in the bile, 
is reabsorbed (enterohepatic circulation). Only a small percentage (1-2%) is found in the 
stools as unchanged drug. The biliary elimination is increased in impaired renal function 
(8,17b). 
35 
3.3 MECHANISM OF ACTION (see also Chapter 1 and 4) 
MTX, 7-OH-MTX, and MTX-P-Glu are inhibitors of folate dependent enzymes such as 
dihydrofolate reductase (DHFR), thymidine synthetase (TS), 5 aminoimidazole-4-carbo-
xamide ribonucleotide (AICAR) transformylase and glycinamide ribonucleotide (GAR) 
transformylase. All these folate dependent enzymes are involved in the pyrimidine (DNA) 
synthesis and the de-novo purine synthesis of DNA and RNA (1,2,18) (Figure 2). Of 
these enzymes, dihydrofolate reductase (DHFR) is the major one. The 7-OH MTX 
compound is a less active inhibitor of DHFR than MTX itself (18). Inhibition of DHFR 
leads to depletion of tetrahydrofolates (FH4). FH4s are essential for DNA, RNA and 
protein synthesis. 
3.4 DRUG INTERACTIONS 
In addition to the data mentioned in Chapter 4, the combination of MTX with other 
antifolate drugs such as trimethoprim and trimethoprim-sulfamethoxazole (=cotrimoxa-
zole), can increase myelosuppression or folate deficiency in some patients (19,20). 
3.5 DOSAGE OF MTX 
In Chapter 4 the dosage of MTX used in RA and other connective tissue diseases is 
discussed. In 1988 low-dose MTX (7.5-15 mg/wk) was approved by the Food and Drug 
Administration (FDA) for the treatment of RA (21). Unlike the situation in psoriasis 
(22), there appears to be little scientific rationale for use of the divided dosage regimen 
of three fractional dosages of 2.5 mg MTX every 12 hours in RA (23). The psoriatic 
epidermal cell has a rapid rate of proliferation: duration of psoriatic cell cycle 37.5 hours 
(hr) compared with 457 hr for the normal epidermal cell (22). Within the period of 36 hr 
almost all psoriatic cells would theoretically enter the MTX-susceptible S-phase [Le DNA 
synthesis period (16 hr)] of the cell cycle (22). 
3.6 LEUCOVORIN 
Leucovorin, the formyl derivative of folinic acid (Figure 2), is used as a 'rescue 
technique' to reduce MTX toxicity. The substance decreases the entry of MTX into the 
cells and repletes the intracellular pool of FH4. From uncontrolled and several placebo 
controlled studies, there are conflicting results about the influence of leucovorin on 
toxicity and efficacy of MTX. In two studies there was decrease in toxicity (e.g stoma-
titis) with unchanged efficacy (24,25) of MTX. In two other studies (26,27) there was no 
effect at all, whereas in one study there was decrease of MTX toxicity but worsening of 
RA activity (28). Probably, different clinical results may be caused by the wide range in 
used dosages (range 1 to 45 mg) and time of administering leucovorin [daily (25) or e.g 
on three consecutive days (28)]. Recently the results of an uncontrolled study (22), were 
confirmed by a double-blind study (29). In this trial folic acid supplementation 1 mg 
daily significantly lowered toxicity scores without affecting the efficacy of MTX during 6 
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months of low-dose therapy with MTX (29). In case of pancytopenia due to MTX (7.5-
15 mg/wk), leucovorin has been recommended as a 'rescue' therapy, in dosages of four 
times 10-20 mg daily until recovery occurs (30). 
3.7 CONTROLLED CLINICAL TRIALS OF MTX (See also Table 1) 
Double-blind trials of MTX compared with either placebo or with other second-line 
antirheumatic drugs in about 700 RA patients have proven the clinical efficacy of MTX 
beyond all doubt. Beside significant decrease in articular indices and disease variables 
such as morning stiffness and pain scores, significant decreases in several laboratory 
values such as ESR (31,32,33,34), rheumatoid factor (33) and immunoglobulins (31) 
were found. The percentage of withdrawals due to side effects of MTX was about 10% 
except for one study (30%) (33). 
Double-blind clinical trials in which MTX was compared with other second-line anti-
rheumatic drugs comprise five studies, our clinical study of AZA versus MTX excluded 
(Chapter 6). In two studies of MTX versus parenteral gold, both drugs had the same 
clinical efficacy (35,36). Side effects were more frequently found in patients treated with 
parenteral gold. Two studies in which azathioprine (AZA) was compared with MTX 
revealed the same clinical efficacy for AZA and MTX (37,38). The numbers of patients 
studied in the latter two trials, however, were too small (42 and 34 respectively) for 
definite conclusions. Recently MTX was found to be more effective and better tolerated 
than oral gold (auranofm) (39). 
In only one controlled clinical trial of MTX were radiographic data reported (37). 
Radiographic results from our double-blind study of AZA versus MTX are described in 
Chapter 7. 
3.8 LONG-TERM EXPERIENCE 
Using life table analysis the overall probability of continuing low-dose MTX in 152 
RA patients was 70 % after 1 year, 55% after 3 years and 50% after 6 years (40). These 
percentages form a positive contrast to the overall probability of less than 20% of three 
other second-line antirheumatic drugs after 5 years: 19% for sulfasalazine, 17% for D-
penicillamine and 8% for parenteral gold (41). Toxic effects (30%) rather than lack of 
effect (8%) were the major reasons for discontinuation of MTX. Gastro-intestinal toxi-
city, elevated liver enzymes included, was the most common side effect in the long run. 
Only the occurrence of side effects independently affected the overall probability of 
continuation of MTX. Other factors such as age, sex, and disease severity failed to affect 
it (42,43). 
37 
00 Table 1. Double-blind controlled trials (placebo controlled and comparing with other second-line drugs) of 
methotrexate in rheumatoid arthitis 
Author 
(ref) 
Number 
of 
patients 
Duration 
study (wk) 
2 x 
2 x 
2 x 
18 
26 
26 
6 
13 
12 
Dosage 
(mg/wk) 
+ drug 
10 i.m * 
vs 25 i.m 
vs placebo 
10-25 * 
i.m 
vs placebo 
7.5-15 * 
oral 
vs placebo 
7.5-15 * 
oral 
vs placebo 
12.5 MTX 
vs# 
50.0 AU 
i.m 
10.0 MTX 
vs# 
50.0 AU 
i.m 
Comments 
Thompson 
(34) 
Andersen 
(31) 
Weinblatt 
(32) 
Williams 
(33) 
Morassut 
(36) 
Suarez 
(35) 
48 
15 
35 
186 
35 
40 
After 6 wk placebo group switched to MTX, other 
groups continued MTX; MTX groups signif. impr. 
in all (6) disease variables; ESR also signif. impr. ; 
Side effects 30%, Withdr. side effects 4%. $ 
Crossover study; Signif. impr. in all (9) disease 
variables; ESR and Iggs also signif. decrease. No 
change in Latex, T-cells, and proliferation tests; 
Side effecu 26%, Withdr. side effects 7%. $ 
Crossover study; Signif. impr. in all (8) disease 
variables but grip strength; ESR and grip strength 
signif. decrease at 24 wk; Side effects 52%, 
Withdr. side effects 3%. 
Signif. impr. in all (13) disease variables; ESR and 
Latex signif. decrease; Withdr. side effects 30% 
(elevated liver enzymes most common). 
Both drugs similar efficacy; Signif. impr. in 9 (AU) 
and 7 (MTX) disease variables; ESR signif. de-
crease; Side effects MTX (35%), AU (50%), 
Withdr. side effects MTX (11%), AU (35%). 
Similar efficacy both drugs; Signif. impr. in 8 
(AU) and 6 (MTX) disease variables; ESR signif. 
decrease; Signif. more withdr. side effects in AU 
(33%) than MTX (11%). 
Table 1. continued 
Author 
(reO 
Number 
of 
patients 
Duration 
study (wk) 
Dosage 
(mg/wk) 
+ drug 
Comments 
Weinblatt 
(39) 
Hamdy 
(37) 
281 36 
Bell 
(38) 
42 
34 
52 
20 
7.5-15 MTX 
oral 
vs 6.0-9.0 
oral gold 
mg/d 
10-15 MTX 
oral 
vs 100-150 
AZA mg/d It 
10-15 MTX 
oral 
vs 100-150 
AZA mg/d 
- Signif. impr. in all (8) disease variables in both 
treatment groups; Response to MTX earlier and 
signif. better; Side effects gold (83%), MTX 
(73%), Withdr. side effects gold (44%), MTX 
(12%). 
- Similar efficacy AZA and MTX. ® 
- Similar efficacy AZA and MTX. 
* Mg weekly methotrexate 
# AU = parenteral gold (mg weekly); AZA = azathioprine; MTX = methotrexate 
$ ESR = erythrocyte sedimentation rate; impr. = improvement; Latex = rheumatoid factor; signif. = significant; withdr. = withdrawal 
@ More details are described in Table 2, Chapter 2 (Azathioprine) 
3.9 ADVERSE REACTIONS 
An overview of the different adverse reactions to MTX is given in Chapter 4. Some 
additional information about central nervous system (CNS) toxicity, hematologic toxicity, 
the risk of infections due to MTX and hepatotoxicity will be presented in this paragraph. 
CNS toxicity is a rare side effect of MTX. It comprises symptoms such as headache, 
dizziness, light-headedness and sometimes confusion and depression. CNS symptoms 
recurred after rechallenge with MTX in 5 RA patients (44). 
With regard to hematological toxicity sustained elevation of MCV (>104 fl) was 
recently found to be a predictor of impending hematologic toxicity (45). The duration of 
MTX therapy in 6 RA patients with hematologic toxicity (pancytopenia n=3; megalo­
blastic anemia, leucopenia, thrombocytopenia, all n = l) ranged between 13 and 62 
months. Four of 6 patients received leucovorin, 10 mg four times daily. Within 48 hours 
blood indices improved. 
Whether the risk of infections is increased in RA patients treated with MTX is 
unknown. In several large scale (retrospective) studies, 2 to 4% of patients experienced 
minor or major (e.g sepsis) infections during MTX therapy (42,46,47). In a case-control 
study no difference in number of infections between patients treated with azathioprine or 
MTX was found (47). From several studies there is lack of evidence of immunosuppres­
sive properties i.e. influence on T-cells of low-dose MTX (31,48). Reactivation of 
hepatitis В virus infection after discontinuation of MTX in one patient (49), Listeria 
meningitis in another patient (46) and Pneumocystis carinii infection in three patients 
(50,51,52) suggest an impairment of the (cellular) immune function in individual patients. 
In a recent retrospective study it was shown that peri-operative MTX therapy did not 
increase the risk of local postoperative complications or poor wound healing in RA 
patients undergoing total joint arthroplasty (53). 
The hepatotoxicity of low-dose MTX therapy in psoriasis has been established. The 
divergent percentages of fibrosis (4-35%) and cirrhosis (0-25%) in psoriasis patients 
treated with MTX are probably caused by differences in study design, dosage regimen 
and total weekly dosage of MTX, duration of follow-up and the presence of risk factors 
(see Chapter 4 and references 54,55,56,57). Furthermore fibrosis and cirrhosis in 
psoriatics not treated with MTX vary considerably (0-20%). Rapidly progressive liver 
disease with clinically important cirrhosis (ascites, esophageal varices) due to MTX 
therapy was reported in four case studies (58,59,60,61). A liver biopsy after a cumu­
lative dosage of 1.5-2.0 g MTX is still being recommended by dermatologists (62) and 
gastroenterologists (54). 
The lack of relevant MTX hepatotoxicity in RA patients after about 1.5-2.0 g MTX 
cumulatively, contrasts strongly with the reports in psoriasis (54). Probably, avoidance 
and awareness of risk factors (mainly alcohol abuse), lower weekly MTX dosage and -
speculatively- lesser propensity for liver damage in RA (54), may explain this 
observation. 
There is agreement among rheumatologists not to perform a pre-MTX liver biopsy, 
unless there is doubt about pre-existent liver disease (63,64,65,66,67). The necessity to 
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Table 2. Hepatotoxicity and low-dose methotrexate (MTX) in rheumatoid arthritis 
Author 
(reference) 
Di Bartholomeo 
(71) 
Mackenzie 
(72) 
Weinstein 
(73) 
Koo 
(74) 
Lanse 
(75) 
Tolman 
(76) 
Aponte 
(77) 
Willkens 
(78) 
Shergy 
(79) 
I^onard 
(80) 
Study 
design 
@ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Γ 
г 
Number 
of 
patients 
26 
60 
17 
82 
30 
29 
21 
59 
210 
29 
Weekly 
dose MTX 
in mg 
7.5-22.5 
7.5-22.5 
5.0-7.5 
2.5-12.5 
7.5-15.0 
7.5 
5.0-15.0 
η.m 
η.m 
7.5-15.0 
Mean dose 
of MTX 
cumulatively 
(range) 
± 1500 
± 1800 
(5004400) 
± 2000 
(915-3705) 
± 3100 
(727-8400) 
± 1500 
(227-6909) 
± 1500 
(787-3355) 
± 8800 
(4750-9990) 
± 1500 
(n.m) 
± 1500 
(1100-2500) 
± 1500 
(n.m) 
Fatty changes 
pre post 
MTX MTX 
(% of patients) 
* 
n.m 
n.d 
n.d 
37 
n.d 
n.d 
n.d 
n.d 
n.d 
n.m 
6%# 
71 
n.d 
37 
n.d 
5 
29 
n.d 
n.d 
Fibrosis 
pre post 
0 
0 
n.d 
0 
13 
n.d 
n.d 
n.d 
n.d 
n.d 
0 
1.5 
(IHa) 
35 
(H) 
5 
(Ша) 
13 & 
(gr n.m) 
33 
(Ша) 
25 
(Illa/b) 
21 
(gr n.m) 
3 
(gr n.m) 
34 
(Ша) 
Cirrhosis 
pre post 
0 
0 
n.d 
0 
0 
0 
n.d 
n.d 
n.d 
n.d 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
¡о Table 2. continued 
Author 
(reference) 
Ytterberg 
(81) 
Bjdrkmann 
(69) 
Rau 
(82) 
Brick 
(66) 
Kremer 
(65) 
Study 
design 
@ 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Number 
of 
patients 
22 
26 
40 
96 
27 
Weekly 
dose MTX 
in mg 
10.0 
η.m 
10.0-15.0 
7.5-25.0 
7.5-17.5 
Mean dose 
of MTX 
cumulatively 
(range) 
± 1000 
(n.m) 
± 2500 
(390-9100) 
± 1300 
(200-3000) 
1500-3400 
1400-3700 
Fatty changes 
pre post 
MTX MTX 
(% of patients) 
n.d 
n.d 
17 
38 
63 
5 
61 
17.5 
41 
43-57 
Fibrosis 
pre post 
n.d 
n.d 
15 
0 
0 
6 
(gr n.m) 
15.4 
(gr n.m) 
25 
(IIIa/b) 
3 $ 
ana) 
8-29 
(IIIa/b) 
·* 
Cirrhosis 
pre post 
n.d 
n.d 
0 
3 
0 
0 
0 
0 
2 
0 
@ 
* 
if 
& 
$ 
** 
n.m 
gr 
ρ = prospective; г = retrospective 
Pre MTX liver biopsies in only 4 patients (grade I or II Roenigk classification (62)) 
Liver biopsy findings in a control group of 25 patients with severe RA 
Pre MTX liver biopsies in 30 patients (9 RA, 18 psoriatic arthritis, 3 psoriasis) 
Pre MTX liver biopsies in 62 patients. Post MTX biopsies in 35 patients 
Measured annually after 2 years (26 patients) and 5 years (7 patients) 
Not mentioned; n.d = not done 
Grade of histologic abnormality in the liver according to the classification of Roenigk (62): grade I = normal; grade II = fatty 
infiltration, nuclear variability, portal inflammation; grade III = fibrosis mild (A) or severe (B); grade IV = cirrhosis 
obtain a liver biopsy after a cumulative dosage of 1.5-2.0 g MTX in RA patients, 
especially in those with no risk factors, remains an unsolved question. In 1987 the 
American College of Physicians recommended a liver biopsy after a cumulative dose of 
1.5 g MTX (63). In the meantime these guidelines have been adjusted and the authors 
(68) now suggest to individualize the decision and to perform a liver biopsy after 
weighing the relative risk of a liver biopsy (1 in 10.000 fatal) against the risk of liver 
damage (1 in 1000). Other authors no longer perform biopsies in low risk patients (65) 
or delay their decision until a cumulative dosage of 2.5 g MTX (66). 
In Table 2, fifteen recent, mostly prospective studies (65,66,69-82) on MTX and liver 
histology in RA patients are listed. Several conclusions can be drawn from the results of 
liver biopsies in about 750 patients: 
Firstly, no cirrhosis developed during MTX therapy. Secondly, there is a tendency to 
more fibrosis in the post-MTX group in some studies. Thirdly, the progression in fibrosis 
in some individual patients after sequential liver biopsies until 5 years was clinically 
unimportant (69). Additionally, in psoriatics with established cirrhosis who continued to 
use MTX, the course of the liver disease was mild and did not lead to overt liver disease 
(83). Fourthly, the experience in RA patients who have received a cumulative dosage of 
more than 2 g MTX is insufficient at this moment to allow determination of the ultimate 
effect of MTX on the liver after prolonged treatment (5-10 years). Therefore, long-term 
studies with serial liver biopsies are still needed. 
MTX induced liver damage can only be detected reliable by liver biopsies. Other (non-
invasive) tests such as repeated measurements of liver enzymes, hepatic ultrasonography 
and scans and aminopyrine breath tests are too insensitive (57,61,64,79). The implication 
of electron microscopic findings (increased number of lysosomes and collagen deposition 
in the perisinusoidal spaces in the liver) in RA patients treated with MTX is still unclear 
(69). Acute reversible hepatic failure due to low-dose MTX in RA has been reported 
(85). Recently it was demonstrated that the concomitant use of (hydroxy)chloroquine and 
MTX decreases the hepatotoxicity of MTX (86). The mechanism of this interaction is 
speculative. Levels of (hydroxy)chloroquine in the liver are several hundred times higher 
than in plasma. Perhaps the inhibitory effect of (hydroxy)chloroquine on (hepatic) lyso-
somes plays a part in this interesting interaction (86). 
In summary, when known risk factors with regard to hepatotoxicity of MTX are 
avoided, low-dose MTX therapy in RA is quite a safe treatment. 
3.10 FELTY'S SYNDROME 
Beside the data mentioned in Chapter 4 about the effect of MTX in extra-articular 
manifestations of RA such as Sjogren's syndrome and vasculitis, MTX was recently 
administered in another (uncommon) extra-articular feature of RA viz. Felty's syndrome. 
Felty's syndrome is characterized by splenomegaly and neutropenia. The cause of the 
neutropenia is probably multifactorial, e.g including abnormal Chemotaxis, reduced 
release of polymorphonuclear leucocytes (PMNs) from bone marrow, shortened lifespan 
of PMNs, interaction of PMNs with immune complexes and presence of IgG neutrophil 
antibodies (87,88). In three case studies (89,90,91), 6 RA patients with Felty's syndrome 
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were successfully treated with low-dose MTX (5-7.5 mg weekly). An elevation of 
neutrophil counts occurred within 1-2 months after starting MTX. Recurrent infections 
ceased in the majority of these patients. MTX was also able to decrease IgG anti-
neutrophil antibodies (89). 
3.11 FERTILITY, PREGNANCY, LACTATION 
MTX can pass the placenta and the drug has teratogenic properties (92). Three of eight 
pregnancies of women with RA, exposed to low-dose MTX in the first trimester, ended 
in spontaneous abortion (92). MTX has probably no effect on ovarian function in patients 
receiving high-dose MTX for malignancies (93,94a). Breast feeding during therapy with 
MTX is contraindicated because of potential toxicity (94b). In male patients with 
malignancy, severe oligospermia was observed, resolving after cessation of MTX therapy 
(95). Although there is one case report of MTX induced oligospermia on low-dose MTX 
(96), two other studies of 10 and 26 psoriasis patients respectively (97,98) revealed no 
unfavourable effects of MTX on semen quantity and quality. 
To our knowledge no oligospermia has been reported in RA patients treated with low-
dose MTX. Recently impotence was described in three RA patients; it improved after 
discontinuation of MTX (99). In view of the established teratogenic effect of MTX, 
adequate contraception during MTX therapy is absolutely indicated. Congenital malfor-
mations due to MTX comprise features such as multiple skeletal abnormalities and even 
anencephaly (100,101). There is no evidence of an increased incidence of congenital 
abnormalities in children bom of women who have been treated with MTX in the past 
(102,103). 
3.12 NEOPLASMS 
Large scale, partly retrospective, studies of psoriasis patients treated with low-dose 
MTX have revealed no increased incidence of malignancy (104,105). In view of the 
increased incidence of neoplasms in RA patients, regardless of their treatment (see 
section Azathioprine 'neoplasms'), the question whether MTX causes an excess of 
malignancies in RA is unsolved. There are only two small, uncontrolled series of 59 and 
78 RA patients in which 6 and no neoplasms, respectively, were found (107,108). One 
case report of a thymoma during MTX therapy has been published (108). Controlled, 
large scale studies concerning this issue are therefore highly necessary. 
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4.1 ABSTRACT 
Low-dose methotrexate (MTX) therapy is now widely used with considerable success in 
refractory rheumatoid arthritis. Experience with the drug in other connective tissue 
diseases and vasculitis has been limited. This article reviews hypotheses about the mode 
of action of MTX, pharmacology and pharmacokinetics, reasons to use cytotoxic agents 
in the different diseases, and results of MTX therapy. Risk factors, adverse reactions 
and drug interactions of MTX with other drugs are mentioned. Although based on a 
small number of patients, data about remarkable clinical improvement in polymyositis, 
systemic lupus erythematosus and vasculitis suggest that MTX is a potent and effective 
drug in connective tissue diseases other than rheumatoid arthritis. However, controlled 
trials are needed to assess the exact value of the drug in these diseases. Neth J Med 
1989; 35: 44-58. 
Key words: Methotrexate; Rheumatoid arthritis; Collagen vascular disease 
4.2 INTRODUCTION 
Since 1980, many reports have been published concerning methotrexate (MTX) therapy 
in rheumatoid arthritis (RA) refractory to other slow-acting antirheumatic drugs, such as 
gold salts and D-penicillamine. Uncontrolled studies and short-term randomized trials 
have demonstrated the efficacy of MTX in RA with acceptable side effects (1-3). 
Considering the enthusiasm and the number of reports on MTX administered in RA, it 
is surprising that controlled trials with MTX used in other connective tissue diseases 
(CTDs) are lacking. Experience with the drug in diseases such as polyarteritis nodosa 
(PAN) and systemic lupus erythematosus (SLE) has been limited to case reports. Poly-
and dermatomyositis are the only CTDs for which MTX has been administered in a 
larger number of patients. 
The purpose of our article is to discuss the mechanism of action of MTX and review 
the literature about the pharmacology, pharmacokinetics and clinical use of MTX in RA, 
other CTDs and vasculitis. Furthermore, we discuss the drug interactions and adverse 
reactions of MTX. Finally, we make some recommendations about the use of MTX. 
4.3 HISTORY 
In 1948, childhood leukaemia was the first disease in which MTX was administered. In 
1951, Gubner et al. (4) described a favourable effect of aminopterin in 3 patients with 
psoriasis, 3 out of 6 with psoriatic arthritis, 6 out of 7 with RA and one patient with 
lupus erythematosus (arthritis and skin lesions in remission). 
The impressive results with corticosteroids, reported at the same time, probably over-
shadowed the interest in MTX until approximately 1980. The only reports of experience 
with MTX in RA published during this time were those by Gross et al. and Hofmeister 
(5,6). Gross used a weekly intravenous dose of 50 mg MTX according to the dosage 
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recommended at that time by Miescher and Riethmüller (7) for collagen vascular 
diseases. During the 1960's MTX was successfully used in the treatment of severe, 
disabling psoriasis and the drug was approved for this indication by the Food and Drug 
Administration in 1971. Weinstein and Frost (8) recommended an intermittent regimen of 
MTX in three fractional doses at 12-hour intervals weekly. This regimen, based on the 
37-h cell cycle of the psoriatic epidermal cell, is still used by many dermatologists and 
rheumatologists. 
4.4 ANIMAL STUDIES 
Immunosuppressive effects of high-dose MTX have already been reported in animals 
and in man (9,10). MTX appeared to have a particular effect on the primary immune 
response (= cellular proliferative phase), but had little or no effect on secondary, de-
layed type hypersensitivity (11). Interpretation of the results of studies using different 
species of animal, different antigens and different modes of drug administration does, 
however, make extrapolation to human RA difficult. Several studies using animal models 
for polyarthritis, such as streptococcal wall arthritis and Freund adjuvant arthritis, have 
demonstrated the efficacy of MTX in suppressing the inflammation in joints and to some 
degree erosive damage (12-14). Inhibition of neutrophil Chemotaxis induced by leuko-
triene B4 and complement C5a in a mouse model, using low-dose MTX, has been 
demonstrated (15). The same effect of MTX had already been described in patients with 
psoriasis (16). In rat adjuvant arthritis it was recently shown that MTX inhibited both the 
influx of activated macrophages into the synovium and also products of macrophage 
activation such as interleukin-l (IL-1) and prostaglandin Ej (17). 
4.5 HYPOTHESIS CONCERNING THE MECHANISM OF ACTION OF MTX 
The cell specific (S phase of DNA synthesis) effect on the rapidly proliferating psoria-
tic cell and inhibition of penetration of leukocytes into the epidermis are grounds for 
treating psoriasis with MTX (8,16). However, the mechanism by which MTX decreases 
rheumatic synovitis has not been clearly identified. The synovitis in RA is a complex 
system of immune and inflammatory processes triggered by an unknown antigen. Several 
factors such as proteolytic enzymes, oxygen radicals, prostaglandins and lymphokines 
cause cartilage and bone damage. In this complex process the central and important role 
of the monocyte/macrophage as an antigen presenting cell to the T-cell has been es-
tablished (18). Due to this close cell-to-cell interaction stimulated by interleukins, B-cells 
are triggered to proliferate and produce immunoglobulins. 
In several studies MTX was shown to reduce the absolute number of circulating 
monocytes as compared with elevated pretreatment values (19,20). However, no effect 
was demonstrated on elevated T4/T8 ratios and in vitro proliferation responses of 
lymphocytes to mitogens (22,23). In the study of Andersen et al. (22) and in our study 
(24), a 20 to 30% decrease in immunoglobulins was found. In one study a significant 
decrease in IgM rheumatoid factor (radioimmunoassay) was demonstrated (23). 
Hypotheses about the mechanism of action of MTX postulated by various authors are: 
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inhibition of progenitor cells of macrophage/monocyte localized in the bone marrow 
(18,19), decrease of proliferation of synovial lining cells (20), interference with chemo-
tactic factors (15), decrease of IL-1 synthesis (17,25,26) and finally an inhibitory effect 
on activated macrophages (17,26). 
How MTX suppresses activity in other CTDs such as polymyositis (PM) and SLE is a 
matter for speculation. In 4 patients with CTD (3 SLE, 1 PM) MTX appeared to sup-
press the primary and secondary immune response associated with partial or complete 
remission (27). 
The relatively rapid onset of MTX in RA (mostly within 4 to 8 wk after initiation of 
treatment), together with the rapid relapse after discontinuation of MTX, suggests a more 
anti-inflammatory effect. The anti-inflammatory effect is possibly created by modulating 
the immune system due to influence on macrophages and/or lymphokines. 
4.6 PHARMACOLOGY AND PHARMACOKINETICS OF MTX 
MTX is classified as an antimetabolite due to folic acid antagonism. Competitive 
blockade of the enzyme dihydrofolate reductase (DHFR) causes inhibition especially of 
DNA synthesis and also RNA and protein synthesis (1). According to pharmacokinetic 
studies the serum level of MTX peaks about 2 h after oral or intramuscular administra-
tion. There is an important interindividual variation between the 24-h MTX serum 
concentration in the same patient when given orally or intramuscularly (28). Low-dose 
MTX kinetic studies in RA patients have revealed a triphasic half-life, resembling that in 
patients receiving high-dose MTX (29). RA patients receiving 7.5 mg or 15 mg weekly 
had about the same serum MTX levels 30 h after administration of the drug (30). 
Measurement of MTX serum levels in low-dose therapy is not of value in assessing the 
effective dosage in a patient, but may be of value in the case of a suspicion of toxicity 
(prolonged and high MTX levels) or in non-responders, who have very low MTX levels 
due to malabsorption (28). 
MTX is a weak acid with a pKa in the range 4.8 to 5.5 (1). It can precipitate in acid 
urine. Renal toxicity due to precipitation of MTX can occur with high-dose MTX but 
very rarely in a low-dose regimen (1). Fifty to seventy percent of MTX is bound to 
protein, mainly albumin. Drug interactions owing to displacement of MTX from albumin 
binding sites, will be discussed below. With regard to the triphasic disappearance of 
MTX, the initial half-life of 1-2 h represents body distribution, the second (2-4 h) renal 
clearance and the third phase (10 h) enterohepatic circulation and redistribution from so-
called third spaces as pleural and peritoneal cavities (31). In low-dose MTX therapy 
about 90-95% of the drug is found unchanged in the urine after 24-30 h (30). At low 
plasma MTX levels tubular reabsorption exists. At higher levels the clearance of MTX 
exceeds that of inulin, indicating active tubular secretion as well as glomerular filtration 
(31). 
The metabolite, 7-hydroxy MTX, found in the urine, may contribute to drug interac-
tions and nephrotoxicity of high-dose MTX (31-33). The significance of that metabolite 
in low-dose MTX is unknown. Accumulation of MTX in the liver occurs chiefly in the 
form of polyglutamates (30). These metabolites can also inhibit the enzyme DHFR (31). 
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Whether these polyglutamates and (severe) folate depletion are responsible for long-term 
toxicity is unclear (34,35). Perhaps some depletion of folate levels is necessary for a 
clinical response to MTX (35). Theoretically, resistance to MTX can be caused by 
extrinsic defects (malabsorption) or intrinsic factors such as decreased affinity to DHFR 
and increased levels of DHFR (35). In RA patients treated with MTX, DHFR levels 
were markedly increased (36). However, no correlation was found between clinical 
efficacy of MTX and the levels of DHFR. 
4.7 DOSAGE OF MTX 
The oral dosage of MTX recommended for RA is 7.5 to 15 mg weekly in one single 
dose or divided into three fractional doses at 12-h intervals. Some authors have used a 
higher dosage of MTX (25 mg) (22). In a study of RA patients in which 10 mg MTX 
was compared with 25 mg parenterally, the higher dose was not found to produce better 
results (37). However, the follow-up of 12 wk was short. There are no trials evaluating 
advantages of intramuscular MTX as compared with oral MTX. In cases of malabsorp-
tion, doubts about patient compliance and in some cases of gastrointestinal complaints, 
the intramuscular route can be used instead of the oral. 
The dosage of MTX administered in other CTDs such as polymyositis is mostly about 
50 mg weekly. That dose has been chosen empirically. It is recommended to increase the 
MTX dosage with weekly fractions of 10 to 15 mg to the final dosage of 50 mg (38). If 
the clinical situation has improved and stabilized, the frequency of drug administration 
can be reduced to biweekly or monthly. Although the intravenous route of MTX is 
sometimes used in the treatment of CTDs, there are neither convincing pharmacological 
data nor controlled trials to show that this route should be preferred to the intramuscular 
or the oral route (39). 
4.8 CLINICAL APPLICATION OF MTX: USE IN RHEUMATOID ARTHRITIS 
In uncontrolled trials comprising about 300 RA patients who received 7.5-25 mg MTX 
weekly, benefit has been found in 48 to 80% of patients with a distinct decrease in 
inflamed joints and erythrocyte sedimentation rate (1). Most of these studies lack 
prospective design and they differ in duration of follow-up, monitoring parameters and 
route of administration. In our own prospective open trial of MTX in refractory RA we 
found a statistically significant improvement in 12 of 14 patients with regard to clinical 
and laboratory variables, also after 12 months follow-up (24). Four placebo controlled 
and partly crossover trials of 300 RA patients have been performed. These short-term 
trials (12-18 wk) were comparable with regard to in- and exclusion criteria and moni-
toring parameters (22,37,40,41). The initial dose in these studies was 7.5 mg and if 
required increased to 15 mg after 6 wk. It was only in the study of Andersen (22) that 
the total dosage was increased to 25 mg. Calculations of the clinical benefit to the 
patients from these 4 controlled trials demonstrated a 39% reduction in pain, 37% 
reduction of joint count for tenderness and swelling and 46% reduction in morning 
stiffness related to a 95% confidence interval (42). The ultimate question whether MTX 
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is a disease modifying drug, i.e. whether the drug has the potential to retard radiographic 
progression, has to be evaluated in larger prospective trials. Kremer et al. have reported 
a disease modifying effect of MTX in an open prospective study in 7 of 11 patients after 
2 yr of treatment (43). In the same patients a sustained clinical improvement was found, 
which reached a plateau after about 6 months. In another study, MTX was effective in 
suppressing disease activity in the long-term, but a disease modifying effect was not 
demonstrated (44). In our opinion the conclusion of Nordstrom et al. (44) had been based 
on findings of too small a patient group. Moreover, the measure points for assessing the 
radiographs showed (too) much inter- and intra-individual variability (45). Finally in a 
recent prospective study of 14 patients with a mean follow-up of 3 yr (range 2.5-3.5 yr), 
worsening of radiographs (6 patients), no change (3 patients) but also healing of erosions 
(5 patients) was observed (46). 
4.8.1 METHOTREXATE AND POLY- AND DERMATOMYOSITIS 
Polymyositis (PM) and Dermatomyositis (DM) are inflammatory disorders of striated 
muscle. The pathogenesis of PM and DM has still not been completely elucidated, but 
there is some evidence that cytotoxic lymphocytes take part in the process of muscle 
inflammation and injury (38). In patients with PM and pulmonary fibrosis an increased 
percentage of anti-Jo-1 antibodies has been found, but the significance of these and other 
antibodies is still uncertain (38,47). Although not based on controlled studies, cor-
ticosteroids are the drugs of first choice in the treatment of PM/DM. The concurrent 
administration of cytotoxic agents such as azathioprine or MTX appears to be beneficial 
in suppressing immune mediated disease activity, steroid sparing effect or in cases of 
steroid resistance. A generally accepted definition of steroid resistance is lacking. Some 
authors define this point after 80 mg prednisone, others after 40-60 mg, administered 
daily for 1-3 months (48-50). Retrospective studies of MTX therapy for PM/DM have 
been listed in Table 1. Bohan et al. (48) suggested a better clinical response to MTX 
than to azathioprine and cyclophosphamide. The results of Medzger et al. (49) were 
impressive, with clinical improvement in 77% of patients and a marked steroid sparing 
effect of 30 mg prednisone daily after more than 1 yr of treatment. In nearly all patients 
benefiting from MTX therapy, CPK values normalized, muscle strength improved and 
skin disease and/or dysphagia resolved. 
Clinical response to MTX of PM/DM is reported between 4 to 20 wk after initiation of 
therapy. Normalization of muscle enzymes almost always precedes the improvement of 
muscle strength by several weeks. Pulmonary involvement in PM/DM is.an important 
cause of morbidity and mortality (47). Whether patients with PM/DM and pulmonary 
fibrosis have an increased risk of developing MTX pneumonitis, has to be evaluated. The 
prognosis of PM/DM patients treated with different immunosuppressive agents is still 
limited. With a follow-up of about 7-8 yr the cumulative mortality varies between 28 and 
47% (38). Prospective controlled trials are therefore necessary to evaluate the efficacy 
and safety of the different cytotoxic drugs especially MTX. 
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Table 1. Methotrexate therapy in polymyositis and dermatomyositis 
Author 
Malaviya 
Sokoloff 
Arnett 
Metzger 
Bohan 
(year) 
ι (1968) 
(1971) 
(1973) 
(1974) 
(1977) 
Patients 
with MTX 
(mg 
weekly) 
4 (25-100) 
7 (35- 60) 
5 (25- 50) 
22 (20- 75) 
25 (avera­
ge 42) 
Patients 
with 
concurrent 
prednisone 
(mg daily) 
3 (100 -150) 
6 ( 1 0 - 80) 
5 ( 20 - 50) 
22 ( 15 -100) 
24(40) 
Average 
follow-
up 
(months) 
6 
4-5 
7 
15 
52 
Results 
4 good clinical 
improvement 
5 good response 
4 good response 
17 good response; 5 
no response. 
Average reduction of 
steroid by 35 mg 
daily. 
16 improved; 6 
stable; 3 no response. 
Average reduction of 
steroids by 25 mg 
daily. 
4.8.2 METHOTREXATE AND SYSTEMIC LUPUS ERYTHEMATOSUS 
SLE is an immunologically mediated multi-organ disorder associated with the presence 
of a variety of circulating auto-antibodies and characterized by antigen-antibody interac­
tion, complement fixation and deposition of immune complexes in the tissues. A de­
creased number of T- and B-cells is a common manifestation in active SLE. In prolifera­
tive nephritis (Classes III and IV), inflammatory cells, mainly monocytes, are localized 
in the glomeruli. These cells may be partly responsible for the glomerular injury owing 
to release of proteolytic enzymes (54). Corticosteroids are still the drugs of choice in the 
treatment of SLE. Cytotoxic drugs, such as cyclophosphamide and azathioprine, can be 
beneficial in cases of nephritis, vasculitis, steroid resistance and undesirable steroid 
complications. 
MTX has only sporadically been used in the management of SLE. In 1965, 10 patients 
with SLE were treated with i.v. MTX, 50 to 100 mg weekly, with very rapid clinical 
improvement. Side effects were absent (7). Clinical improvement was reported in 6 SLE 
patients with severe systemic complications treated alternately with MTX 12.5-20 mg 
weekly and azathioprine 1.5-2.0 mg/kg/day (55). Successful treatment of one patient with 
severe SLE (vasculitis, pleuro-pericarditis) has recently been reported (56). In another 
recent study with a follow-up of 4-30 months, 6 of 11 patients improved (7.5 mg MTX 
weekly) (57). Despite caution in cases of decreased renal function, it is worthwhile 
evaluating the efficacy of MTX in both cutaneous LE as SLE. 
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4.8.3 METHOTREXATE AND SCLERODERMA, SJOGREN'S SYNDROME, 
MIXED CONNECTIVE TISSUE DISEASE 
As far as we know, MTX has not been administered in patients with Mixed CTD and 
primary Sjogren's syndrome. In one patient with RA and secondary Sjogren's syndrome 
treated with MTX, a favourable response of ocular manifestations was documented (58). 
Experience with MTX in scleroderma has also been limited to one study (59). In that 
study two patients were described: one with CREST syndrome (calcinosis, Raynaud, 
oesophagus dysmotility, sclerodactyly, teleangiectasia) and the other with diffuse sclero-
derma. Both patients were also suffering from Sjogren's syndrome with biopsy proven 
lesions in salivary and parotid glands. The renal function was normal. In the second 
patient there was significant pulmonary fibrosis. In both patients the general condition, 
flexibility of the skin and Raynaud phenomenon improved with 25 mg MTX biweekly 
(59). 
4.8.4 METHOTREXATE AND VASCULITIS 
The vasculitis in RA and SLE is mostly a leukocytoclastic vasculitis of the small 
vessels manifesting in cutaneous ulcers and/or purpura and nailfold lesions (60). In rare 
cases a severe vasculitis resembling PAN occurs. Vasculitis in RA is an expressions of 
the severity of the disease (61). 
Treatment of the underlying disease (61) is essential in the management of the 
vasculitis. In less severe forms without imminent organ dysfunction corticosteroids alone 
can achieve complete remission. In cases of rapidly deteriorating organ function addition 
of cytotoxic drugs is recommended. The striking response and improved survival of 
patients suffering from Wegener's granulomatosis and treated with cyclophosphamide (2 
mg/kg/day) and corticosteroids (initially 1 mg/kg/day) have led to the use of that regimen 
for other forms of severe vasculitis (61). 
However, trials comparing the efficacy and safety of the different cytotoxic drugs are 
lacking. Several case studies have reported successful treatment with MTX and cor-
ticosteroids in PAN (62-65), Wegener's granulomatosis (66), unclassified vasculitis and 
rheumatoid vasculitis (65,67,68). In these patients MTX was administered in doses 
between 10 and 50 mg weekly orally or parenterally. Tiliakos described the healing of 
severe rheumatoid ulcers unresponsive to cyclophosphamide and skin grafting with 10-15 
mg MTX weekly. The ulcers as well as the synovitis disappeared within 45-100 days 
(67). Another study reported a dramatic clinical response to 10 mg MTX weekly in 8 
patients with rheumatoid vasculitis (68). In other vasculitis syndromes such as Behcet 
disease or giant cell arteritis, no studies of MTX treated patients are known to us. 
Contrary to the beneficial effect of MTX on vasculitis, one author reported induction of 
small vessel vasculitis due to low-dose MTX (69). Whether subcutaneous nodules 
develop in RA during MTX treatment is debatable. In a controlled trial nodules receded 
more often than they appeared (41). 
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4.9 RISK FACTORS, DRUG INTERACTIONS AND ADVERSE REACTIONS 
TO METHOTREXATE 
Risk factors. MTX toxicity depends on several factors such as duration of exposure to 
the drug, interval of dosage (daily more toxic than weekly) (2) and susceptibility of 
target tissues, especially those with high cell turnover like bone marrow and gastrointes­
tinal epithelium. For each tissue there is a critical threshold level and minimal duration 
of exposure necessary for damaging that tissue (2). On the basis of large scale toxicity 
studies of psoriasis patients, the following risk factors were found to have an increased 
toxicity potential (70): diminished renal function (clearance <50 ml/min) (70,71), liver 
disease, alcoholism, leukopenia (<3.5 χ 10*/1), thrombocytopenia (<150 χ 1071), active 
peptic ulcer disease, active infections (e.g. pyelonephritis), obesity and diabetes mellitus. 
In RA the last two conditions are debatable as risk factors (2,71,72). Development of 
hypalbuminaemia during MTX therapy as a predictor of liver disease has to be confirmed 
(42). The problem of pre-existent lung fibrosis will be discussed below. 
Drug interactions. The mechanisms by which other drugs can increase the toxicity 
potential of MTX are: (a) displacement from albumin binding sites, (b) competition with 
renal tubular transport, (c) inhibition of renal excretion, and (d) impairment of MTX 
efflux from cells. In Table 2 the drugs are listed in which mechanisms (a) and (b) play 
an important role in drug interactions with MTX. The metabolite 7-OH-MTX (91-93% 
bound to protein) is probably more involved in drug interactions than the parent com­
pound (50-60% bound to protein) (33,73). Potentially nephrotoxic drugs such as amino­
glycosides and amphotericin В decrease the renal excretion of MTX (31,73). Simul­
taneous administration of low-dose MTX and NSAIDs rarely gives rise to nephrotoxicity 
(42). Reports about this side effect mainly concern high-dose MTX used in oncology (75-
77) or with pre-existent decreased renal clearance (79). Addition of diuretics to NSAIDs 
and MTX is potentially more dangerous (decrease of renal blood flow due to inhibition 
of renal prostaglandins). Examples of drugs impairing MTX efflux from cells are 
coumarin and probenecid (31). The combination of MTX with etretinate (vitamin A 
derivative) is probably more hepatotoxic (78). 
In contrast with drugs increasing MTX toxicity, there are drugs which decrease the 
effect (and toxicity) of MTX due to several mechanisms such as reduction of intestinal 
absorption (non-absorbable antibiotics), inhibition of cellular uptake (hydrocortisone, 
folates, cephalotin), elevation of the enzyme DHFR (triamterene) and accumulation of 
intracellular purines (allopurinol) (73). 
Adverse reactions (see Table 3). No HLA association between either side effects or 
clinical response to MTX has been found in RA patients (80-82). Gastrointestinal 
complaints (nausea, vomiting, diarrhoea) may be mild. In high-dose MTX severe 
gastrointestinal ulceration and haemorrhage have been reported (83). In low-dose therapy 
they are rare (80,84). In cases with mild gastrointestinal symptoms one can diminish the 
dosage of MTX or try to administer MTX intramuscularly. 
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Table 2. Drug interactions with MTX (increased toxicity potential) 
Competition tubular secretion Displacement albumin 
binding sites 
NSAIDs NSAIDs1 
Sulphonamides Sulphonamides2 
Diuretics Tetracyclines 
Penicillins Penicillins 
Probenecid Probenecid3 
Phenytoin 
Barbiturates 
Sulphon urea derivatives 
Coumarin and derivatives 
Rarely in low-dose MTX therapy. The combination NSAIDs + diuretics + MTX is potentially 
more dangerous (see text). 
Theoretically also additive folate antagonism. 
Increased toxicity also due to inhibition of MTX efflux from the cell. 
Elevation of liver enzymes was a frequent occurrence (10-58%), but led to cessation of 
therapy in only 5% of cases (85). Liver function tests do not predict the presence or 
development of liver fibrosis/cirrhosis (82,85,88). Levels of hepatic MTX polyglutamates 
or depleted hepatic folate levels do not correlate with either elevated liver enzymes or 
liver biopsy findings (30). It is recommended that MTX be temporarily discontinued, 
when elevated liver enzymes attain two to three times the normal value. In psoriasis 
patients there is probably an increased risk of hepatotoxicity after cumulative administra-
tion of 2-4 g MTX (86). Long-term studies in RA patients do not reveal increased liver 
toxicity after 2 g (= 5 yr of 7.5 mg MTX weekly) (43,85,87). Although there are data 
on liver biopsy findings in RA patients treated with 3-4 g MTX as compared with a 
control RA group (87), the number of patients is insufficient to allow determination of 
the ultimate effect of MTX on the liver. Although debatable, it is still recommended to 
obtain a liver biopsy after a cumulative dose of 1.5-2 g MTX (82,89). 
The clinical picture of MTX pneumonitis is characterized by fever, non-productive 
cough, dyspnoea, bibasilar rales on auscultation and hypoxaemia (90,91). The leukocyte 
count is mostly normal, with sometimes eosinophilia. Early in the course, the chest 
radiograph may be clear, but later on bilateral interstitial infiltrates develop and some-
times hilar adenopathy and pleural effusion. MTX pneumonitis has not been related to 
the cumulative dose, age or route of administration. The clinical course, together with 
the histological findings (93), suggests a hypersensitivity reaction. However, after 
rechallenge this side effect did not always recur (91). Pulmonary function tests after 2 
years of MTX therapy have revealed no substantial changes (92). 
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Table 3. Adverse reactions to methotrexate 
Frequent Less frequent Rare(<l%) 
Gastrointestinal Stomatitis Nephrotoxicity 
( 3-20%) (2-10%) Alopecia 
Elevation liver enzymes Haematological Dermal toxicity 
(10-58%) (0- 3%) Headache, dizziness 
Pulmonary Photosensitivity 
(0- 5%) Gynaecomastia 
Oligospermia 
Possible predisposing risk factors (pre-existent lung disease, other pneumotoxic drugs) 
have to be further evaluated (91,93). 
Important risk factors in the development of haematological toxicity (leucopenia, 
thrombocytopenia, megaloblastic anaemia, pancytopenia) are: impaired renal function, 
decreased serum albumin, pre-existent marrow abnormality and concurrent other drugs, 
especially sulphonamides (94). The possible influence on human folate metabolism, 
displacement of albumin binding sites and inhibition of tubular secretion are factors 
responsible for drug toxicity between MTX and trimethoprim-sulphamethoxazole 
(Bactrimel) (95,96). 
Rare side effects are dermal toxicity (urticaria, erythema, impetiginous lesions), 
photosensitivity (97), gynaecomastia (98), oligospermia (99) and possibly increased 
susceptibility to infections (100). Because MTX is teratogenic, adequate birth control 
measures have to be taken. Finally at this time there is no evidence that MTX is a 
carcinogenic drug (101,102), but further long-term prospective studies are necessary. 
4.10 CONCLUSIONS AND RECOMMENDATIONS 
In the past few years low-dose MTX (7.5-15 mg weekly) has become an important and 
effective second line drug in RA. The disease modifying effect of the drug, i.e. its 
potential to decelerate radiographic progression is not yet known because too few patients 
have been studied. The mechanism of action of MTX remains unclear, but it probably 
has anti-inflammatory and immune modulating properties. Although based on uncon-
trolled studies and sometimes a small number of patients, there are convincing data that 
MTX is a potent and effective drug in the treatment of several other rheumatic diseases 
and vasculitis. With the present knowledge of the pharmacology, drug interactions and 
risk factors and an adequate control scheme, the use of MTX in rheumatic diseases 
appears to be a quite safe procedure with acceptable side effects. Baseline blood and 
urine measurements should include: haemoglobin, leukocytes and differential count, 
platelets, hepatic enzymes, serum albumin, creatinine, ECC, urinalysis. 
Various drug monitoring schedules have been proposed for MTX, but they differ 
considerably in the time required to perform the blood tests (42,70,72,89,103). The 
guidelines we used in our department are partly based on the aforementioned schedules, 
but partly also on our own experience with MTX in RA. This control scheme is as 
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follows: during the first 4 wk, blood cell counts, and in the second and fourth weeks, 
renal and liver function tests as well. Thereafter (if the values are normal), monthly 
blood tests for the following 5 months. After 6 months (if there is a stable situation), 
blood tests every 1-2 months. 
Pre-treatment liver biopsies are only necessary in the case of suspected pre-existing 
liver disease. The need to perform a liver biopsy after a cumulative dose of more than 
1500 mg is debatable, but still recommended until more data are available (82,89). 
Baseline chest radiograph and pulmonary function tests (for instance spirometry, CO 
diffusion, arterial blood gas analysis) should strongly be considered (42). 
Adverse reactions focused on long and liver toxicity and the risk of malignancy have to 
be evaluated in long-term prospective studies. 
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5. i ABSTRACT 
Fourteen patients with severe rheumatoid arthritis refractory to hydroxychloroquine, 
gold-thioglucose, D-penicillamine and azathioprine completed a б-month open study 
with oral methotrexate (2.5 to 5 mg every 12 hours, three doses weekly). Twelve of 
them were followed up for 12 months. Compared with pretreatment values, there was a 
significant reduction in duration of morning stiffness (p<0.01), in the number of 
tender or painful joints (p<0.02), number of swollen joints (p<0.01), visual analog 
scale, patient's assessment of joint discomfort and overall well-being (p<0.01) after 2, 
6, and 12 months. Likewise there was an improvement in the erythrocyte sedimentation 
rate (p< 0.001), C-reactive protein (p<0.01) and the levels of IgG, IgM and IgA 
(p<0.01). Two patients were withdrawn from the study, one for severe diarrhoea and 
one because of a depression. Adverse reactions during methotrexate therapy included 
nausea (5/16) and transaminase elevation (4/16). We conclude that this pilot study 
provides evidence that a weekly low-dose of methotrexate is effective in the short-term 
treatment for patients with rheumatoid arthritis, refractory to hydroxychloroquine, 
aurothioglucose, D-penicillamine and azathioprine. 
Key words: Refractory Rheumatoid Arthritis, Methotrexate, Immunoglobulins 
5.2 INTRODUCTION 
Methotrexate (MTX), a folic acid antagonist, has already been used in the treatment of 
rheumatoid arthritis (RA) as early as 1951 (1). In spite of favourable effects of MTX, it 
was not until after 1980 that further reports in open (2-4) and double-blind controlled (5-
8) studies were published. In all these studies the patients had previous therapeutic failure 
or unacceptable side effects with gold salts and/or D-penicillamine. In West European 
countries patients of this category are usually treated with azathioprine and less often 
with cyclophosphamide (9-11). 
We report the antirheumatic efficacy and safety and the associated immunoglobulin 
changes during low-dose oral weekly methotrexate for patients with severe adult onset 
rheumatoid arthritis in whom hydroxychloroquine, gold-thioglucose, D-penicillamine and 
azathioprine had failed to produce a response or had been toxic. 
5.3 PATIENTS AND METHODS 
Patients 
Sixteen patients with classical or definite rheumatoid arthritis according to the 
American Rheumatism Association criteria (12) gave informed consent and entered into 
the predetermined protocol. All patients were Caucasian. Clinical characteristics of the 
patients studied are given in Table I. All patients had previously been treated with 
hydroxychloroquine, gold-salt therapy, D-penicillamine and azathioprine. These drugs had 
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Table 1. Characteristics of the 16 patients at the study entry 
Age (yr) 
mean 59 
range 45 - 70 
Female/male 9 / 7 
Disease duration (yr) 
mean 16 
range 5 - 33 
Functional class 
II 7 
III 9 
Rheumatoid factor 
Latex ¿1/80 14 
Waaler Rose ¿1/64 14 
HLA-DR4 positive 9 
Previous hip, knee or shoulder 
arthroplasty 5 
Prednisone (^ 10 mg daily) 8 
NSAIDs 16 
been discontinued because of ineffectiveness or toxicity. Except in cases of toxicity, each 
of these second-line antirheumatic drugs had been given for at least 6 months. Other 
criteria for entry were onset of the disease after the age of 16 and the presence of active 
disease, defined by at least 6 tender joints or painful on motion and 3 swollen joints and 
one of the following two features, 45 minutes of morning stiffness or a Westergren 
erythrocyte sedimentation rate (ESR) > 2 8 mm/hour. All of the patients were taking 
contraceptive precautions if appropriate. Excluded from the study were patients with a 
history of renal, liver or cancer disease, liver enzyme levels 2 times the upper limit of 
normal, abnormal serum creatinine levels ( > 1 2 0 /imol/1), insuline-dependent diabetes, 
alcoholism, active peptic ulcer disease, white cell counts < 3 . 5 χ lO'/I, platelet count 
< 150 χ 10'/ and functional class IV according to the criteria of Steinbrocker et al. (12). 
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) was permittted. 
Dosage of these drugs was kept constant from one month prior to the start of MTX 
therapy until the end of the study period. A maximum dose of 10 mg prednisone daily 
was allowed. Decrease of the dose was allowed during the study. All changes on dose of 
prednisone were recorded. The study protocol was approved by the Ethics Committee of 
the hospital. 
Administration of MTX 
MTX tablets of 2.5 mg were ingested in equal numbers on three consecutive occasions 
at 12-hour intervals beginning on the same day of each week. For the first 8 weeks, 
three tablets were taken weekly. At 8 weeks thereafter the dose could be increased to six 
tablets weekly if no satisfactory response was noted by the investigator. Satisfactory 
response was defined as a decrease of at least 30 percent compared with the pretreatment 
values of all of the following clinical disease variables: 1) duration of morning stiffness, 
2) Ritchie articular index, 3) the patient's overall assessment of disease activity and well-
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being on a visual analog scale (VAS). In case of side effects the doses could be dimini­
shed to S mg weekly, given on two doses of 2.5 mg 12 hours apart. 
Clinical assessments 
Each patient was examined monthly for 6 months and then every 2 months by the same 
investigators (AB or HT). The clinical disease variables determined at each visit consis­
ted of: 1) duration of morning stiffness, 2) the patient's overall assessment of disease 
activity and well-being on a visual analog scale (VAS) of 10 cm with a score of 10 being 
the worst (100%) and 0 being absent or normal (0%) respectively, 3) number of diarthro-
dial joints with swelling, 4) number of joints with tenderness on pressure and/or pain on 
passive motion, 5) Ritchie articular index (13), 6) functional class according to Stein-
brocker (14), 7) daily prednisone consumption in mg. Joints with prosthesis or ankylosis 
and joints which received intra-articular injections during the study were excluded from 
analysis. 
Laboratory assessments 
Laboratory tests for drug toxicity were obtained every week during the first month, 
monthly during the following 5 months and then every 2 months. These tests included 
haemoglobin concentration (Hb) leucocyte count and white blood cell differentiation, 
platelet counts, serum levels of creatinine, serum glutamic oxaloacetic transaminase, 
glutamic pyruvic transaminase and alkaline phosphatase. Serum was also analyzed for 
titers of rheumatoid factor (Latex fixation and Waaler-Rose test), C-reactive protein 
(radioimmunodiffusion assay), Westergren erythrocyte sedimentation rate (ESR), concen­
trations of immune complexes by a Clq-binding assay (15), quantitative determination of 
immunoglobulin levels of IgG, IgM and IgA class (16); urinalysis of protein excretion 
were performed every 2 months. 
The mean ESR of the patients one year before entering the study was 59 mm/h. The 
ESR was measured every 2 months. Methotrexate was withheld, if the white blood cell 
count decreased below 3.5 χ lO'/l, the platelet count decreased below 150 χ l(f/l, the 
creatinine level rose above 130 μπιοΙ/Ι, or liver enzymes increased to more than twice 
the upper limit of normal. These tests were repeated weekly until normalisation of the 
test(s). Thereafter methotrexate therapy was restarted in an equal or lower dose. 
IILA typing 
HLA typing was done with standard NIH microlymphocytotoxicity techniques. DR 
typing was done on B-lymphocyte enriched suspensions obtained after resetting with 
AET-treated sheep red blood cells. A control group consisting of 66 patients with definite 
or classical RA were also DR typed (17). All sera were standardized according to the 8th 
and 9th International Histocompatibility Workshop sera. 
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-j Table 2. Clinical and laboratory changes (mean ± SEM) at entry and after 2 and б months methotrexate treatment 
"^  in 14 patients 
Variable 
Duration of morning stiffness 
(min) 
No. of joints tender to pressure 
or painful on passive motion 
Ritchie-articular index 
No. of swollen joints 
Visual analog scale joint dis­
comfort and overall well-being 
(0-100%) 
Westergren sedimentation rate 
(mm/h) 
C-reactive protein (mg/1) It 
Hemoglobin (mmol/1) 
Immunoglobulin levels (g/1) * 
IgG 
IgM 
IgA 
Prednisone (mg/day) 
Entry 
98 + 22 
21.3 ± 3.7 
20.1 + 3.2 
16.9 ± 1.5 
63.8 ± 5.1 
65.6 ± 8.2 
45.9 ± 6.5 
7.2 ± 0.4 
16.8 + 1.4 
2.9 + 0.5 
3.6 ± 0.3 
5.0 ±5.0 
2 months 
52 ± 17 
14.5 ± 3.1 
12.4 ± 2.4 
11 ± 0.9 
38.2 ± 3.2 
37.4 ± 4.3 
26.1 ± 6.5 
7.4 ± 0.3 
14.6 ± 1.3 
2.5 + 0.5 
3.1 ± 0.2 
5.0 ± 1.5 
Ρ 
< 0.002 
<0.02 
0.001 
0.001 
0.002 
0.001 
0.01 
NS 
<0.01 
0.002 
0.001 
NS 
6 months 
47 ± 16 
14.1 ± 3 
12.2 ± 2.2 
10.8 ± 1.8 
36.8 ± 7.3 
33.8 ± 7.1 
16.0 ± 3.9 
7.8 ± 0.3 
13.0 ± 1.0 
2.3 ± 0.4 
2.8 ± 0.3 
3.5 ± 1.2 
Ρ 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
< 0.001 
<0.01 
NS 
< 0.002 
<0.01 
< 0.002 
NS 
If Normal serum C-reactive protein < 8.6 mg/1 
* Normal serum immunoglobulin concentrations (mean ± SD): IgG 12.5 ± 2.1 g/1, IgM 1.1 ±0.4 g/1, IgA 2.0 ± 0.6 g/1 
Statistical analysis 
Continuous disease variables were analyzed using the Student's t-test for paired sam-
ples, comparing changes after 2, 6 and 12 months therapy with the entry visit in the 
same patients. A value of <0.05 was considered to be statistically significant. 
5.4 RESULTS 
Patients and study course 
Sixteen patients fulfilled the 4 entry criteria of active disease and started with MTX 
therapy. Fourteen patients completed 6 months of the protocol and 12 patients completed 
12 months. Two of 16 patients were excluded from analysis due to side effects. One 
patient was withdrawn because of diarrhoea two weeks after initiation with methotrexate 
and one was withdrawn after 2 months of therapy because of complaints from depres-
sion. Two other patients were withdrawn because of unsatisfactory results after 6 months 
of therapy. The weekly doses of methotrexate could be maintained at 7.5 mg during the 
study in 9 patients. It had to be increased to 15 mg in 3 patients because of inefficacy 
and decreased to 5 mg in 2 patients because of side effects. 
All patients had concomitant medication of NSAIDs. The prednisone dosage could be 
decreased in 4 patients (Table 2). 
Effects on disease 
Significant improvement occurred in 12 of the 14 patients who were followed over a 6-
month period. In comparison with entry values improvement was noted at months 2 and 
6 in the duration of moming stiffness, the number of joint discomfort and overall well-
being. Also the erythrocyte sedimentation rate and the C-reactive protein improved signi-
ficantly. Haemoglobin was slightly increased from 7.2 (SEM 0.4) to 7.8 (SEM 0.3) after 
6 months of methotrexate therapy (Table 2). 
Figure 1 and 2 show the clinical and laboratory improvement in the 12 patients who 
were followed-up for 12 months. A marked improvement in these patients was already 
seen after one month of therapy increasing up to 6 months; thereafter changes were 
minimal 
Changes in serologic tests 
No significant changes in mean rheumatoid factor titres and Clq-binding were 
associated with methotrexate therapy. Rheumatoid factor titers decreased in the Latex 
fixation test by two tube dilutions in 3 patients and increased by 2 tube dilutions in one 
patient during the treatment with methotrexate. All the immunoglobulin levels in the 
patients studied were increased before methotrexate therapy and decreased significantly 
after methotrexate treatment. Decreases of serum IgG, IgM, IgA levels were respectively 
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Figure 1. Mean changes in selected clinical variables in 12 patients after methotre­
xate therapy. 
percent i m p r o v e m e n t 
8 0 • Ritchie articular index 
о No of joint tenderness 
о No of joint swelling 
8 10 12 
months a f t e r e n t r y 
23%, 21% and 22% after 6 months of methotrexate therapy in 14 patients. The decrease 
of the immunoglobulins in the 12 patients with a follow-up of 12 months showed a 
progressive decrease till approximately 6 months (Figure 2). Only the IgG and IgA levels 
decreased to normal values. 
No difference in HLA-DR4 frequency between these RA patients (9 out of the 16, 
56%) and the RA control group (36 out of the 66, 55%) was found. 
Toxicity 
Serious side effects during methotrexate therapy were noticed in one patient who 
developed severe diarrhoea after 2 weeks of methotrexate therapy (cumulative dose 15 
mg). Without the drug the diarrhoea resolved during a six-day hospitalization. Methotre­
xate therapy was not restarted in this patient. Another patient developed a depression; 
after 3 months the methotrexate therapy was restarted, but now intramuscularly. The 
depression did not disappear after stopping MTX. During 12 months of methotrexate 
therapy, 8 of 16 patients (50%) had one or more types of adverse reactions, chiefly 
gastrointestinal or elevated transaminase levels (Table III). These side effects were mild 
and disappeared after the medication was decreased or withheld for a short period. 
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Time sequence of chan-
ges in erythrocyte sedi-
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tive protein, IgM, IgA 
and IgG serum levels. 
Data are presented as 
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5.5 DISCUSSION 
Treatment of patients with severe longstanding rheumatoid arthritis refractory to 
hydroxychloroquine, gold-salt, D-penicillamine and azathioprine is a difficult problem. 
Data on treatment with methotrexate for these groups of patients are lacking. In this 
prospective open study, most of these patients treated with a weekly low-dose methotre-
xate therapy showed a marked clinical improvement after 2, 6 and 12 months. The 
results of this study were in accordance with uncontrolled (2-4) and controlled (5-8) 
reports, in which the patients were at least resistant to gold and/or D-penicillamine. 
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Table 3. Adverse reactions and withdrawals during methotrexate therapy in 16 
patients 
Adverse reaction 
Elevated transaminase 
Nausea 
Vomiting 
Diarrhoea 
Abdominal pain 
Anorexia 
Headache 
Depression 
No. of patients 
4 (25%) 
5(31%) 
No. of withdrawals 
(months after MTX) 
1 (1/2) 
1(2) 
Improvement of all clinical variables measured was associated with a decreased ery-
throcyte sedimentation rate, C-reactive protein and immunoglobulin levels IgG, IgM and 
Ig A. Decreases of IgG, IgM, IgA in approximately the same magnitude, as in our study, 
were also described by Andersen et al. (5) in a double-blind methotrexate-placebo study. 
It was not, however, established in a double-blind methotrexate-azathioprine trial (18), 
but in that study the exact values of immunoglobulin levels were not noted. A possible 
reason for the difference in results could be the fact that the immunoglobulins were not 
or less increased at the start of methotrexate. Two patients did not complete the 6 month 
study, one because of severe diarrhoea and one because of depression, the latter probably 
not being related to methotrexate therapy. Two other patients were withdrawn because of 
unsatisfactory results after 6 months therapy. Gastrointestinal problems (31 percent) and 
transaminase elevation (25 percent) were the most common adverse reactions to metho-
trexate in this open study. These side effects disappeared after diminishing the metho-
trexate dosage. 
Reported frequencies of minor side effects as stomatitis, nausea, abdominal cramps, 
diarrhoea, malaise and liver function test abnormalities ranged from 6.25% to 63.9% 
(5,7,19). The close control of the patients which enabled us to detect early signs of 
toxicity and stop the medication and the small number of patients in our study may 
explain why the most serious side effects that can occur with low-dose methotrexate 
administration, e.g. bonemarrow suppression (20) or acute pulmonary toxicity (21,22,23) 
were absent. The dosage schedule selected for this study was based on experience with 
methotrexate treatment of psoriasis. Weinstein and Frost (24) suggested a regimen of 3 
doses weekly at 12-hour intervals to provide a pharmacologic effect for the 37-hour cycle 
of rapid psoriatic cell turnover. However, there appears to be little difference in therapy 
for patients with psoriasis between this regimen and that in which methotrexate is given 
in a single weekly dose (20). To our knowledge there is no double-blind study in patients 
with rheumatoid arthritis, in which a series of three divided doses administered on an 
intermittent oral schedule over a 36-hour period each week is compared with a single 
weekly oral dose. 
Only in 3 out of the 12 patients with a follow-up of 12 months was the dosage 
increased from 7.5 to 15 mg methotrexate after 2 months of therapy. In the double-blind 
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placebo-methotrexate multicentre study of Williams et al. (8) the dosage was increased 
after 6 weeks of therapy in 2/3 of the patients. There were many differences, however, 
among their patient population and ours. 
In conclusion, this open pilot study shows that patients with rheumatoid arthritis, 
unresponsive to or with a toxic reaction to hydroxychloroquine, gold, D-penicillamine 
and azathioprine and able to tolerate low-dose pulse methotrexate therapy, improved 
significantly with methotrexate therapy. Side effects were common, but mild, except in 
one patient with severe diarrhoea. All side effects disappeared after discontinuation of the 
drug. Of course, lengthy prospective trials with a greater number of patients are required 
to determine the ultimate place of methotrexate in the treatment of patients with severe 
recalcitrant rheumatoid arthritis. To compare the efficacy and the safety of methotrexate 
and azathioprine in the treatment of refractory RA, we started a double-blind trial. 
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6.1 ABSTRACT 
We conducted a double-blind, randomized trial comparing azathioprine (AZA) and 
methotrexate (MTX) in the treatment of patients with rheumatoid arthritis in whom 
parenteral gold and/or D-penicülamine treatment had been unsuccessful. Patients were 
randomly assigned to receive either AZA (100 mg daily) or oral MTX (7.5 mg weekly). 
After 8 weeks, the dosage was increased depending on the clinical improvement. Sixty-
four patients were followed up for 48 weeks (33 AZA, 31 MTX). Comparison of values 
at week 24 with baseline values revealed significant improvement in 12 of 13 disease 
variables in the MTX group and in 6 of 13 in the AZA group. Comparison between the 
2 treatment groups at 24 weeks, by area-under-the-curve analysis, showed significantly 
more improvement in the MTX group in terms of the swollen joint count, pain score, 
erythrocyte sedimentation rate, C-reactive protein level, hemoglobin level, thrombocyte 
level, and disease activity score. A significant overall clinical improvement (disease 
activity score) was found in 7 of 20 patients treated with AZA and 18 of 30 patients 
treated with MTX qfter 24 weeks of therapy, and in 6 of 12 AZA-treated patients and 
19 of 25 MTX-treated patients qfter 48 weeks. The number of withdrawals due to side 
effects was significantly higher in the AZA group. After 48 weeks, only 12 patients 
from the AZA group (36%), but 25 from the MTX group (81%), were still using the 
initial drug. These results demonstrate MTX to be superior to AZA in the treatment of 
rheumatoid arthritis, with a more rapid clinical improvement which is sustained after 1 
year, accompanied by a lower rate of serious adverse reactions. 
6.2 INTRODUCTION 
The role of cytotoxic drugs, especially low-dose methotrexate (MTX; 7.5-15 mg week-
ly), in the treatment of rheumatoid arthritis (RA) is currently the subject of much debate 
(1-3). Since immune mechanisms are considered to play a crucial role in the pathogenesis 
of RA, immunosuppressive, cytotoxic drugs have been used in RA for many years, but 
almost exclusively in disease that has already been demonstrated to be refractory to other 
disease-modifying antirheumatic drugs. Until recently, most rheumatologists in Western 
Europe have used azathioprine (AZA) or, less often, cyclophosphamide, to treat RA 
patients in whom parenteral gold and/or D-penicillamine (DP) have been ineffective 
and/or have produced side effects (4). In an open study, we have demonstrated the 
clinical efficacy of MTX for patients whose RA had failed to respond to, or who had 
unacceptable side effects from, hydroxychloroquine, aurothioglucose, DP, and AZA (5). 
Many controlled trials have compared AZA with other second-line drugs in the treatment 
of RA at all stages, and have not demonstrated superiority of AZA (6-11). In RA 
patients not previously treated with second-line drugs, low-dose MTX was found to act 
earlier than parenteral gold, but its efficacy was similar to that of the gold (12,13). 
Studies of the value of MTX treatment in advanced RA that has been unresponsive to 
parenteral gold and/or DP have consisted of placebo-controlled trials (14-17) and long-
term, open prospective trials (18-21). 
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To date, 2 short-term, double-blind studies comparing AZA with MTX in the treatment 
of RA have been reported (1 in abstract form) (22,23). No statistically significant dif-
ferences were found between the 2 drugs, but there was a trend toward more efficacy in 
the MTX group. The number of patients in these studies, however, was small. To obtain 
more data about the role of MTX in the treatment of RA patients who have experienced 
side effects or lack of efficacy with parenteral gold and/or DP, we conducted a double-
blind trial comparing AZA and MTX, focusing on the efficacy and toxicity of both 
drugs. Influences on serologic and immunologic parameters were also evaluated. 
6.3 PATIENTS AND METHODS 
Patients. To participate in the trial, patients were required to meet the following 
criteria: 1) active classic or definite rheumatoid arthritis according to the 1958 criteria of 
the American Rheumatism Association (ARA) (24) (patients also fulfilled the 1987 
revised ARA criteria for RA (25); 2) active disease defined by the presence of ¿ 3 
swollen joints, ^ 6 joints that were painful or tender on motion, erythrocyte sedimenta-
tion rate (ESR) ^28 mm/hour, and morning stiffness of >45 minutes (at least 3 of these 
4 features had to be present); 3) age between 16 and 75 years; and 4) unsuccessful 
treatment with parenteral gold, DP, or both (lack of efficacy after a minimum treatment 
period of 6 months or development of unacceptable adverse effects). Exclusion criteria 
consisted of 1) previous therapy with AZA or MTX; 2) childbearing potential; 3) 
functional class IV according to the Steinbrocker criteria (26); 4) acute or chronic 
infection (e.g., pyelitis, tuberculosis); 5) obesity (>15 kg above ideal body weight); 6) 
liver function abnormality, defined as the result of any liver function test exceeding twice 
the normal value, or presence of a known liver disease; 7) renal disease, defined by a 
serum creatinine level >130 μΓηο1ε5/ΗΐεΓ and/or a creatinine clearance rate of <50 
ml/minute as estimated according to the method of Cockcroft and Gault (27); 8) hemato­
logic abnormality e.g., leukocyte count <3.5 χ lO'/liter or platelet count < 150 χ 
lO'/liter; 9) malignancy; 10) insulin-dependent diabetes mellitus; 11) alcoholism or alco­
hol abuse ( > 4 oz/day); 12) use of other antifolate drugs (such as sulfonamide deriva­
tives) or allopurinol; 13) active peptic ulcer disease; 14) history of poor compliance with 
medication regimens. 
Study design. Sixty-four eligible patients from 5 different clinics were enrolled in the 
trial, during the period November 1986 through November 1988. The protocol was 
approved by each institution's ethics committee, and each patient gave informed consent 
prior to study entry. Medical treatment and clinical evaluation of all patients was 
performed by the same rheumatologist (MECJ). All clinical evaluations were performed 
at roughly the same time of the day. Other second-line-drugs were discontinued at least 4 
weeks before study entry. 
The first phase of the study was a double-blind, parallel trial of 24 weeks duration. 
Patients who showed good response were continued in the double-blind trial until the 
forty-eighth week. Those who were partial or poor responders began an open phase of 
treatment, also until the forty-eighth week. Patients were randomly allocated to either the 
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MTX group or the AZA group in blocks of 6 patients, stratified for functional class II or 
III. All patients were followed up on an outpatient basis as much as possible. Seven of 
the 64 patients were hospital inpatients at the start of their therapy. 
As in other studies (10,12,16,17) good (or marked) improvement of a disease variable 
was defined as ^50% improvement over the initial value, partial (or moderate) response 
as 30-49% improvement, lack of response (stable condition) as 0-29% improvement, and 
worsening if the final values were worse than the initial values. We used a definition of 
"overall" clinical improvement that was based on the following parameters, similar to 
those used to define active RA in the study inclusion criteria: 1) patient's pain assess-
ment, using a 100-mm visual analog scale (VAS; 0 mm = no pain and 100 mm = very 
severe pain); 2) Ritchie articular index (28); 3) ESR; 4) morning stiffness. Good overall 
improvement was defined as ^50% improvement in at least 3 of these 4 disease 
variables, partial (moderate) improvement as 30-49% improvement in at least 2 of the 4 
variables (and no worsening in the other variables), stable disease as 0-29% improvement 
in the 4 disease variables, and worsening as deterioration in the variables compared with 
baseline values. 
In patients who had less than moderate overall improvement 8 weeks after start of the 
trial, the dosage of the study drug was increased. Depending on a patient's overall 
clinical improvement at 24 weeks, it was decided whether the double-blind procedure 
should be continued. The study drug was withdrawn in patients with no effect, worse-
ning, or serious adverse reactions. Patients in whom the initial study drug was withdrawn 
received the alternative drug in an open phase (i.e., AZA instead of MTX, and vice 
versa), unless there were contraindications. In order to assess disease activity in one 
composite score without the need of correction for multiple statistical testing, we used the 
previously validated disease activity score (DAS), which includes the variables Ritchie 
articular index, number of swollen joints, ESR, and general health (by VAS) (29,30). To 
measure patient compliance, remaining pills were counted every 2 months. 
Medication regimens. Using a double-dummy technique, all patients were initially 
given the normal dosage of the study drug, i.e., either 2 daily tablets each containing 50 
mg AZA with 3 weekly placebo capsules resembling MTX (in 3 divided doses every 12 
hours) or 3 weekly capsules each containing 2.5 mg MTX with 2 daily placebo tablets 
resembling AZA. Depending on the clinical effect after 8 weeks, the dosage was 
increased to either 150 mg AZA daily with 6 MTX placebo capsules weekly or 15 mg 
MTX weekly with 3 AZA placebo tablets daily. If toxicity occurred, trial medication 
could be temporarily reduced to 50 mg AZA/day or 5 mg MTX/week. 
The dosages of nonsteroidal anti-inflammatory drugs (NSAIDs) and prednisone (<10 
mg daily) were kept stable for at least 4 weeks before study entry. Patients were 
instructed not to change the dosage of any medication throughout the study. Intra-arti-
cular corticosteroid injections were administered only in rare instances. Injected joints 
and joints on which surgery had been performed were excluded from all assessments. 
Clinical assessment. Eight clinical variables were assessed monthly during the first 6 
months and every 2 months thereafter, until the forty-eighth week. These were (a) 
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Ritchie articular index (possible range 0-78); (b) number of swollen joints (possible range 
0-46); (c) number of tender joints (possible range 0-53); (d) patient's assessment of pain, 
using a 100-mm VAS (possible range 0-100); (e) patient's general health assessment, 
using a VAS; (0 morning stiffness; (g) grip strength, using a sphygmomanometer (Tono­
meter, von Recklinghausen, FRG) (possible range 0-300 mm Hg; the mean value of 3 
measurements of each hand was recorded); (h) functional class according, to the Stein-
brocker criteria. 
Adverse reactions and withdrawals from the study. At each visit, patients were 
routinely questioned about symptoms possibly related to AZA or MTX toxicity. Minor to 
moderate toxicity (e.g., gastrointestinal [GI] symptoms, stomatitis) sometimes required 
dosage adjustment or temporary discontinuation (1-3 weeks) of trial medication. Trial 
medication was temporarily withheld if the leukocyte count decreased to <3.5 χ lO'/liter 
or the platelet count to <150 χ lO'/liter, if the serum creatinine level rose to >130 
^moles/liter, or if liver enzyme levels exceeded twice the upper limit of normal. Patients 
were permanently withdrawn from the initial treatment if they experienced severe adverse 
reactions or if their clinical condition deteriorated to such an extent as to necessitate 
other therapy. Permanent withdrawal also occurred if patients failed to take trial medica­
tion or to keep scheduled clinic appointments. 
Laboratory assessment. During the first month of treatment, hemoglobin (Hgb) levels 
and leukocyte (and differential count) and platelet counts were measured weekly, and 
kidney and liver function were assessed (by measurement of serum creatinine levels, and 
gamma glutamyl transferase (GGT) levels, alkaline phosphatase, serum aspartate amino­
transferase (AST), and serum alanine aminotransferase (ALT) respectively) every 2 
weeks. Thereafter, these values were obtained every 4 weeks. The following laboratory 
variables were measured every 4 weeks from the initiation of treatment: ESR (Wester-
gren), C-reactive protein (CRP), mean corpuscular volume. The estimated creatinine 
clearance rate was calculated at baseline and at 24 weeks and 48 weeks. Urinalysis, 
measurement of total serum protein and serum protein electrophoresis, and testing for 
serum IgA, IgG, IgM, antinuclear antibody, rheumatoid factor (RF; by the latex fixation 
and Rose-Waaler methods), C3, and C4 were performed every 8 weeks. Patients were 
regarded as RF positive if the latex fixation titer was > 1:80 and/or the Rose-Waaler titer 
was >1:64. Tissue typing for HLA-A, B, and D phenotypes was performed using 
standardized sera from the 8th and 9th Intemational Histocompatibility Workshops. To 
obtain uniformity in testing methods and laboratory units used with patients from the 5 
cooperating clinics, all laboratory tests were performed at University Hospital, Nijmegen, 
except for ESR, blood cell counts, and kidney and liver function tests. 
Statistical analysis. Because patients were randomly assigned to the 2 treatment groups, 
there was only a 5% chance of statistically significant differences occurring in baseline 
variables. Nevertheless, we investigated the validity of the treatment group allocation 
procedure, using standard statistical tests. The differences in baseline and demographic 
characteristics were assessed using the chi-square test for nominal variables and Student's 
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2-tailed test for other variables, such as age and duration of RA. 
After 24 weeks of treatment, all clinical data were analyzed using 2 different 
approaches. First, the degree of change from baseline to week 24 values was compared 
between the 2 treatment groups, using a Student's 2-tailed test for those patients who 
completed 24 weeks of treatment with the originally assigned drug. We also performed 
an intent-to-treat analysis, whereby all patients who were initially randomized to receive 
either AZA or MTX were assessed at the twenty-fourth and forty-eighth weeks regardless 
of whether they had withdrawn from the original drug and switched to another second-
line drug. Second, the area-under-the-curve (AUG) was calculated, to utilize all data at 
each 4-week interval during the first 24 weeks. For this analysis, a relative value is used 
[AUC/(baseline χ 24)]. The relative AUG was compared between the 2 groups, using 
both an intent-to-treat approach and an approach that included only patients who con­
tinued taking the same drug throughout the 24 weeks. Moreover, in the AZA group, a 
comparison was made between patients who withdrew (n = 13) and patients who con­
tinued to take AZA for 24 weeks (n=20). 
All efficacy results are presented as mean differences from baseline. Ninety-five 
percent confidence intervals were calculated. An improvement of the DAS by > 1.08 was 
considered statistically significant (29). All randomized patients were included in the 
safety analysis. 
6.4 RESULTS 
Patient characteristics. Of the 64 patients enrolled in the study, 33 were randomized to 
receive AZA and 31 to receive MTX. There were no significant differences between the 
2 treatment groups in any demographic or clinical variables at study entry, except that 
the MTX group had a higher proportion of women (P<0.01) (Table 1) and the AZA 
group had a higher proportion of patients who were taking prednisone (P=0.04). No 
significant differences in disease variables (number of swollen joints, Ritchie articular 
index, pain score, duration of morning stiffness, ESR) were found between AZA patients 
who were and those who were not taking prednisone at entry into the study. These 
disease variables also did not differ significantly between female and male patients in the 
AZA group at study entry. Previous therapy with other second-line drugs was com­
parable between the 2 groups (Table 1). The duration of RA was comparable in the 2 
groups (7 patients in the AZA group and 7 in the MTX group had relatively early 
disease [defined arbitrarily as 1.5-4.5 years], 11 in the AZA group and 9 in the MTX 
group had disease duration of 4.5-9 years, and 15 in the AZA group and 15 in the MTX 
group had disease of > 9 years duration). 
Efficacy in patients who received the same drug for 24 weeks and for 48 weeks. 
Since only patients who completed at least 24 weeks of the same drug were included in 
the analysis of the efficacy of AZA versus MTX, 50 patients (20 AZA, 30 MTX) were 
eligible for this analysis. Thirteen patients in the AZA group permanently stopped taking 
the trial medication within the first 3 months because of severe side effects. One MTX 
patient was withdrawn before week 24 because of noncompliance. In this patient, MTX 
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Table 1. Patient characteristics at baseline, by treatment group 
Variable 
Age (years) 
Mean ± SD 
Range 
Disease duration (years) 
Mean ± SD 
Range 
Female/males 
Steinbrocker functional 
class II/III 
HLA-DR4 positive 
Rheumatoid factor positive 
(latex fixation titer a 1:80) 
Subcutaneous nodules 
Joint prosthesis 
Previous second-line drugs 
Aurothioglucose 
D-penicillamine 
Hydroxychloroquine 
Sulfasalazine 
Auranofin 
Azathioprine 
group 
(n = 33) 
55.8 ± 9.3 
34 - 71 
9.4 ± 5.6 
1.5 - 26.5 
17 / 16 
26 / 7 
22 
33 
11 
7 
33 (100) 
23 ( 70) 
26 ( 79) 
8 ( 24) 
4 ( 12) 
Methotrexate 
group 
(n = 31) 
57.3 ± 9.5 
38 - 71 
12.8 ± 10.0 
1.5 - 40 
26 / 5 
25 / 6 
19 
29 
11 
7 
30 (97) 
25 (81) 
25 (81) 
7 (23) 
2 ( 6) 
Unless otherwise indicated, values are the number of patients; values in parentheses are per­
centages. 
Ρ = 0.01 
was resumed in an open phase 5 weeks later. 
When week 24 values were compared with baseline values within each treatment group 
(Table 2), the MTX group had significant improvement in more clinical and laboratory 
variables than did the AZA group (12 of 13 versus 6 of 13). After 48 weeks of treatment 
with the same drug, 13 of 13 variables had improved significantly from baseline in the 
MTX group, compared with 10 of 13 in the AZA group. At both 24 weeks and 48 
weeks, improvement was consistently more pronounced in the MTX group than in the 
AZA group for nearly all efficacy measures. After 24 weeks, the difference in improve­
ment between the AZA-treated patients and the MTX-treated patients was significant for 
the swollen joint count, ESR, and Hgb (P<0.02) (Table 2). 
Figure 1 shows the mean values for 5 clinical and laboratory variables as measured at 
each 4-week interval up to week 24, in both treatment groups. In order to use these 
findings from each 4-week assessment, an AUC analysis for weeks 0-24 was performed 
(Table 3). This analysis showed significantly greater improvement in the number of swol-
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Table 2. Clinical and laboratory variables: mean ± SD values at baseline and changes from baseline after 24 weeks and 48 weeks of 
treatment with the same drug @ 
Variable 
Ritchie articular 
index 
Tender joint 
count 
Swollen joint 
count 
Pain 
(0-100 mm VAS) 
General health 
(0-100 mm VAS) 
Morning stiffness 
(minutes) 
Grip strength, 
right (mm Hg) 
Grip strength, 
left (mm Hg) 
Erythrocyte sedi­
mentation rate 
(mm/hour) 
C-reactive protein 
(mg/liter) 
Hemoglobin 
(mmoles/liter) 
Thrombocytes 
(xlOVl) 
Disease activity 
score # 
Baseline 
AZA group 
(n = 33) 
22.4 ± 9.6 
23.0 ± 10.7 
18.7 ± 7.0 
54.6 ± 21.7 
31.9 ± 19.3 
109.2 ± 83.2 
79.3 ± 18.2 
70.6 ± 44.1 
60.2 ± 27.9 
50.6 ± 28.2 
7.8 ± 1.0 
377 ± 95 
5.24 ± 0.87 
MTX group 
(п=ЗП 
19.6 ± 6.5 
22.5 ± 10.1 
18.8 ± 7.2 
49.6 ± 18.7 
28.0 ± 22.9 
82.1 ± 79.2 
58.9 ± 37.1 
62.4 ± 44.5 
57.5 ± 27.9 
39.0 ± 26.5 
7.3 ± 0.7 
390 ± 110 
5.07 ± 0.65 
Week 24 
AZA group 
(n=20) 
-5.9 
(-10.3,-1.4) + 
-3.7 
(-9.2, +1.8) 
0.0 
(-2.9, +2.9) 
-13.1 
(-27.1, +0.8) 
-4.1 
(-13.6, +5.6) 
-60.1 
(-100.6, -19.5) * 
+ 25.1 
( + 5.6, +44.6) + 
+ 31.7 
( + 16.2, +47.1)* 
-11.4 
(-18.4, -4.5) · 
-18.4 
(-27.9, -8.9) * 
-0.2 
(-0.5, +0.01) 
-42.0 
(-95.1, +11.1) 
-0.62 
(-1.12,-0.12) 
MTX group 
(n = 30) 
-8.5 
(-11.5,-5.4)* 
-10.4 
(-13.6,-7.1)* 
-4.3 
(-6.8, -1.8) * $ 
-25.5 
(-35.5, -15.4) * 
-2.4 
(-17.4, +10.4) 
-45.6 
(-62.6, -28.6) * 
+23.7 
(+11.4, +36.1)* 
+41.0 
(+27.7, +54.2) * 
-25.1 
(-32.9, -17.3) * $ 
-22.9 
(-31.1,-14.7)* 
+0.2 
(+0.02, +0.5) * $ 
-89.0 
(-125.1,-52.8)* 
-1.20 
(-1.59,-0.81)* 
Week 48 
AZA group 
(n=12) 
-8.4 
(-13,2, -3.6) * 
-7.0 
(-13.2, -0.8) * 
-2.8 
(-7.2, +1.6) 
-24.4 
(-46.1,-2.6)* 
-3.5 
(-15.3, +10.5) 
-90.0 
(-148.5, -35.5) * 
+29.0 
(+2.9, +55.1) * 
+45.6 
(+19.5, +71.6)* 
-17.9 
(-36.0, +0.17) 
-26.7 
(-39.1,-13.8)* 
-0.2 
(-0.5,-0.1)* 
-88.0 
(-141.5,-34.5)* 
-1.09 
(-1.73,-0.45)* 
MTX group 
(n=25) 
-11.0 
(-13.1,-8.6)* 
-12.2 
(-15.6, -8.7) * 
-5.9 
(-8.8, -3.0) * 
-32.8 
(-41.0,-24.5)* 
-12.0 
(-23.2, -0.8) * 
^7.7 
(-61.1,-34.3)* 
+46.5 
(+29.0, +64.0) * 
+51.9 
(+33.7, +70.1) * 
-29.4 
(-37.3,-21.5)* 
-26.2 
(-33.8, -13.5) • 
+0.4 
(+0.2, +0.7) * 
-80.0 
(-114.0,-45.8)* 
-1.62 
(-1.96,-1.29)* 
@ Values in parentheses are 95% confídence intervals. AZA = azathioprine; MTX = methotrexate; VAS = visual analog scale 
* Significant change from baseline 
$ Significant difference from the AZA group (P<0.02) 
if See Patients and Methods for description of the disease activity score. An improvement of ä 1.08 is significant 
oo 
Table 3. Relative area-under-the-curve (AUG) between week 0 and week 24, 
by intention-to-treat analysis (IT) and by analysis of patients who 
continued the same treatment for the 24 weeks (same) * 
AZA group MTX group P, AZA 
vs MTX 
Variable IT Same IT Same IT Same 
(n=33) (n=20) (n=31) (n=30) 
Ritchie articular 0.81 0.82 0.74 0.74 0.08 0.07 
index (0.71,0.90) (0.67,0.96) (0.65,0.82) (0.65,0.82) 
Tender joint 0.89 0.95 0.73 It 0.17 0.12 
count (0.74,1.04) (0.72,1.18) (0.65,0.81) 
Swollen joint 1.03 1.08 0.94 # 0.10 0.02 
count (0.94, 1.12) (0.95, 1.21) (0.85, 1.02) 
Pain (VAS) 0.87 0.93 0.66 # 0.04 0.03 
(0.72,1.01) (0.70,1.15) (0.54,0.7η 
Morning stiffiness 0.65 0.68 0.68 » 0.95 0.97 
(0.51,0.78) (0.49,0.86) (0.56,0.79) 
Grip strength, 1.25 1.23 1.64 It 0.22 0.18 
right (1.09,1.41) (1.00,1.46) (1.21,2.06) 
Grip strength, 1.41 1.48 2.02 It 0.15 0.35 
left (1.19,1.62) (1.15,1.80) (1.41,2.62) 
Erythrocyte sedi- 0.86 0.72 0.67 # 0.002 0.009 
mentation rate (0.77, 0.95) (0.63,0.80) (0.60,0.73) 
C-reactive 0.74 0.75 0.42 It 0.002 0.004 
protein (0.62,0.86) (0.58,0.91) (0.30,0.53) 
Hemoglobin 0.96 0.95 1.00 It 0.01 0.01 
(0.94,0.98) (0.93,1.02) (0.98,1.02) 
Thrombocytes 0.96 0.99 0.85 It 0.004 0.003 
(0.88,1.03) (0.86,1.11) (0.81,0.89) 
Disease activity 0.93 0,94 0.86 It 0.03 0.02 
score (0.88,0.97) (0.88,0.99) (0.83,0.90) 
* Values in parentheses are 95% confidence intervals. AZA — azathioprine; 
MTX = methotrexate; 
VAS = visual analog scale. 
tt Equal results as in IT. 
len joints, pain score, ESR, CRP level, thrombocyte count, Hgb level, and DAS in the 
MTX group, compared with the AZA group. 
Efficacy as assessed by intention-to-treat analysis at weeks 24 and 48. To assess the 
final outcome of all patients who entered the study, an intention-to-treat analysis was 
performed. Twenty-four weeks after initiation of the study, the 31 patients originally 
allocated to the MTX group showed significantly more improvement in the pain score, 
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Table 4. Number of patients with good (к50%) improvement, partial (30-49%) 
improvement, stable condition (0-29% improvement), or worsening in 
clinical and laboratory variables, after 24 weeks of treatment with the 
same drug, by treatment group 
Azathioprine group Methotrexate group 
(n = 20) (n = 30) 
Variable 
Ritchie articular 
index 
Tender joint 
count 
Swollen joint 
count 
Pain (visual ana­
log scale) 
Morning stiffness 
Grip strength, 
right 
Grip strength, 
left 
Erythrocyte sedi­
mentation rate 
C-reactive 
protein 
Thrombocytes 
good/partial 
improvement 
9/2 
7/1 
3/1 
8/2 
9/4 
4/6 
6/6 
3/4 
8/4 
0/3 
stable/ 
worse 
4/ 5 
6/ 6 
6/10 
4/ 6 
4/ 3 
5/ 5 
5/ 3 
11/ 2 
6/ 2 
14/ 3 
good/partial 
improvement 
12/ 7 
15/ 4 
5/ 8 
17/ 4 
13/11 
6/ 9 
10/ 8 
15/ 4 
20/ 1 
4/ 4 
stable/ 
worse 
8/3 
10/1 
10/7 
4/5 
6/0 
12/3 
9/3 
10/1 
8/1 
19/3 
ESR, CRP level, Hgb level, thrombocyte count, and DAS, compared with the 33 patients 
assigned to the AZA group, as shown by AUG analysis (Table 3). After 48 weeks, there 
were no significant differences in the mean values of clinical and laboratory variables 
compared with baseline (results not shown). 
Percentage improvement in disease variables and clinical response. As shown in 
Table 4, more MTX-treated than AZA-treated patients had good or partial improvement 
(judged by percentage change) in each individual disease variable after 24 weeks of 
treatment with the same drug. After 24 weeks of treatment with the same drug, 23 of 30 
patients in the MTX group and 12 of 20 in the AZA group had achieved good and/or 
partial overall improvement (as defined in Patients and Methods). A lack of clinical 
effect after 24 weeks was found in 4 MTX-treated patients and 8 AZA-treated patients. 
When the clinical response was assessed according to the composite DAS, 18 of 30 
MTX-treated patients (60%) and 7 of 20 AZA-treated patients (35%) had improved 
significantly after 24 weeks of treatment with the same drug. After 48 weeks of treatment 
with the same drug, 6 of 12 patients in the AZA group (50%) and 19 of 25 in the MTX 
group (76%) had significant improvement in the DAS. 
Time to response. In addition to the more pronounced clinical response to MTX, a more 
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Figure 1. 
Mean ± SD changes in the Rit-
chie articular index, number of 
swollen joints, pain score (visual 
analog scale [VAS]), number of 
tender joints, and erythrocyte 
sedimentation rate, during 24 
weeks of treatment with azathio-
prine (AZA) (η=20) or methotre­
xate (MTX) (n=30). 
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rapid and sustained clinical response to MTX was demonstrated. Among those who 
continued treatment with the same drug, the numbers of patients in the AZA group and 
the MTX group, respectively, who had significant improvement in the DAS were as 
follows: 1 and 0 at week 4, 1 and 7 at week 8, 1 and 8 at week 12, 3 and 12 at week 
16, 5 and IS at week 20, and 6 and 18 at week 24. 
Effects on serologic and immunologic variables. Mean baseline values of Ig A, IgG, 
and IgM were above-normal in both treatment groups. After 24 weeks and 48 weeks, 
there was a 10-25% decrease in the immunoglobulin levels in both groups (the greatest 
decrease was in Ig A, the smallest in IgG). During therapy, the mean C3 level decreased 
significantly (P<0.02), to the high end of the normal range, in both groups, whereas C4 
levels fell only slightly. The mean RF titer by latex fixation, which was 1:2,523 in the 
AZA group and 1:1,753 in the MTX group at baseline, had decreased by more than 60% 
(P=0.001) in both groups after 24 weeks and 48 weeks. 
Dosage of the trial medication, and treatment with NSAIDs and corticosteroids. 
More patients from the AZA group (58%) than from the MTX group (43%) needed to 
have their drug dosage increased after 8 weeks. The number of patients who switched to 
another second-line drug after discontinuation of the trial drug is shown in Figure 2. The 
mean ± SD dosage of AZA for patients who took the drug for up to 24 weeks was 2.06 
± 0.67 mg/kg body weight daily. The mean ± SD dosage of MTX in that period was 
8.80 ± 2.22 mg weekly. In 3 patients (2 AZA; 1 MTX), the dosage of NSAIDs was 
increased during the trial; the mean corticosteroid dosage did not change in any patient. 
During the double-blind phase of the study, 5 patients (3 AZA; 2 MTX) required a 
single intra-articular injection of steroid. 
Adverse reactions. Table 5 summarizes the adverse reactions that occurred in the 2 
treatment groups. The frequency of side effects was similar in both groups. GI reactions 
were the most frequent side effect of AZA. In 2 of 5 patients who discontinued AZA 
treatment within the first 10 weeks because of GI side effects, severe vomiting developed 
after ingestion of only a single tablet. In contrast to the liver enzyme abnormalities found 
in the MTX group, which were characterized mainly by elevated AST and ALT levels, 
the liver dysfunction seen in the AZA group was of a cholestatic nature in 3 patients. 
These liver function abnormalities occurred initially within 2-4 weeks after starting the 
trial, and again, to a greater extent, after rechallenge with AZA. Levels of alkaline 
phosphatase and GGT rose to 3-10 times the normal values. In 1 of the AZA-treated 
patients, liver dysfunction was accompanied by fever and acute dermatitis (31). Hyper-
sensitivity reactions consisting predominantly of fever occurred in 2 other patients (31). 
The major side effect of MTX found in this trial was elevation of liver enzyme levels, 
in 58% of the patients. The elevation was generally 2-3 times the normal values; the 
increase was 5-fold over normal in 1 patient. After temporary discontinuation of the drug 
or adjustment of the dosage, these values returned to normal in all patients. In 7 of 9 
MTX-treated patients who developed mouth ulcers, elevated liver enzymes were also 
found, after a mean treatment duration of 8.3 weeks. In 4 patients who started treatment 
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Table 5. Adverse reactions and withdrawals during 48 weeks of therapy, by treat­
ment group * 
Reaction 
Gastrointestinal 
Mouth ulcers 
Nausea, vomiting, 
or abdominal pain 
Ulcer (gastric/ 
duodenal) 
Diarrhea 
Elevated liver 
enzymes 
Hematologic 
Leukopenia 
Thrombocytopenia 
Pancytopenia 
Hypersensitivity 
Dermatitis 
Fever 
Other 
Central nervous 
system 
Nodulosis 
Infection 
Total withdrawals 
Azathioprine group 
(n = 
reaction 
18 
3 $ 
3@ 
33) 
withdrawal 
due 
to reaction 
5 
3 $ 
1 
1 
3 $ 
1 
13 ** 
Methotrexate \ 
(n = 
reaction 
9/C 
9 
18 
1 
3 
2 
2 
1 
4 
31) 
group 
withdrawal 
due 
to reaction 
1 
1 
2 
Values are the number of patients. Several patients had more than 1 adverse reaction. All 
withdrawals of azathioprine due to side effects occurred between week 0 and week 12; 
withdrawals of methotrexate occurred at week 24. 
Seven of 9 patients also developed elevated liver enzyme levels after a mean treatment period of 
8.3 weeks after development of mouth ulcers. 
One patient bad a triad of fever, dermatitis, and severe liver dysfunction. 
Two of 3 patients also had chills. 
Ρ = 0.03 versus the methotrexate group. 
with AZA but switched to MTX, mouth ulcers also developed during MTX treatment, 
followed by elevations in liver enzyme levels. 
Hematologic side effects leading to permanent withdrawal from the trial occurred in 2 
AZA-treated patients: 1 developed pancytopenia (32) and the other developed recurrent 
leukopenia (2.8 χ lO'/liter) and tonsillitis. In 3 MTX-treated patients, thrombocytopenia 
(>110 χ lO'/liter) developed, but in all 3 cases it disappeared after temporary disconti­
nuation of or lowering the dosage of MTX. Central nervous system symptoms (headache, 
dizziness) became so troublesome in 1 AZA-treated patient as to necessitate discontinua­
tion of the drug. Development of nodules in uncommon sites was the cause of disconti­
nuation of MTX in 1 patient (33). No increase or decrease of subcutaneous nodules was 
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Figure 2. 
Course of treatment in patients 
randomized at baseline (t = 0) to 
receive azalhioprine (AZA) (η = 
33) or methotrexate (MTX) (η = 
31). The follow-up period was 48 
weeks; assessments of treatment 
course are shown for week 24 (t 
= 24 wk) and week 48 (t = 48 
wk). Stop side eff. = stopped 
because of side effects; DMARD 
= disease-modifying anti­
rheumatic drug, such as sul­
fasalazine or D-penicillamme; 
stop no eff. = stopped because of 
lack of effect; predn. = pred­
nisone; stop non-com pi. = 
slopped because of non-com­
pliance. 
DMARD 
< n = 1) 
found in other patients during the follow-up period. Infection developed in 4 MTX-
treated patients (pneumonia in 2, sinusitis in 1, pyelitis in 1). MTX was withdrawn for 2-
3 weeks during antibiotic treatment in these patients, then resumed without further com­
plication, including in the patient with pyelitis, who underwent surgery for a large pyelic 
stone. 
6.5 DISCUSSION 
In the traditional rheumatoid arthritis treatment pyramid, azalhioprine is prescribed 
after parenteral gold and DP (34). The place of methotrexate in this pyramid has not yet 
been established. Time to clinical response, short- and long-term efficacy, toxicity 
profile, and long-term safety are important factors in determining the place of a second-
line antirheumatic drug. Since AZA (35,36) and MTX (14-17) have already proven to be 
superior to placebo in the treatment of RA, a comparison with placebo was not included 
in the present study. 
The dosages of AZA and MTX used most frequently in RA range between 1.25 mg/kg 
and 2.5 mg/kg daily (6-11,35,37) and between 7.5 mg and 15 mg weekly (7-12), respec-
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lively. The mean dosages of AZA (2.06 mg/day) and of MTX (8.8 mg/week) in this 
study were in accordance with the dosages used in previous investigations. Following 
randomization, the 2 treatment groups (33 AZA, 31 MTX) were comparable with regard 
to demographic (Table 1), clinical, and laboratory variables (Table 2). The baseline dif-
ferences between the groups in the female: male ratio and the use of steroid therapy 
probably did not influence the study results, since baseline disease variables did not differ 
significantly between patients in the AZA group who were and those who were not 
receiving prednisone, or between female and male patients in the AZA group. To avoid 
interobserver variability, all patients were evaluated by the same physician. 
Individual clinical and laboratory variables were assessed both in terms of changes 
from baseline values within each treatment group (Table 2) and in terms of between-
group differences in the degree of the changes (Tables 2 and 3), after 24 weeks of 
therapy. It is clear from the data in both Table 2 and Table 3 that MTX was superior to 
AZA. Although differences in clinical and laboratory variables in the 12 AZA-treated 
and 25 MTX-treated patients who completed 48 weeks of the same therapy were not 
significantly different, there was a trend toward more improvement in the MTX group 
(Table 2). Statistically significant differences between the groups could have been missed 
because of the low number of patients remaining in the AZA group at 48 weeks. 
The area-under-the-curve analysis (Table 3) provided additional information, from each 
4-week assessment up to week 24. By this analysis, the number of swollen joints, pain 
score, ESR, CRP level, Hgb level, thrombocyte count, and disease activity score all 
showed significantly greater improvement in the MTX group compared with the AZA 
group. Figure 1 shows the course of the disease variables during that period. As recom-
mended by others (10,12,16,17), we also measured the percent improvement in each 
disease variable after 24 weeks (Table 4). More patients from the MTX group than from 
the AZA group had good (^ 50%) or partial (30-49%) improvement in individual 
clinical and laboratory variables. The percentages of MTX-treated patients with good 
improvement in the tender joint count (50%) and in the swollen joint count (17%) in our 
study were comparable with percentages reported by Williams and colleagues (32% and 
21%, respectively) (17) and by Weinblatt and colleagues (54% and 39%, respectively) 
(16). The percentages of AZA-treated patients with at least partial improvement in the 
tender joint count (40%) and the swollen joint count (20%) were comparable with 
percentages reported by Paulus and colleagues (44% and 38%, respectively) (10). 
To assess outcome in all patients who were entered into the study, regardless of 
whether they completed the protocol, an intent-to-treat analysis was performed. After 24 
weeks, there was significantly more improvement in the patient group that was started on 
MTX (n=31) compared with the group that started on AZA (n=33) (Table 3). After 48 
weeks, no significant differences in the individual disease variables were found. 
To measure the clinical response to AZA and MTX according to a single parameter, 
we used the disease activity score (29,30). After 24 weeks and 48 weeks of treatment 
with the same drug, a higher percentage of MTX-treated patients than AZA-treated 
patients had significant improvement in the DAS. In the period between week 8 and 
week 24, 2-3 times more MTX-treated than AZA-treated patients had significant 
improvement in the DAS. This underscores again the more pronounced and earlier 
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response to MTX compared with AZA. 
The number of patients who were still taking MTX after 1 year (80%) is consistent 
with results from other studies after at least 1 year (19-22,38). The much smaller 
percentage of patients who were still taking AZA after 1 year (36%) is also consistent 
with other published results (11). The 10-25% decrease in immunoglobulin levels in both 
treatment groups, although significant, was somewhat less than was found in our open 
trial of MTX study treatment (5) and in a placebo-controlled study of MTX treatment 
(15). 
The major adverse reactions noted in this trial (Table 5) were elevated levels of liver 
enzymes in MTX-treated patients and gastrointestinal complications in AZA-treated 
patients, which is consistent with earlier reports (38-43). The rate of withdrawal due to 
side effects of AZA (39%) was comparable with that occurring in some double-blind 
studies (6,23,36), but higher than that found in others (-20%) (9,10). Adverse reactions 
to MTX, though common, were mostly mild and transient. A notable observation was the 
high number of severe liver dysfunction reactions and severe hypersensitivity reactions in 
AZA-treated patients, most of which developed within 4 weeks (Table 5). Similar 
findings have been reported previously (23). Severe vomiting after 1 single dose of AZA 
in 2 patients might also be considered a hypersensitivity reaction (44). We do not have 
an explanation for the high number of severe adverse reactions to AZA. No differences 
in HLA tissue type, clinical disease variables, type of NSAID used, or previous adverse 
reaction to other second-line drugs were found between the patients who withdrew from 
AZA treatment and those who were able to continue the treatment. To our knowledge, 
mouth ulcers heralding liver dysfunction after approximately 8 weeks of treatment with 
MTX, which we found in 7 patients, has not been reported before. In all patients mouth 
ulcers were mild and alleviated with local therapy. Whether the infections observed in 
MTX-treated patients were coincidental or were treatment-related is unclear. Both 
patients with pneumonia (causative agent unknown) were nonsmokers and had no 
immunoglobulin deficiency. After recovery and reinstitution of MTX, no infections have 
recurred thus far. A diagnosis of MTX pneumonitis was unlikely, based on the clinical 
findings, response to antibiotics, and disease course. 
The absence of a significant difference in efficacy between AZA and MTX reported by 
Hamdy et al. (22), in a double-blind study of 42 RA patients, was not confirmed by our 
results. Patient selection criteria, demographic characteristics, and dosage of trial 
medication were comparable in their study and ours. Our patients may have had more 
active disease at baseline, as reflected by higher mean values in the ESR and VAS pain 
score, and lower grip strength. The disease variables used in the 2 studies were almost 
identical. In contrast with our results, there was almost no decrease in the ESR in either 
treatment group in the study by Hamdy et al., whereas the swollen joint count decreased 
markedly in both groups. Their report gives no data on changes in the Hgb, throm-
bocyte, or CRP levels. Differences in the number of patients studied (42 versus 64) and 
in the dropout rate (10% versus 39%) may also be causes for the divergence between our 
results and those reported by Hamdy and colleagues. 
It was difficult to compare our results with those of a second double-blind trial of AZA 
versus MTX (23), since the findings of that study are presented in abstract form. AZA 
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and MTX were shown to have similar efficacy in that short-term (20-week) study of 34 
patients. Improvement in grip strength was the only variable for which there was a statis­
tically significant difference between the 2 treatment groups, with greater improvement 
among those who received MTX. Those authors also found a high percentage of 
withdrawals due to side effects in the AZA group (>40%). 
In conclusion, this double-blind trial demonstrated superiority of methotrexate to 
azathioprine in the treatment of RA, as indicated by most of the clinical and laboratory 
variables individually and by the overall clinical response, after 24 weeks and 48 weeks 
of therapy. The earlier and more sustained clinical improvement in MTX-treated patients 
was accompanied by a significantly lower rate of serious adverse reactions. These results 
suggest that MTX should precede AZA in the treatment pyramid for rheumatoid arthritis. 
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7.1 ABSTRACT 
Objective: To compare the effects of azathioprine and methotrexate on progression of 
radiologic damage in patients with rheumatoid arthritis. 
Design: Double-blind, randomized 48-week trial. 
Patients: Sixty-four patients with active rheumatoid arthritis who either have not 
responded to or who have reacted with side effects to at least parenteral gold and D-
penicillamine. 
Interventions: Either azathioprine, 100 mg daily, or methotrexate, 7.5 mg weekly, was 
administered orally. Depending on the clinical effect after 8 weeks, the dosage was 
increased to either azathioprine, ISO mg, or methotrexate, 15 mg. The dosages for 
nonsteroidal anti-inflammatory drugs and prednteone were held stable. 
Measurements: Clinical and laboratory assessments were done by the same physician 
every 4 weeks for the first 24 weeks and every 8 weeks thereqfter. Radiographs of 
hands, wrists, and feet obtained at baseline and qfter 24 and 48 weeks were scored by 
one rheumatologist blinded to medication and clinical findings. 
Main Results: Initial radiologic scores were comparable in both groups and correlated 
with disease duration (r=0.38). An intention-to-treat analysis after 24 and 48 weeks 
showed significantly fewer new erosions in the methotrexate group compared with the 
azathioprine group (difference, 2.0 [95% CI, 0.2 to 3.9] and 3.5 [CI, 1.3 to 5.8], 
respectively). The change in total joint score was also significantly less pronounced in 
the methotrexate group compared with the azathioprine group after 24 weeks (differen-
ce, 2.8 [CI, 0.2 to 5.2]) and qfter 48 weeks (difference, 3.9 [CI, 0.3 to 7.4]). Radiolo-
gic stabilization qfter 48 weeks was present in 10% of the azathioprine group compared 
with 29% of the methotrexate group. 
Conclusions: Patients with rheumatoid arthritis treated with low-dose methotrexate 
showed significantly less radiologic progression than patients treated with azathioprine. 
This result suggests that methotrexate therapy is clinically superior in these patients. 
7.2 INTRODUCTION 
Radiologic damage is one of the most important outcome measures for rheumatoid 
arthritis (1). Besides suppression of joint inflammation leading to reduction in pain and 
stiffness, one of the major objectives of therapy with slow-acting antirheumatic drugs is 
the prevention or slowing of progression of radiologic damage. 
Slowing of radiologic progression has been demonstrated for oral gold (2) and sulfasa-
lazine (3) in early rheumatoid arthritis ( ¿ 2 years) and for parenteral gold (4,5) and 
perhaps for cyclophosphamide (6) in patients with disease of longer duration. Comparison 
between azathioprine and other second-line drugs such as parenteral gold (7), D-penicil-
lamine (8), and methotrexate (9), with regard to their inhibitory effect on radiologic 
progression in patients with disease of long duration, has not shown significant intergroup 
differences. 
On the basis of results of five open prospective studies of low-dose methotrexate in 
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rheumatoid arthritis, no definite conclusions can be drawn about a slowing effect of me­
thotrexate on radiologic progression. Two investigators found no radiologic progression 
and even radiologic improvement after 2 years of therapy in most of their patients (10, 
11). Three others found no radiologic improvement and found progression in several 
patients despite clinical improvement (12-14). 
In order to compare the influence of azathioprine and methotrexate on the radiologic 
progression in rheumatoid arthritis, we evaluated the radiographs of hands, wrists, and 
feet obtained during a double-blind 48-week study of patients with rheumatoid arthritis. 
Results described previously (15) have shown the clinical superiority of methotrexate 
therapy in these patients after 24 and 48 weeks of therapy. 
7.3 PATIENTS AND METHODS 
Patients 
Sixty-four patients with active definite or classical rheumatoid arthritis from five clinics 
were enrolled from November 1986 to November 1988. The protocol was approved by 
each institution's ethics committee, and each patient gave informed consent before the 
study. All patients were either unresponsive to or had had side effects to parenteral gold. 
Further, three quarters of the patients had received previously hydroxychloroquine and 
the same percentage of patients had had D-penicillamine. A few patients had also recei­
ved oral gold and salazopyrine. The dosages of nonsteroidal anti-inflammatory drugs 
(NSAIDs) and prednisone (< 10 mg/d) were held stable for at least 4 weeks before study 
entry. 
Active rheumatoid arthritis was defined by the presence of at least three of four 
criteria: six or more joints that were tender or, during motion, were painful; three or 
more swollen joints; an erythrocyte sedimentation rate above 28 mm/h; and morning 
stiffness for at least 45 minutes. Exclusion criteria included abnormal liver function (any 
liver function test result exceeding twice the normal value), abnormal renal function 
(creatinine clearance <50 ml/min), hematologic abnormalities (leukocyte count <3.5 χ 
lO'/l, platelet count < 150 χ lO'/l), marked obesity (15 kg above ideal weight), insulin-
dependent diabetes mellitus, malignancy, alcoholism, active peptic ulcer disease, functio­
nal class IV according to Steinbrocker (16), inadequate contraception, infections, use of 
allopurinol or antifolate drugs such as sulphonamides, and age less than 16 years or over 
75 years. 
Study design and medication 
After they were stratified by functional class, patients were randomly allocated by the 
statistician in blocks of six to receive either methotrexate or azathioprine. The initial 
dosage of methotrexate was 7.5 mg weekly given in divided doses of 2.5 mg each in 
three consecutive 12-hour intervals. The initial dosage of azathioprine was 100 mg daily 
(50 mg twice daily). Using a double-dummy technique, all patients received either two 
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tablets containing 50 mg of azathioprine daily with three methotrexate-placebo capsules 
weekly or three capsules weekly, each containing 2.5 of mg methotrexate (divided-dosage 
regimen), with two azathioprine-placebo tablets daily. If the overall clinical improvement 
(see definition below) was less than partial after 8 weeks, the trial medication was in-
creased to methotrexate, 15 mg weekly, or azathioprine, 150 mg daily. The double-blind 
protocol was maintained until week 48 for patients with a good overall improvement after 
24 weeks. Patients who had no effect after 24 weeks or who had side effects received the 
alternative drug in an open phase (that is, azathioprine instead of methotrexate and vice 
versa) and were followed until week 48. 
Clinical assessments 
Clinical and laboratory evaluations were done every 4 weeks for the first 24 weeks and 
every 8 weeks thereafter. During the study period, clinical investigations and treatment 
of the patients studied in the different participating clinics were always done by the same 
physician. The overall clinical response arbitrarily comprised four disease variables: 
patient's pain assessment using a visual analog scale from 0 mm (no pain) to 100 mm 
(very severe pain); Ritchie articular index; Westergren erythrocyte sedimentation rate in 
mm/h; and morning stiffness expressed in minutes. A good overall improvement was 
defined as 50% or more improvement of at least three variables, and partial or moderate 
improvement was defined as 30% or more and less than 50% of at least two of four 
(and no worsening of other) disease variables. In accordance with other studies (17,18) 
improvement by 50% or more in one separate disease variable was considered to be good 
(marked) improvement, whereas improvement by 30% or more and less than 50% was 
considered to be partial (moderate) improvement. 
Radiographic assessment 
Radiographs of hands, wrists, and feet were taken at baseline and after 24 and 48 
weeks of treatment. All radiographs had the same quality and granulation. They were all 
scored by one experienced rheumatologist who was unaware of the clinical and labora-
tory findings and the drugs the patients had received. The radiographs were evaluated 
under identical conditions and in chronologic order for each patient. The radiographs of 
the hand were scored according to the modified method of Sharp (19). Because there is 
no agreement on scoring radiographs of the feet, we decided to score the radiographs in 
the way that was recently described in another double-blind trial of rheumatoid arthritis 
(3). In that study, the maximum possible score of erosions in the joints of the feet was 
fixed at 10 and that of the hands at 5 because erosions in the feet were much more 
pronounced than those in the hands. 
Erosions in the following joints were counted: the 8 proximal interphalangeal joints, 
the 2 interphalangeal joints of the thumbs, the 10 metacarpophalangeal joints, the right 
and left first metacarpal bone, distal right and left bones of the radius and ulna, bones of 
the right and left carpus (trapezium bone and trapezoid bone [as one unit; multangular], 
navicular bone and lunate bone). Further, 10 metatarsophalangeal joints and the right and 
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left inter-phalangeal joints of the big toes were scored. Erosions were qualitatively scored 
between 1 to S depending on the amount of damage. A minimal interruption of the corti­
cal surface was scored as 1, whereas larger defects were scored as 2 to 5, depending on 
the size of involved surface of the joint. As mentioned before, the maximal erosion score 
in a joint in the foot was 10 compared with 5 in the hand. The maximum scores for 
erosions were therefore 160 in the hands and 120 in the feet. 
The grades of joint space narrowing were defined as ranging from 1 to 4 (1 = focal 
doubtful; 2 = general; [that is, less than 50% of the original space involved]; 3 = gene­
ral but more than 50% involved, or subluxation; 4 = ankylosis). Joint-space narrowing 
was assessed in the 8 proximal interphalangeal joints, the 10 metacarpophalangeal joints, 
third, fourth, and fifth carpometacarpal joints of the right and left hand, right and left 
multangular-navicular joints, right and left capitate-navicular-lunate joints, right and left 
radiocarpal joints, the 10 metatarsophalangeal joints, and the 2 interphalangeal joints of 
the big toe. The maximum scores for joint space narrowing were 120 in the hands and 
48 in the feet. The total radiologic score included the erosion score and the joint-space 
narrowing score. 
Depending on the degree of radiologic progression, patients were divided into four 
categories: no change, change between 1 and 5, change between 6 and 10, or change 
between 11 and 30. No change in the total score after 24 or 48 weeks was considered to 
be radiologic stabilization. A change by more than 10 units was considered to be marked 
radiologic deterioration. To analyze for intra-observer agreement, 30 pairs of radiographs 
from five patients, chosen at random, were scored twice. To measure the interobserver 
agreement, the same radiographs were scored by a second experienced rheumatologist. 
The results with regard to the reliability of measurements (R, also called intraclass 
correlation), calculated according to Fleiss (20), were as follows: The intra-observer 
scores showed almost no variation, with an R of 0.99 for erosions and joint-space 
narrowing in hands and feet. Some degree of variation between observers was found in 
the measurement for joint-space narrowing in the left hand (R=0.67) and right hand 
(R=0.87), but very little was found in the feet (R=0.99). The variation between 
observers with regard to the measurement of erosions in hands and feet was very low 
(R=0.98). Because scoring of radiographs was time consuming and the variation between 
observers was low, all trial radiographs were scored by one observer. 
Statistical analysis 
For a group size of 30 patients each, real differences in mean values of at least 0.7 χ 
SD (SD = the standard deviation of the variate under interest, for example, the 24-week 
change in erosions) will result with a probability of 80% in a statistically significant dif­
ference between the two corresponding sample means (alpha [type I error] = 0.05, beta 
[type II error] = 0.20, two sided t-test). So, in this study it could be expected that real 
differences in mean 24-week changes in erosions with a magnitude of 3 or more would 
be significant (P<0.05). 
Differences in demographic characteristics between the two treatment groups were jud-
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Table 1. Demographic, Clinical and Laboratory Variables at Baseline * 
Baseline Variable 
Age, y 
Disease duration, y 
Women:men, η 
Functional class 
II:III, η 
Number of patients with 
HLADR4 
Latex titer a 1:80 
Subcutaneous nodules 
Joint prosthesis 
Tender joints count 
Ritchie articular index 
Swollen joints count 
Pain score (VAS), nun 
Morning stiffness, min 
Erythrocyte sedimenta-
Azathiop 
(n=33) 
55.8 
9.4 
17 
26 
22 
33 
11 
7 
23.0 
22.4 
18.7 
54.6 
109 
60.2 
± 
± 
+ 
± 
± 
± 
± 
± 
rine 
9.3 
5.6 
16 
7 
10.7 
9.6 
7.0 
21.7 
83 
27.9 
Methotrexate 
(n=31) 
57.3 
12.8 
26 
25 
19 
29 
11 
7 
22.5 
19.6 
18.8 
49.6 
82 
57.5 
± 
+ 
: 
+ 
± 
± 
± 
± 
± 
9.5 
10.0 
5 
6 
10.1 
6.5 
7.2 
18.7 
79 
27.9 
Ρ value 
>0.2 
>0.10 
0.01 
>0.2 
>0.2 
>0.2 
>0.2 
>0.2 
>0.2 
0.2 
>0.2 
>0.2 
0.19 
>0.2 
tion rate, mm/h 
* Where appropiate, values are expressed as means ± SD. VAS = visual analog scale; HLADR4 = 
Human leukocyte antigen DR4. 
ged using chi-square tests for nominal variables whereas for other variables, such as age 
and disease duration, the Student two-sample test was used. Results of radiologic scores 
were analyzed for patients who completed 24 and 48 weeks of the same drug. These 
results were also analyzed using an intention-to-treat approach, that is, regardless of 
whether patients discontinued the trial medication and switched to other second-line 
drugs. The mean changes in the radiologic scores after 24 and 48 weeks between the two 
groups were compared first without including possible confounders, using the Student 
two-sample test, and second including possible confounders, using multiple regression 
analysis. Ninety-five percent confidence intervals (95% CI) were calculated for the 
differences between those groups in averaged changes for radiologic scores. 
7.4 RESULTS 
Except for gender (P =0.01), demographic and baseline clinical variables did not dif­
fer between the 33 patients in the azathioprine group and the 31 patients in the metho­
trexate group (Table 1). No significant differences in clinical disease variables such as 
erythrocyte sedimentation rate, Ritchie index, swollen joints, and pain score, however, 
were found between the female and the male patients treated with azathioprine. Eight 
patients from the azathioprine group and two patients from the methotrexate group 
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already used prednisone (< 10 mg/d) at the start of the study. Initial disease variables did 
not differ significantly between patients from both treatment groups with and without 
prednisone. The two treatment groups comprised almost the same number of patients 
whose disease duration was between 1.5 and 4.5 years (azathiopnne, 7; methotrexate, 7); 
patients whose disease duration was between 4.5 and 9 years (azathiopnne, 11; metho-
trexate, 9); and patients whose disease duration was longer than 9 years (azathiopnne, 
15; methotrexate, 15). 
Clinical response to therapy 
During the treatment period, 13 patients from the azathioprine group were withdrawn 
within 12 weeks because of severe side effects such as hypersensitivity reactions (n = 3), 
liver dysfunction (n = 3), hematologic adverse reactions (n = 2), or severe gastro-
intestinal symptoms (n = 5) (Figure 1). Eight patients in the azathioprine treatment 
group discontinued azathioprine therapy after 24 weeks because of lack of clinical effect. 
Fourteen patients who discontinued azathioprine because of side effects or lack of effect 
switched to methotrexate. The remaining seven patients switched to prednisone (n = 2), 
salazopyrine (n = 3), D-penicillamine (n = 1), or no drug (n = 1) for various reasons, 
such as severe pancytopenia or prolonged liver dysfunction (both due to azathioprine). 
In the methotrexate group four patients discontinued therapy after 24 weeks because of 
lack of effect and switched to azathioprine. At 24 weeks, two patients from the metho-
trexate group were withdrawn because of side effects (dermatitis and severe nodulosis, 
respectively). One of these patients was given azathioprine; the other patient refused 
other therapy. The number of withdrawals because of side effects in the methotrexate 
group (n = 2), was less than the number of withdrawals because of side effects in the 
azathioprine group (n = 13) (P<0.03). 
After 8 weeks, 21% of the patients in the azathioprine group and 54% in the metho-
trexate group had a good or partial overall clinial improvement. Twenty patients in the 
azathioprine group and 30 in the methotrexate treatment group completed 24 weeks of 
the same drug therapy. A good or partial overall improvement in these same-drug groups 
at 24 weeks was found in 60% of the patients treated with azathioprine and in 80% of 
patients treated with methotrexate. After 48 weeks, 12 patients in the azathioprine treat-
ment group were still using azathioprine, whereas 24 patients in the methotrexate group 
were still using methotrexate. A good or partial overall improvement at 48 weeks in 
these same-drug groups was found in 75% of the patients treated with azathioprine and 
91% of the patients treated with methotrexate (Figure 1). A good or partial overall im-
provement at 24 weeks in the intention-to-treat groups was present in 70% of the azathio-
prine and 78% of the methotrexate group. At 48 weeks, a good or partial improvement 
was present in 70% of the azathioprine group and 90% of the methotrexate group. 
Radiologic response to therapy 
All available radiologic data were used. The baseline radiographs for one patient from 
the methotrexate group were missing, and after 24 weeks radiographs for 3 patients from 
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Figure 1. Clinical course. Sixty-four patients with rheumatoid arthritis were randomized to 
receive azathioprine or methotrexate therapy and were followed for 48 weeks. The 
amount of clinical improvement and the number of patients leaving the trial and their 
reasons for doing so are shown at various time points. Numbers = number of 
patients. 
entered trial η 
Azathioprine 
ІЖІ 
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of therapy η 
— 1 3 — dropped out because of 
side effects 
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both treatment groups were missing or incomplete. After 48 weeks, radiographs for 3 
patients from the methotrexate group were incomplete. At the start of the study the two 
treatment groups showed no significant differences in erosion score or in total radiologic 
score (that is, erosions plus joint-space narrowing; Table 2). Scores changed, at most, by 
0.2 after adjusting for possible confounders (gender, disease duration) with multiple 
regression analysis. Clinical activity measurements (Ritchie index, pain score, morning 
stiffness) also changed only slightly. Therefore only unadjusted estimates are presented. 
In the patients who completed 24 weeks of azathioprine, the mean number of new 
erosions was 3.1 compared with 1.1 in patients who completed 24 weeks of methotrexate 
therapy (Table 2). After 48 weeks, the number of new erosions was 4.7 and 1.5, 
respectively (P=0.01). Total joint damage was also less in patients in the methotrexate 
group. According to an intention-to-treat analysis, results were similar. Fewer new ero­
sions were found in the methotrexate group after 24 weeks (1.2 compared with 3.2) and 
48 weeks (1.8 compared with 5.3). The change in total joint score also favored the 
methotrexate group. 
The changes in mean erosions (3.1) and in mean total joint score (5.1) in the azathio­
prine group in the first 24-week period were higher than in the second 24 weeks of the 
same drug therapy (1.6 and 2.5, respectively). This was also the case in the methotrexate 
group when the first 24 weeks of therapy (1.1 and 2.3) and the second 24 weeks (0.4 and 
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Table 2. Radiographic scores for patient groups who completed 24 and 48 weeks on the initial drug and according to an 
intention-to-treat analysis 
Variable 
E score * 
Baseline 
24 weeks 
48 weeks 
Analysis confined to those patients who 
completed therapy with the initial drug 
Azathioprine 
η 
33 
19 
12 
mean (SE) 
37.5 (4.1) 
3.1 (1.1) 
4.7 (1.5) 
Methotrexate 
η 
30 
26 
24 
mean (SE) 
34.4 (4.7) 
1.1 (0.3) 
1.5 (0.4) 
Difference 
(95% CI) 
2.0 
(-0.1 to 4.0) 
3.2 
(0.7 to 5.3) 
Intention-to-treat analysis 
Azathioprine 
η 
33 
30 
33 
mean (SE) 
37.5 (4.1) 
3.2 (0.8) 
5.3 (0.9) 
Methotrexate 
η 
30 
27 
27 
mean (SE) 
34.4 (4.7) 
1.2 (0.3) 
1.8 (0.5) 
Difference 
(95% CI) 
2.0 
(0.2 to 3.9) 
3.5 
(1.3 to 5.8) 
Τ score it 
Baseline 33 60.5 (6.8) 
24 weeks 19 5.1 (1.3) 
48 weeks 12 7.6 (1.8) 
30 
26 
24 
62.7 
2.3 
4.0 
(8.4) 
(0.8) 
(1.0) 
2.8 
(-0.2 to 5.6) 
3.6 
(-0.5 to 7.7) 
33 
30 
33 
60.5 
5.1 
8.6 
(6.8) 
(1.0) 
(1.2) 
30 
27 
27 
62.7 
2.4 
4.7 
(8.4) 
(0.8) 
(0.9) 
2.7 
(0.2 to 5.2) 
3.9 
(0.3 to 7.4) 
* Erosion score at baseline and change in erosion score after 24 and 48 weeks 
# Total score (is the score for erosions plus the score for joint-space narrowing) at baseline and change in total score after 24 and 48 weeks 
1.6) were compared (Table 2). 
When radiologic scores were analyzed according to the degree of progression and 
according to an intention-to-treat analysis (Table 3), after 48 weeks of therapy, 11% of 
the methotrexate group and 43% of the azathioprine group had marked radiologic 
deterioration (>10 units change in total score). Radiologic stabilization after 48 weeks 
was found in 29% of the methotrexate group and in 10% of the azathioprine group. 
Calculation of correlation coefficients between the total radiographic score and all 
demographic, clinical, and laboratory variables at baseline revealed no relation except for 
disease duration (r=0.38). 
7.5 DISCUSSION 
This study showed that after 48 weeks, fewer new erosions developed in patients who 
completed 48 weeks of methotrexate therapy than in patients who completed 48 weeks of 
azathioprine therapy. The total radiologic score at 48 weeks in these patients did not 
reach statistical significance (P=0.08). The small number of patients on azathioprine who 
completed 48 weeks of therapy (12), however, limits the statistical power. The number of 
Table 3. Changes in radiographic scores according to their degree of change (four 
categories) and according to an Intention-to-treat analysis 
Variable 
Change in erosions 
0 
1 to 5 
6 to 10 
11 to 30 
Change in total 
score* 
0 
1 to 5 
6 to 10 
11 to 30 
Azathioprine 
(n = 30) 
24 wk 
11 
10 
7 
2 
4 
15 
6 
5 
48 wk 
7 
11 
7 
5 
3 
10 
4 
13 
Methotrexate 
(n= :27) 
24 wk 
12 
14 
1 
0 
12 
11 
2 
2 
48 wk 
11 
13 
2 
1 
8 
12 
4 
3 
The total score is the score for erosions plus the score for joint-space narrowing. A significant 
difference in distribution of the total score after 24 weeks (P=0.02) and after 48 weeks (P=0.01) 
was found in favor of the methotrexate group, 
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of patients who dropped out because of severe side effects was significantly higher in the 
patients on azathioprine (Figure 1). An intention-to-treat analysis done to study the final 
radiologic outcome of all patients after 24 and 48 weeks of therapy also found signifi-
cantly slower radiologic joint damage after 24 and 48 weeks in the methotrexate group. 
When patients were divided into four categories according to the severity of radiographic 
damage during the study period, methotrexate treatment was superior. Although we did 
not find radiographic improvement in any patient, the number of patients with radiologic 
stabilization was approximately three times higher in the methotrexate group than in the 
azathioprine group after 24 and 48 weeks of follow-up. The number of patients with 
marked radiologic deterioration after 48 weeks of therapy was four times higher in the 
azathioprine group. 
The change in mean number of erosions (that is, new erosions) and mean total joint 
scores in the first 24 weeks of the same drug therapy was higher than the scores in the 
second 24 weeks. Although this finding occured in both treatment groups, the changes in 
the methotrexate group were less than those found in the azathioprine group for both 
periods. Because radiologic changes spread over time and it takes several months before 
second-line antirheumatic drugs exert their effect, the favorable radiologic results of 
metho-trexate compared with the azathioprine group probably reflect the earlier response 
and the more pronounced clinical effect of methotrexate in this study. 
Factors that have been reported to correlate with progression of joint destruction in 
rheumatoid arthritis are disease duration (21, 22); persistently elevated erythrocyte sedi-
mentation rate (23) or C-reactive protein (22-24); Ritchie index (22); hemoglobin (22); 
immunoglobulin M (22); human leukocyte antigen HLADR4 (25); rheumatoid factor (21, 
25); antiperinuclear factor in seronegative patients (26); and clinical outcome, based on 
the variables of functional grade, joint score, grip strength, and moming stiffness (27). 
In our patients we found only a modest correlation between the initial mean radiologic 
score and the disease duration of patients. In both treatment groups a similar number of 
patients had relatively short and long disease duration. Because all but two patients were 
positive for the rheumatoid factor, we could not judge the effect of the presence of the 
rheumatoid factor on the degree of joint destruction. 
In three of five open prospective radiologic studies of low-dose methotrexate, radio-
graphs were taken at variable intervals (10, 13, 14). In two studies (13, 14) the interval 
between the first radiograph (that is, the time of start of methotrexate therapy) and the 
second ranged from 10 to 50 months (mean, 30 months). In the third study, follow-up 
radiographs were taken after a minimum of 28 months (10). In two other studies (11, 
12), there was a fixed interval of 2 years between the first two radiographs followed by 
annual radiographs in one study (11). Hand and wrist radiographs were evaluated in three 
studies (10, 12, 14), whereas, in the other two studies (11, 13) (as in our study), radio-
graphs of the feet were also evaluated. Mean disease duration, method of radiologic 
assessment, and criteria used for defining clinical improvement were not always compa-
rable in these studies. One group of investigators demonstrated worsening of radiographs 
in 6 of 14 patients, no change in 3, and radiologic improvement in 5 patients (10). A 
second group of investigators (11) found radiologic stabilization in all patients and impro-
vement in radiologic scores in several patients after 2 years. After 3 years of methotre-
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xate therapy, however, 36% of patients had radiologic deterioration (11). Hanrahan and 
colleagues (12) found radiologic stabilization in 18 of 47 patients on methotrexate after 2 
years and marked radiologic deterioration (that is more than 10 units of change in the 
radiologic score) in 16 patients despite clinical improvement. Nordstrom and colleagues 
(13) suggested that methotrexate could not significantly alter the rate of radiologic pro­
gression. Reykdal and colleagues (14) showed slowing of radiologic progression in 8 of 
15 patients. The mean rate of radiologic progression in IS patients during methotrexate 
therapy, however, did not differ significantly from the rate of radiologic progression 
before methotrexate treatment (14). Interpretation of the results of all five studies is 
limited by lack of an adequate control group. Comparison of our radiologic results with 
those from another double-blind trial of azathioprine compared with methotrexate (9) is 
difficult, because the number of patients with radiographs available for evaluation after 
one year in that study was probably too small (azathioprine, 12; methotrexate, 9) to yield 
significant results. 
We have shown that after 1 year of therapy, patients who started on methotrexate 
therapy had significantly better radiologic results compared with patients who started on 
azathioprine therapy. The slowing of damage in the joints of the hands, wrists, and feet 
in favor of methotrexate suggests that administering methotrexate before azathioprine is 
preferable in patients with rheumatoid arthritis. 
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8.1 ABSTRACT 
The aim of Ms study was to investigate whether periodu pubnonary function tests 
and chest radiographs were useful for detecting methotrexate (MTX)-ùiduced pubnona-
ry toxidty in rheumatoid arthritis (RA). It was also investigated whether pre-existent 
pubnonary abnormalities were a risk factor for development of MTX pneumonitis. 
In a randomized, double-band study of 64 patients with active refractory rheumatoid 
arthritis (RA), patients received initially either azathioprüu (AZA), 100 mg daily, or 
MTX, 7.5 mg weekly orally. Depending on the clinical effect qfter 8 weeL· the dosage 
was increased to 150 mg AZA or 15 mg MTX. Extensive pubnonary function tests (spi-
rometry, flow volume curves, CO diffusion, compliance) and chest radiographs were 
performed at baseline, qfter 24 weeks and qfter 2 years. 
Results of baseline pulmonary function tests, performed in 52 patients (27 AZA; 25 
MTX), were not significantly different between the two groups and showed abnormal 
results in one or more function tests in 15 to 50% of patients. Five patients had radio-
gruphu signs of lung fibrosis, one pleural effusion, and one pulmonary nodules. After 
24 weeks and 2 years, results of pubnonary function tests and chest radiographs 
showed no changes either within the two groups or between both groups. Patients with 
pre-existent lung abnormality did not develop MTX-induced pubnonary toxicity. An 
association between presence of keratoconjunctivitis sicca and small airways disease in 
RA was confirmed. 
Conclusion: The results of titis study suggest no need for periodic pubnonary func-
tion tests and chest radiographs during MTX therapy in RA. Patients with pre-existent 
pubnonary abnormalities did not develop MTX-induced pulmonary toxicity, suggesting 
that these patients are not more at risk for MTX-induced pneumonitis than others. 
8.2 INTRODUCTION 
Methotrexate-induced pulmonary toxicity is an uncommon but potentially fatal adverse 
reaction of low-dose methotrexate therapy in rheumatoid arthritis (RA) (1,2). Therefore 
pulmonary function tests and chest X-rays were performed in RA patients who entered a 
double-blind study of azathioprine (AZA) compared with methotrexate (MTX) (3). 
The major objective of this study was to investigate whether periodic pulmonary 
function tests and chest X-rays were useful for detecting MTX-induced pulmonary 
toxicity. The patients on azathioprine therapy served as a control group. We also were 
interested in the question whether pre-existent pulmonary abnormalities (mainly lung 
fibrosis) were a risk factor for development of MTX-induced pulmonary toxicity. A 
question of secondary importance was whether there was an association between the 
presence of keratoconjunctivitis sicca in RA and the presence of small airways disease. 
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8.3 PATIENTS AND METHODS 
Patients. Sixty-four patients with active classical or definite RA, were enrolled in the 
period November 1986 and November 1988. All the patients were refractory to or reac­
ted with toxicity to at least parenteral gold. Three quarters of the patients had used 
hydroxychloroquine and also three quarters of patients had previously received D-peni-
cillamine. Active RA was defined by the following four criteria: six or more joints 
tender or painful at motion, three or more swollen joints, Westergren erythrocyte sedi­
mentation rate (ESR) above 28 mm/first hour, morning stiffness for at least 43 minutes. 
Excluded from the study were patients with abnormal liver function tests (liver enzymes 
twice the normal value), renal clearance less than SO ml/min, hematological abnormalities 
(leucocytes <3.5 χ 10'/1 or platelets <150 χ lO'/l), insulin dependent diabetes mellitus, 
malignancy, alcohol abuse (more than 4 oz/day), active peptic ulcer disease, (recurrent) 
infections, inadequate contraception, use of allopurinol or antifolate drugs such as 
sulfonamide derivatives, age <16 or >75 years, and functional class according to 
Steinbrocker (4). The protocol of the study was approved by the Ethical Committee and 
each patient gave informed consent prior to the study entry. 
Patients were randomly allocated to receive either MTX or AZA in blocks of six 
patients. Stratification for functional class (4) II or III was made. Initially patients 
received either two tablets of 50 mg AZA daily and three placebo capsules MTX weekly 
at three consecutive 12-hour intervals or 3 capsules each containing 2.5 mg MTX 
(divided dose regimen) weekly and two placebo tablets of AZA daily (double dummy 
technique). Patients with less than partial 'overall' improvement (definition see below) 
after 8 weeks received the increased dosage schedule viz. AZA, 150 mg daily, or MTX, 
15 mg weekly, during the double-blind phase of the study. 
A good 'overall' improvement was defined as 50 percent or more improvement of at 
least three of four disease variables [Ritchie articular index, ESR, pain score (visual 
analogue scale) and morning stiffness]. A partial improvement was defined as improve­
ment of 30 to 50 percent in at least two of the four disease variables and no worsening 
of the remaining variables compared with initial values. Only in patients with good 
overall improvement at week 24 was trial medication continued until week 48 using the 
double-blind protocol. Withdrawal of the initial drug followed in patients with no effect 
after week 24, or in patients with serious adverse reactions to the drug at any time 
during the study period. These patients received the alternative drug in an open phase 
viz. AZA instead of MTX and vice versa, unless contraindicated. Therapy with AZA or 
MTX was also continued after week 48 depending on the clinical effect at that time and 
on absence of toxicity. The disease activity was assessed with the validated disease 
activity score (DAS) (5), consisting of the variables Ritchie articular index, swollen joints 
count, ESR and general health (visual analog scale). 
The dosages of nonsteroidal anti-inflammatory drugs (NSAIDs) and prednisone ( ¿10 
mg/day) were held stable for at least 4 weeks before study entry and also throughout the 
study. 
Patients came from 5 different clinics, but clinical investigation of all the patients 
during the study period was done by the same physician (M.J). Clinical assessments 
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(number of tender joints, Ritchie articular index, number of swollen joints, assessment of 
pain and general health using a visual analog scale of 0-100 mm, morning stiffness, grip-
strength) and laboratory assessments were carried out every 4 weeks for the first 24 
weeks and thereafter every 8 weeks until week 48. A complete medical history and 
physical examination were performed at the start of the study and repeated after 24 and 
48 weeks, and after 2 years. With regard to smoking status, smokers were considered to 
be those who currently smoked, non-smokers those who had never smoked, ex-smokers 
those who had smoked. A Schirmer test was considered abnormal when S mm or less of 
the paper slip was wet. Only patients with sicca symptoms and/or abnormal Schirmer test 
(twice < 5mm) were examined by an ophthalmologist. In these latter patients rose 
bengal staining on slit lamp examination of the eyes was performed. A chest radiograph 
was made at baseline and after 2 years. 
Pulmonary function tests. Lung volumes were obtained by standardized helium dilution 
techniques with a spirometer (Pulmonet III, Gould). All volumes were corrected for 
standard conditions of BTPS (body temperature, pressure, saturation) and expressed as 
percentages of the predicted values (6,7). Forced expiratory volume in one second 
(FEV,) was assessed from a forced expiration into the spirometer. Flow-volume curves 
and forced vital capacity (FVC) were assessed by means of the pneumoscreen of Jaeger. 
Flow-volume curves were obtained by plotting flow (V in 1/sec) against volume (V in 1) 
during a maximal expiration manoeuvre. The parameters MEF50 and MEF25 (Maximum 
Expiratory Flow) were defined as the values when 50% and 25% of FVC, respectively, 
still have to be expelled (8). The diffusion capacity (DLCO) was measured using the 
single breath method with carbon monoxide (Transfer screen II, Jaeger). The values of 
DLCO were corrected for hemoglobin concentration (8). The lung compliance (semi-
static) was obtained by means of an esophageal balloon and measured in the body box 
(Body screen II, Jaeger). According to the guidelines of the American Thoracic Society, 
normal values of total lung capacity (TLC), vital capacity (VC), DLCO and compliance 
are ± 20% of the predicted values (6). The ratio FEV/FVC had to exceed 75% of the 
predicted values (6). A ratio FEV/FVC below 75% is indicative of obstructive lung 
disease (6). MEF50 and MEF25 are considered abnormal if the values of these para-
meters are less than 60% of the predicted values (7,8). Isolated MEF50 < 60% suggests 
small airways disease (8), whereas TLC and VC <80% suggest restrictive lung disease 
(9). 
Statistical analysis. Since patients were randomly allocated to the two treatments, there 
was only a 5% chance of statistically significant differences in baseline variables. 
Nevertheless we assessed the results of the allocation procedure by standard statistical 
tests. Differences in characteristics between the two treatment groups were assessed with 
chi-square tests for nominal variables whereas for continuous variables such as age and 
disease duration, Student two-sample test was applied. Differences in results of pulmona-
ry function tests after 24 weeks and 2 years within each group were assessed with the 
Student one-sample test. Clinical and laboratory variables and changes in patients who 
continued on the same drug for 24 weeks and for 2 years were assessed. 
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Table 1. Demographie characteristics and disease variables at baseline of 64 
patients with rheumatoid arthritis treated with either azathioprine or 
methotrexate 
Azathioprine 
(N=33) 
Methotrexate 
(N = 31) 
Age (years) 
Disease duration (yr) 
Functional class II:III, (n) 
Sex, F:M, (n) 
Smokers, (n) 
Ex-smokers, (n) 
COPD, (η) φ 
Number of patients with: 
Rheumatoid factor 
(latex titers 1:80) 
Antinuclear antibody (ANA) 
HLA-DR4 
Subcutaneous nodules 
Sicca syndrome 
Lung fibrosis 
(chest X-ray) 
Disease variables: 
Ritchie articular index 
Swollen joints 
Pain score (VAS) § 
Morning stiffness (min) 
ESR (mm/Phr) $ 
55.8 ± 9.3 
9.4 ± 5.6 
26 : 7 
17 : 16 
10 
7 
1 
33 
20 
22 
11 
6 
3 
22.4 ± 9.6 
18.7 ± 7.0 
54.6 ± 21.7 
109 ± 83 
60.2 ± 27.9 
57.3 + 
12.8 ± 
25 
26 : 
5 
3 
1 
29 
14 
19 
11 
3 
2 
19.6 + 
18.8 ± 
49.6 ± 
9.5 
10.0 
6 
5 « 
6.5 
7.2 
18.7 
82 ± 79 
57.5 ± 27.9 
Mean ± s.d. 
Significant difference (p=0.01) between the two groups 
Chronic obstructive pulmonary disease 
Visual analogue scale, 0 mm meaning no pain and 100 mm very severe pain 
Erythrocyte sedimentation rate in mm in first hour 
Regarding to the clinical disease activity, an improvement by 1.08 of the disease activity 
score (DAS) was considered to be significant (5). 
8.4 RESULTS 
Demographic and clinical features of the 33 AZA and 31 MTX patients at the start of 
the study were comparable except for a significant difference in gender (Table 1). 
Twenty AZA and 30 MTX patients completed 24 weeks of AZA and MTX respectively. 
At the time of data collection 35 patients (18 AZA; 17 MTX), had completed 2 years of 
follow-up. A significant improvement of the DAS at 24 weeks was found in 6 AZA and 
18 MTX patients. After two years, 4 of the 18 patients from the AZA group still used 
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Table 2. Baseline values of pulmonary function tests and changes after 24 weeks of 
azathioprine or methotrexate therapy expressed as percentages of predic­
ted values 
Azathioprine Methotrexate 
baseline change baseline change 
0 wk 24 wk 0 wk 24 wk 
N=27 N=15 N=25 N=25 
Total lung capacity * 
(TLC) 
Vital capacity (VC) * 
FEV,® 
FEV./FVC ratio φ 
CO diffusion 
MEF50 § 
MEF25 § 
Lung compliance 
101% ± 18% 
101 
98 
92 
91 
68 
48 
121 
± 2 0 
± 2 1 
± 12 
± 16 
± 3 0 
± 2 6 
± 90 
1.4% 
1.2 
2.4 
-1.0 
-0.0 
-3.6 
-1.3 
-26 
± 
± 
± 
± 
± 
± 
± 
± 
7.6% 
8.0 
8.8 
5.7 
14.8 
15.6 
12.2 
109 
95% ± 11% 
96 
100 
96 
87 
69 
52 
93 
± 14 
± 2 5 
± 2 1 
± Π 
± 3 0 
± 3 1 
± 61 
-1.8%± 5.8 
-0.5 
-2.1 
-2.5 
1.5 
-2.2 
-5.5 
-5.9 
± 9.7 
± 10.8 
± 21.9 
± 8.8 
± 15.9 
± 19.2 
± 24.3 
* ± Standard deviation (normal value of TLC and VC ¿80%) 
@ FEV, = forced expired volume in one second (normal value ¿80%) 
φ FVC = forced vital capacity (normal value of FEV,/FVC ä75%) 
§ MEF50 and MEF25 mean maximal expiratory flow when 50% and 25% respectively of FVC 
still had to be expelled (normal values ¿60% of predicted) 
AZA, whereas 11 of the 17 patients from the MTX group still used MTX. Significant 
clinical improvement after 2 years was found in 4 AZA and 7 MTX patients. The num-
ber of withdrawals due to severe side effects was significantly (P=0.03) higher in the 
AZA group compared with the MTX group (13 versus 2 patients). In 2 MTX-treated 
patients pneumonia was diagnosed. The causative agent was unknown. MTX was tempo-
rarily (3 weeks) discontinued and patients received antibiotics. 
At study entry pulmonary function tests were performed in 27 AZA and 25 MTX 
patients. In the first 6 patients of the trial (4 AZA, 2 MTX), no pulmonary function tests 
were performed. Owing to other reasons (technical difficulties, refusal), pulmonary 
function tests were performed in 15 of 20 AZA and 25 of 30 MTX patients (Table 2). At 
2 years we had results of pulmonary function tests from 19 of 35 patients. None of the 
patients had respiratory symptoms at the start of the study. In 9 patients (6 AZA, 3 
MTX) basal rales were heard on initial physical examination. During follow-up no increa-
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Table 3. Number of RA patients with normal or decreased pulmonary function 
tests at the start of the study and after 24 weeks of therapy with 
azathioprine or methotrexate 
Normal TLC * 
Decreased TLC @ 
Normal VC 
Decreased VC 
Normal FEV, 
Decreased FEV, 
Normal FEV,/FVC 
Decreased FEV, /FVC 
Normal CO diffusion 
Decreased CO diffusion 
Normal MEF50 
Decreased MEF50 
Normal MEF25 
Decreased MEF25 
Normal static compliance 
Decreased static compliance 
Azathioprine 
Owk 
N=15 
24 wk 
N=15 
Number of patients 
13 
2 
13 
2 
11 
4 
13 
2 
10 
5 
8 
7 
5 
10 
Π Φ 
4 
13 
2 
12 
3 
12 
3 
12 
3 
9 
6 
9 
6 
6 
9 
12 φ 
2 
Methotrexate 
0 wk 
N=25 
20 
5 
21 
4 
21 
4 
21 
4 
18 
7 
i ; + 
7Φ 
14 
I* 
24 wk 
N=25 
22 
3 
20 
5 
20 
5 
20 
5 
16 φ 
8 
12 φ 
9 
7 φ 
14 
f * 
TLC = Total lung capacity; VC = vital capacity; FEV, = forced expiratory flow in one second 
FVC = forced vital capacity; MEF50 and MEF25 = maximal expiratory flow when 50 and 
25% respectively of FVC still have to be expelled. 
Decreased values of TLC, VC, FEV,, CO diffusion and Static Compliance are values below 
80% of predicted; FEV./FVC ratio <75% is abnormal; decreased MEF50 and 25 are results 
below 60% of predicted values. 
Several functions tests were measured in fewer patients than the total group of 15 AZA and 25 
MTX patients due to refusal, technical difficulties or other reasons. 
se of rales was found. After 24 weeks we found no significant changes in pulmonary 
function tests either within each group or between the two groups (Table 2). 
In Table 3 pulmonary function tests are presented in a different way. For each of the 
function tests, patients were divided in two categories: having normal or decreased values 
at baseline and week 24. At study entry 15% of the patients had restrictive lung disease. 
Thirty-seven percent of the patients had abnormal CO diffusion, whereas in 50% abnor­
mal flow/volume curves were found. Half of the patients with abnormal flow/volume 
curves were smokers or ex-smokers. A low semistatic compliance was observed in more 
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Table 4. Pulmonary function tests expressed as percent predicted values after 24 
weeks and 2 years of continued MTX therapy in 9 RA patients 
TLC® 
VC 
FEV, 
FEV,/FVC 
CO diffusion 
MEF50 
MEF25 
Semistatic compliance 
0 wk 
95 ± 9% * 
94 ± 13% 
92 ± 31% 
85 ± 24% 
84 ± 20% 
70 ± 47% 
54 ± 39% 
121 ± 88% 
24 wk 
94 ± 9% 
93 ± 14% 
93 ± 26% 
97 ± 16% 
84 ± 20% 
77 ± 35% 
61 ± 20% 
109 ± 73% 
2 years 
98 ± 7% 
96 ± 10% 
99 ± 26% 
91 ± 17% 
86 ± 20% 
69 ± 36% 
54 ± 27% 
107 ± 55% 
* Mean ± SD 
@ Abbreviations as in Tables 2 and 3 
than 50% of the patients who started on MTX and in 25% who started on AZA. The 
number of patients who had abnormal pulmonary function tests at the start of the study 
was almost equal to the number of patients with abnormal function tests at week 24 
(Table 3). Because of the low number of AZA patients (3 patients) who completed 2 
years of the same therapy and of whom pulmonary function tests were done, only the 
results of pulmonary function tests of 9 MTX patients at 2 years are listed in Table 4. 
This table shows no changes in pulmonary function tests after 2 years of weekly MTX. 
Otherwise the pulmonary function tests of the three AZA patients did also not change. 
Comparison of initial chest radiographs with those at 2 years did not show any sub-
stantial changes. 
A Schirmer test performed in 58 patients was abnormal in 14 patients. A false positive 
test (absence of sicca symptoms and normal rose bengal test) was found in 5 of the 14 
patients (36%). In 9 patients (15%) keratoconjunctivitis sicca was diagnosed. Two of the 
9 patients lack sicca symptoms. Labial salivary gland biopsies were not performed. In 
Table 5 it is demonstrated that 6 of the 9 patients with keratoconjunctivitis sicca had 
small airways disease based on the findings of MEF50. All but one patient was positive 
for HLA-DR4 antigen and rheumatoid factor. 
8.5 DISCUSSION 
To our knowledge this is the first controlled study in which the role of periodic 
pulmonary function tests and chest radiographs is evaluated for monitoring MTX-induced 
pulmonary toxicity in RA. In 1987 it was recommended to perform baseline and annual 
chest radiographs and pulmonary function tests in RA patients treated with low-dose MTX 
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Table 5. Characteristics of 9 RA patients (б AZA; Э MTX) with keratoconjuncti­
vitis sicca (KCS) * 
Variable Number of patients 
Decreased MEFSO @ 6 
Decreased MEF25 @ 6 
Abnormal FEV,/FVC =j= 1 
Abnormal CO diffusion § 2 
Lung fibrosis (chest X-ray) 0 
Non smokers 6 
Latex titer à 1:80 9 
ANA 4 
HLA-DR4 8 
Subcutaneous nodules 8 
* Diagnosis based on least 2 of 3 criteria: history of dry eyes, abnormal Schirmer, abnormal rose 
bengal staining on slit lamp examination 
@ ¿60% of predicted values 
4= £75% of predicted values 
§ ¿80% of predicted values 
until more data were available (10). The prevalence of MTX-induced pneumonitis in 
large scale studies of RA patients ranges from 3 to 5.5% (1,11,12). 
At study entry demographic and clinical characteristics (except for gender) as well as 
values of pulmonary function tests were equal in patients treated with AZA or MTX. The 
clinical data revealed that more patients on MTX than on AZA showed significant 
clinical improvement, whereas more patients on AZA developed serious (non-pulmonary) 
side effects leading to withdrawal. 
In order to get detailed information of possible changes in the lung, extensive pulmo-
nary function tests and chest radiographs were performed. Baseline pulmonary function 
tests showed that a considerable percentage (15-50%) of RA patients had one or more 
abnormal pulmonary function tests. These percentages agree with percentages reported in 
the literature: 0 to 20% foi restrictive lung disease (8,13), 30 to 80% for small airways 
disease (8,13,14,15,16), and 25 to 70% for decreased CO diffusion (8,16). Results of 
studies evaluating chronic obstructive airways disease in RA are often difficult to inter-
pret due to confounding effects of smoking and concurrent restrictive lung disease (17). 
However, obstructive lung disease in a subgroup of non smoking RA patients with Sicca 
syndrome has been demonstrated (13,17,18). 
The mean results of pulmonary function tests expressed as percentages of predicted 
values in our study were comparable with results reported elsewhere (17), except for 
lower results of MEF50 in our patients. After 24 weeks we found no significant changes 
in pulmonary function tests either within each treatment group or between the patients 
from the MTX or the AZA group (Tables 2 and 3). In an uncontrolled study of 34 RA 
patients treated with MTX also no significant changes in three measured pulmonary 
function tests (VC, FEV,, and CO diffusion) were found. The time of pulmonary func-
tion testing in that study ranged from 34 to 52 weeks (19). 
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After 2 years of continued MTX therapy we did not find important changes in 
pulmonary function tests or chest radiographs. The 24 weeks and 2 years findings of this 
study suggest that there is no need for periodic testing of pulmonary function or chest 
radiographs during treatment with MTX in RA. The number of studied patients, 
however, was relatively small, mainly the 2-year group. 
Based on retrospective findings and small numbers of patients two authors (12,20) have 
suggested that pre-existent lung disease (lung fibrosis, decreased CO diffusion) and 
smoking history (12) may predispose to MTX pneumonitis. In a large sized (154 RA 
patients) study, clear predisposing factors for MTX pneumonitis were lacking (11). In 
our study we did not find MTX-induced pulmonary toxicity, not even in patients with 
pre-existent pulmonary abnormalities: ten patients on MTX had one or more signs of 
pulmonary abnormalities of whom 4 had decreased CO diffusion, 3 radiographic signs 
compatible with lung fibrosis, 1 had pulmonary nodules, decreased VC and CO diffusion 
(<50% of normal), 1 pleural effusion and 1 patient chronic obstructive pulmonary 
disease (FEV, 40% of normal value). In all these patients pulmonary function tests and 
chest radiographs remained stable during MTX therapy. The 2 MTX-treated patients with 
pneumonia were nonsmokers, had no immunoglobulin deficiency or pre-existent lung 
abnormality. The clinical findings, response to antibiotics, and disease course, argued 
against a diagnosis of MTX pneumonitis. 
In accordance with the literature (13,18) we could confirm the association between 
presence of keratoconjunctivitis sicca in RA and presence of small airways disease and 
the HLA-DR4 antigen. We also found that all but one patient in this subgroup of RA 
patients (N=9) had subcutaneous nodules. Since only 3 of these 9 patients smoked, none 
of them had recurrent respiratory infections or restrictive lung disease, abnormal flow-
volume curves in this subgroup may represent small airways disease as an extra-articular 
feature of RA. Airflow obstruction in these patients is considered to be caused by lym-
phocytic infiltration of bronchioles (13,18). 
In conclusion we have demonstrated that pulmonary function tests and chest radio-
graphs do not change in RA patients treated with MTX (or AZA). Patients with pré-
existent lung disease did not develop MTX-induced pulmonary toxicity in this study. An 
association between the presence of keratoconjunctivitis sicca in RA and small airway 
disease was confirmed. In view of the prevalence of MTX-induced pulmonary toxicity, 
we recommend to have baseline chest radiographs and pulmonary function tests 
(spirometry, CO diffusion) before starting MTX in RA patients. The results of this study 
suggest no need for periodic pulmonary function tests and chest radiograph during MTX 
therapy. Long-term prospective studies of larger number of patients are necessary for 
definite conclusions. 
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ABSTRACT 
Two patients with rheumatoid arthritis developed pancytopenia during treatment with 
azathioprine 100 mg daily. In one patient this side effect occurred qfter three weeks, in 
the other qfter eight weeks of treatment. Rapid fall of platelets in one patient necessi­
tated platelet transfusion. In the other patient additional treatment with aUopurinol was 
probably responsible for the toxic effect. Haematological side effects of azathioprine 
are discussed. 
Key words: adverse drug reaction, bone marrow suppression 
Azathioprine has been extensively used for more than 20 years in the treatment of 
patients with rheumatoid arthritis (RA) who are unresponsive or react with side effects to 
gold salts or D-penicillamine, or both. At a dosage of 1.5-2.5 mg/kg/day the toxic reac­
tions of azathioprine are moderate and limited mainly to gastrointestinal and mild haema­
tological complications (1,2). 
Pancytopenia in relation to this drug is a rare side effect. So far, 18 cases of pancy­
topenia during azathioprine treatment used for a variety of diseases, given in different 
dosages and in combination with different other drugs, have been reported world wide 
(3). Detailed descriptions of these cases are mostly lacking. 
We report two patients with rheumatoid arthritis who developed pancytopenia while 
receiving azathioprine 100 mg daily. In one patient platelet transfusion was necessary 
because of severe thrombocytopenia. The pancytopenia disappeared in both patients after 
azathioprine treatment was stopped. 
CASE REPORTS 
Case 1. 
A 36 year old woman was diagnosed as suffering from seropositive RA in November 
1974. Besides non-steroidal anti-inflammatory drugs she was treated successively with 
hydroxychloroquine, gold thioglucose, and D-penicillamine. 
D-Penicillamine had to be discontinued twice owing to dermatitis. In August 1985 this 
drug had to be stopped permanently on account of leucopenia (2.4 χ lO'/l) and throm­
bocytopenia (60 χ 10*/1). Other abnormal laboratory findings were a positive antinuclear 
antibody (ANA) test and on immunoblotting weak anti-Sm and antihistone antibodies. 
Physical examination was normal and there were no signs of active arthritis. Drug 
induced systemic lupus erythematosus was suspected, and she was treated with predniso­
ne for several months. 
Because of active erosive RA involving wrists, knees, and proximal interphalangeal 
joints of the hands treatment with azathioprine 100 mg daily was started on 12 February 
1987. Except for indomethacin 150 mg daily she took no other drug. Three weeks after 
starting azathioprine RA activity was diminished. Blood tests showed leucopenia of 1.6 χ 
10'/1 and thrombocytopenia of 78 χ lO'/l. Azathioprine was immediately stopped. Five 
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Figure 1. Haematological changes during azatbioprine and indomethacin treatment 
in patient 1. (• = one unit of platelet transfusion) 
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days later the platelet count fell to 27 χ 10'/1. Petechiae developed on her legs and she 
was admitted to hospital. Examination showed little RA activity. Laboratory findings 
were erythrocyte sedimentation rate (ESR) 60 mm/lst h, haemoglobin 90.2 g/1, platelets 
18 χ lO'/l, leucocytes 1.8 χ 10'/1 with 47% granulocytes. Mean corpuscular volume 
(MCV) was 81 fmol/1, reticulocytes 0.2%. Except for a positive ANA test and anti-
double-stranded DNA (anti dsDNA) of 57 U/1 (normal less than 20 U/1), other laboratory 
tests, including lactic dehydrogenase, direct Coombs', antibodies to platelets and 
granulocytes, complement, and immunoblotting, showed no abnormalities. HLA analysis 
was A2, A28, B15, Bw4, Bw6, DR1, DQwl. A bone marrow biopsy showed a hypocel-
lular marrow with a shift of the myeloid series towards immaturity. Megakaryocytes 
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were absent and the erythroid precursors were partly megaloblastic. 
The pancytopenia was considered most probably to be related to azathioprine. From 
the first day in hospital indomethacin was also stopped. Treatment with prednisone 60 
mg daily was started and reduced in 10 days to a S mg maintenance dose. Two days 
after admission platelet transfusion was necessary because of a rapid fall of the platelets 
to 4 χ lO'/l. Otherwise there were no other problems. The lowest value of the leucocytes 
was 1.4 χ 10*/1 and of haemoglobin 75.7 g/1 (Fig. 1). 
After three weeks in hospital the patient was dismissed with a haemoglobin of 90.2 g/1, 
reticulocytes 4.5%, leucocytes 2.7 χ 10'/1, and platelets 173 χ 10*/1. Later a marrow 
biopsy specimen was completely normal and anti-dsDNA was repeatedly negative. At this 
time she felt well. Her only treatment being prednisone 5 mg daily. 
Case 2. 
A 68 year old man was diagnosed as suffering from seropositive RA in January 1976. 
He was then treated successively with hydroxychloroquine and gold thioglucose. Because 
of a recurrent duodenal ulcer he received a maintenance dosage of Cimetidine 400 mg 
daily. In January 1985 hyperuricaemia and nephrolithiasis from urate calculi were 
detected, and treatment with allopurinol 100 mg daily was started. One year later he was 
admitted to hospital because of active RA involving wrists, knees, proximal inter-
phalangeal and metacarpophalangeal joints of the hand. Subcutaneous nodules were 
present. Abnormal laboratory findings were ESR 81 mm/lst h, haemoglobin 114.3 g/1, 
creatinine 118 /tmol/1, and a creatinine clearance of 70 ml/min. Treatment with azathio­
prine 100 mg daily was started. In addition to allopurinol and Cimetidine, the patient had 
taken indomethacin 125 mg daily for several years. At the end of February 1986 a 
declining haemoglobin (82.1 g/1) occurred without melena or positive benzidine reaction. 
Values of leucocytes and platelets were normal. Gastroscopy showed superficial erosions 
in the bulbus. Two weeks later the patient was readmitted with pancytopenia. Physical 
examination was unchanged. Laboratory results were as follows: ESR 122 mm/lst h, 
haemoglobin 69.2 g/1, MCV 90 fmol/1, reticulocytes 0.1%, platelets 50 χ lO'/l, leuco­
cytes 2.8 χ 10'/1 with normal differential cell count. Renal function was unchanged. 
Other laboratory values were normal, including iron, folic acid, and vitamin B^. 
Bone marrow biopsy showed only a decreased number of megakaryocytes. After 
discontinuation of azathioprine, allopurinol, and indomethacin the counts of leucocytes 
and platelets returned to normal in two weeks. Two units of packed red blood cells were 
administered. Because of active RA azathioprine was restarted three weeks after admis­
sion at a dosage of 50 mg but now without allopurinol. Daily blood tests were 
performed. The dosage was increased after one week to 100 mg, but the drug had to be 
discontinued owing to isolated thrombocytopenia of 107 χ ltf/1. As the RA activity 
persisted, prednisone 10 mg daily was started and the platelet count became normal 
within one week. 
DISCUSSION 
These two patients with RA developed pancytopenia induced by azathioprine. Bacon et 
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al. have reported two patients with this serious side effect (4). They emphasized in one 
patient the possible additional role of allopurinol. In our second patient also allopurinol 
probably played a part in the development of pancytopenia. 
Azathioprine is an imidazole derivative of 6-mercaptopurine with immunosuppressive 
and anti-inflammatory effects. Its mode of action is based on incorporation of a false 
purine, leading to alteration and inhibition of the purine, DNA, and RNA synthesis. 
Haematological side effects of azathiopiine are dependent on the dosage. When the usual 
dosage (1.5 - 2.5 mg/kg/day) is given the interval before maximum bone marrow sup­
pression is about two weeks (5). We found the same interval in patient 1. 
Leucopenia is the most frequent haematological complication of azathioprine treatment. 
In published reviews about this adverse drug reaction in patients with RA the incidence 
of leucopenia ranges from 11 to 14.5% (1,2). Agranulocytosis within one week of aza­
thioprine administration is very rare and possibly an idiosyncratic reaction (5). Other 
haematological changes are thrombocytopenia, anaemia, and macrocytosis. Thrombocyto­
penia is an uncommon side effect reported in 0.8 - 4.8% of cases (1,2). It rarely deve­
lops without leucopenia. In our second patient isolated thrombocytopenia developed two 
weeks after restarting azathioprine. Pure red cell aplasia induced by azathioprine is a 
very rare adverse reaction. It reflects a selective toxic effect of azathioprine on erythro-
poiesis (6,7). Macrocytosis has been reported in transplant recipients and ascribed to 
interference with DNA synthesis (7-9). It is unrelated to the metabolism of folic acid or 
vitamin B12, or both. In our patients we could not find a significant alteration in the 
MCV. In the second patient a declining haemoglobin concentration occurred two weeks 
before the leucopenia and thrombocytopenia. When the negative result of the gastroscopy 
and the laboratory values are considered the anaemia appears to be related to azathio­
prine. 
In the case of patient 1 the general practitioner had not brought to our notice the 
haematological changes (leucocytes 3.3 χ 10'/1, platelets 123 χ 10'/1) a week before she 
visited us. At that time we could have discontinued or diminished the dosage. An 
additional toxic effect of indomethacin on the bone marrow was unlikely because she had 
taken that drug for many years. In retrospect, owing to the absence of megakaryocytes 
from the bone marrow and the absence of antibodies to granulocytes and platelets, the 
indications for administering high dosage prednisone were debatable. As she had deve­
loped leucopenia and thrombocytopenia while taking D-penicillamine in the past she may 
have been predisposed to bone marrow suppression due to different drugs. 
There are several reports of pancytopenia due to the combination of azathioprine and 
allopurinol (10-12), as occurred in patient 2. Azathioprine is rapidly converted to 6-
mercaptopurine. The major metabolite of 6-mercaptopurine, 6-thiouric acid, is excreted 
in the urine. The enzyme xanthine oxidase is responsible for this oxidation. Allopurinol 
inhibits this enzyme and so administration of azathioprine together with allopurinol gives 
rise to an increased 6-mercaptopurine blood concentration, which can induce bone 
marrow toxicity. If it is necessary to administer both drugs it is advisable to reduce the 
usual dose of azathioprine by about 75% (3,5). In patient 2 this mie was unfortunately 
not applied. 
Finally, when azathioprine is prescribed, close clinical and laboratory controls are 
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necessary. Increased toxicity due to additional drugs has to be considered. Fortunately, 
both these patients recovered completely irom this rare but dangerous adverse reaction to 
azathiopnne. 
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ABSTRACT 
Within one year three of 25 patients with rheumatoid arthritis treated with azathio-
prine 100 mg daily developed the following adverse reactions less than two weeks qfter 
starting treatment: patient one showed fever wùh chiUs, rash, and severe liver function 
abnormalities suggestive of cholestasis; the second patient had fever, nausea, diar-
rhoea, and moderately raised liver enzymes; the third patient showed very high fever 
and severe chills. In two patients the drug was rechallenged, with more rapidly arising 
and more severe symptoms. In one case raised liver enzymes persisted until seven 
months qfter discontinuation of azathioprine. Hypersensitivity reactions and hepato-
toxicity of azathioprine are discussed. 
Hypersensitivity reactions to azathioprine -for example, fever, myalgia, arthralgia, and 
rash- are well known, but rare, adverse reactions to the drug (1). To our knowledge the 
combination of liver function abnormalities with fever, chills, and rash has been reported 
before in only two patients (2). Recently, we observed in one year three patients with 
rheumatoid arthritis (RA) treated with 100 mg azathioprine daily who developed fever 
and chills with liver function abnormalities (two patients) and rash (one patient). 
The clinical picture of these three patients is described and allergic adverse reactions to 
azathioprine and the hepatotoxicity of the drug are discussed. 
CASE REPORTS 
Case 1. A 49 year old man was diagnosed as having seropositive RA since 1972. He 
had been successively treated with parenteral gold and D-penicillamine. Both drugs were 
ineffective. For several years he also took diclofenac 150 mg daily. 
In April 1988 treatment with azathioprine (100 mg daily) was started because of active 
RA involving shoulders, elbows, hands, and feet. Laboratory findings were as follows: 
erythrocyte sedimentation rate (ESR) 42 mm/h and haemoglobin 130 g/1. Apart from an 
increased concentration of IgA 4.5 g/1 (normal <2.6 g/1), other laboratory values were 
normal. Ten days after starting azathioprine he developed fever (38.50C) with severe 
chills, diarrhoea, and dermatitis of his hands. Azathioprine was discontinued and labo-
ratory values showed a greatly increased ESR of 108 mm/h, alkaline phosphatase 317 U/l 
(normal <120 U/l), and gamma-glutamyltransferase 176 U/l (normal <40 U/l). Two 
days later the clinical situation worsened and he was admitted to hospital. Apart from 
severe dermatitis of his hands with vesicles and pustules and a moderately active RA, 
physical examination on admission was normal. Laboratory findings were as follows: 
ESR 93 mm/h, haemoglobin 120 g/1, leucocytes (including eosinophils) and platelets 
normal. Alkaline phosphatase 810 U/l, gamma-glutamyltransferase 295 U/l, serum aspar-
tate aminotransferase (AST) 127 U/l (normal <25 U/l), serum alanine aminotransferase 
(ALT) 150 U/l (normal <30 U/l). Bilirubin total and direct slightly raised at 26 and 18 
μΐηοΐ/ΐ (normal < 10 pmol/l and 1 μπιοΐ/ΐ respectively), lactic dehydrogenase and amyla­
se normal. 
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Figure 1. Changes of liver function tests [alkaline phosphatase (AP), G-glutamyl-
transferase (GGT), serum aspartate aminotransferase (AST), serum alani­
ne aminotransferase (ALT)] during treatment of patient No 1 with aza-
thioprine and diclophenac. 
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Blood cultures showed no growth. Tests for syphilis, hepatitis A and B, and cytomegalo-
vims were negative. Antinuclear antibody, antibodies against mitochondria and smooth 
muscle were also negative. HLA typing: A2, B5, B15, Bw62, Bw4, Bw6, DR4, DRw52, 
DQw2, DQw3. Ultrasonography of gall bladder, biliary tract, liver, and pancreas was 
normal. 
Because all liver enzymes rose further (maximum alkaline phosphatase 935 U/1, AST 
290 U/1) a liver biopsy was performed. Histological examination showed only some 
(peri)portal infiltration and several necrotic liver cells, but neither cholestasis nor 
cirrhosis. The figure shows the course of the liver function tests. He was dismissed with 
diclofenac 150 mg. In July 1988 the RA was more active and prednisone 7.5 mg daily 
was started. The liver enzymes normalized only seven months after dismissal. 
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Case 2. A 63 year old woman had been suffering from seropositive RA since 1977. 
Besides indomethacin ISO mg daily she had been treated with hydroxychloroquine 
sulphate, D-penicillamine (thrombocytopenia), oral gold tablets (ineffective), and sulpha-
salazine (fever, exanthema). She refused parenteral gold treatment. In March 1987 she 
was admitted to hospital because of active RA involving knee, hands, wrists, and 
shoulders. The ESR was 97 mm/h, haemoglobin 115 g/1, IgA 4.9 g/1, IgG 16.3 g/1 
(normal < 14.6 g/1). Other laboratory findings were normal. HLA typing: A2, Awl9, 
B13, B15, Bw4, Bw6, DR4, DR7, DRw53, DQw2, DQw3. 
Thirteen days after starting azathioprine 100 mg daily she developed fever (39 0C), 
nausea, vomiting, and diarrhoea. Blood tests showed raised alkaline phosphatase (240 
U/l) and gamma-glutamyltransferase (76 U/l). Blood cells counts were unchanged. 
Transaminase and amylase were normal. Blood cultures showed no growth. Ultrasono­
graphy of the abdomen was normal. Azathioprine was discontinued. Five days later one 
tablet of azathioprine was given by accident and within two hours diarrhoea and fever 
(39.50C) again occurred. Liver enzymes returned to normal in two weeks. She was 
successfully treated with 15 mg methotrexate orally weekly. This drug caused no liver 
dysfunctions. 
Case 3. A 74 year old woman was diagnosed as suffering from seropositive RA since 
1984. Besides diclofenac 100 mg daily she had been treated with parenteral gold for one 
year and D-penicillamine 750 mg daily for 18 months. Both drugs were ineffective. In 
October 1987 azathioprine 100 mg daily was started because of active RA involving 
wrists, hands, left shoulder, and jaws. Laboratory findings showed an ESR of 30 mm/h, 
С reactive protein 51.0 mg/1 (normal <6.0 mg/1), haemoglobin 125 g/1. Apart from a 
diminished renal function (estimated creatinine clearance 60 ml/min) and raised IgA (4.1 
g/1) and IgG (21.6 g/1), other laboratory values were normal. HLA typing: A2, A29, 
B12, B27, Bw4, Bw6, DR4, DRw53, DQw3. 
On the 13th day of azathioprine treatment she showed fever (38.50C), dry cough, and 
some nausea. Laboratory studies showed slight leucopenia (3.1 χ 10'/1) with normal dif­
ferential count. A viral infection was suspected and azathioprine was temporarily dis­
continued. Two weeks later azathioprine was restarted. Within two hours of taking one 
tablet severe fever (41.5CC) with chills occurred which necessitated hospital admission. 
Examination showed no hypotension and no other findings to explain the high fever. 
Repeated blood tests showed an ESR of 35 mm/h. Leucocytes, differential count, and 
liver function tests were normal. Blood cultures showed no growth and a chest radio­
graph was normal. Two days after admission and discontinuation of azathioprine she was 
afebrile. Treatment with oral methotrexate (7.5 mg weekly) had to be discontinued five 
months later because of stomatitis and dermatitis. 
DISCUSSION 
Our finding of azathioprine hypersensitivity reactions in three of 25 (12%) patients 
with RA followed up for one year is remarkable. Bell et al. (ARA meeting, Houston, 
May 1988) have also reported a high percentage of azathioprine hypersensitivity reactions 
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(4/17; 24%). The presence of these side effects in larger numbers of patients with RA, 
our own previous study included, was between < 1% and 5% (1,3,4,5). 
To our knowledge the triad (severe liver function abnormalities, rash, fever with chills), 
as shown in patient 1, has been reported only once before in two out of a series of 50 
patients with RA (2). Hypersensitivity reactions or hepatotoxicity, or both, due to aza-
thioprine have also been reported in patients with diseases other than RA (6-10). 
Although a genetic predisposition to azathioprine toxicity is speculative, we found a 
striking similarity of HLA typing in patients 1 and 2, both having the phenotypes A2, 
B15, Bw4, Bw6, DR4, DQw2, DQw3. Patient 3 also had these phenotypes except B15 
and DQw2. In 171 other patients with RA treated with different drugs we did not find 
the HLA typing of cases 1 and 2. We could not confirm an association between a low 
Ig A concentration and azathioprine hepatotoxicity (11) because the patients we described 
all had repeatedly raised IgA concentrations. 
Hypersensitivity reactions to azathioprine have been found to occur mostly within two 
weeks of starting treatment (2,6). That interval was also seen in our three patients. 
Hepatotoxicity associated with azathioprine can develop between two weeks and 33 
months after starting treatment (6,8), possibly depending on the origin of hepatotoxicity. 
The mechanisms of azathioprine hepatotoxicity may be threefold-namely (a) allergic (with 
simultaneous systemic allergic symptoms); (b) direct hepatotoxic [exact mechanism 
unknown (12)]; (c) blockade of the liver blood outflow at the junction of sinusoids and 
centrilobular veins, causing peliosis hepatitis (13). Davis et al. have suggested that the 
imidazole moiety of azathioprine causes the allergic symptoms and the 6-mercaptopurine 
moiety the liver injury (10). Histologically, the picture of azathioprine hepatotoxicity 
consists of intrahepatic cholestasis with variable degrees of liver cell necrosis and slight 
(peri)portal inflammatory reaction. Biochemically, abnormal liver function tests are 
found, ranging between a cholestatic pattern and increase of transaminase (6,12). Aza-
thioprine hepatotoxicity is mostly a reversible process, but normalization of liver 
enzymes can take several months (8), as shown in patient 1. For different reasons it 
seems unlikely that diclofenac had a role in the production of liver dysfunctions in patient 
1. Firstly, he had already used that drug for several years without side effects. Secondly, 
liver function returned to normal (very slowly) while treatment with diclofenac was conti-
nuing. Thirdly, the pattern of liver enzyme increase (cholestatic) is unusual for diclofenac 
hepatotoxicity (14). 
Reintroduction of a smaller dose of azathioprine in dose related hepatotoxicity seems 
justified (9), but rechallenge of azathioprine when there is a suspicion of hypersensitivity 
can be dangerous and lead to life threatening shock (15-17). 
In patient 2 the reintroduction of azathioprine was not our intention but happened acci-
dentally. Retrospectively, the first period of fever and malaise in patient 3 was not recog-
nized as azathioprine toxicity. If there is a compelling reason for reintroducing aza-
thioprine it must be done under very careful clinical observation (17). For completeness 
we point out that the spectrum of azathioprine hypersensitivity can include more 
symptoms (18). 
In summary, with these three case reports of azathioprine hypersensitivity in patients 
with RA we draw attention to this serious complication and recommend that liver 
146 
function tests are carried out two weeks after starting azathioprine and thereafter every 
one to two months. 
Addendum 
Very recently we saw a new case of severe azathioprine hypersensitivity in a patient 
whose clinical picture was similar to that of patient 1. 
The patient, a 27 year old man who had had destructive seropositive RA since 1983, 
was admitted to hospital because of fever (39.20C), chills, nausea, cough, and рифига 
on his legs. He had taken azathioprine 100 mg for 12 days and piroxicam 20 mg daily 
for several years. Both drugs were discontinued. Laboratory investigation of this severely 
ill patient disclosed an ESR of 126 mm/h (78 mm/h), (figures in brackets show the 
values before the start of azathioprine treatment), haemoglobin 101 g/1 (127 g/1), leuco­
cytes 27 χ 1071 (11.8 χ lO'/l) with shift to the left in the differential count, bilirubin 
total 63 ¿tmol/l, direct 46 μπιοΐ/ΐ, alkaline phosphatase 422 U/l (77 U/l), gamma-gluta-
myltransferase 73 U/l, ALT 87 U/l (8 U/I), AST 32 U/l (11 U/l). Chest radiograph was 
normal. Blood cultures showed no growth. All serological tests (see patient 1) were 
negative. Because all liver enzymes rose further in three weeks (alkaline phosphatase 800 
U/l, gamma-glutamyltransferase 175 U/l, ALT 192 U/l, AST 63 U/l) a liver biopsy was 
performed, which disclosed a moderate portal infiltration of eosinophil leucocytes around 
small bile canaliculi (without bile stasis). Sporadic necrotic liver cells were present. A 
skin biopsy showed aspecific perivascular inflammation. Six weeks after admission this 
patient is still in hospital (May 1989) and liver enzymes are still greatly raised (alkaline 
phosphatase 900 U/l, gamma-glutamyltransferase 254 U/l, ALT 148 U/l). HLA typing: 
AW19, B15, B40, Bw6( DR4, DQw3. 
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To the Editor: 
Kozarek and colleagues (1) found a dramatic clinical improvement in patients treated 
with methotrexate who had refractory Crohn colitis and an incomplete remission of 
chronic ulcerative colitis. Of 21 patients, 14 were also receiving either sulfasalazine or 
metronidazole (exact number of patients not mentioned). 
The risk of bone marrow suppression is increased when other antifolate drugs 
(derivatives of sulfonamides, trimethoprim) are used simultaneously with methotrexate. 
Besides additive folate antagonism, other pharmacologic mechanisms, such as competition 
with tubular secretion and displacement from albumin binding sites, play an important 
role in interactions of sulfonamides and methotrexate. Moreover, it was shown that 
sulfasalazine inhibits the hydrolysis of polyglutamyl folate and the intestinal transport of 
folate in patients with ulcerative colitis (2). Pancytopenia due to the combined use of 
methotrexate and trimethoprim-sulfamethoxazole has been reported in two patients with 
rheumatoid arthritis (3,4). We report two additional cases of this severe side effect. 
In case 1, an 81-year-old woman had refractory rheumatoid arthritis and impaired renal 
function (creatinine, 166 μπιοΐ/ΐ) and was treated with methotrexate, 5 mg weekly for 6 
weeks. Cystitis (Escherichia coli) was treated with trimethoprim, 300 mg daily. One 
week after starting trimethoprim, bone marrow suppression developed (leukocytes, 1.9 χ 
lO'/l; platelets, 15 χ lO'/l; hemoglobin, 6.3 mmol/1). Both methotrexate and trimetho­
prim were discontinued. Blood cell counts returned to normal in 2 weeks. One month 
after discharge she died of severe bronchopneumonia (determined at autopsy). 
In case 2, a 75-year-old woman with refractory rheumatoid arthritis and impaired renal 
function (estimated creatinine clearance, 40 ml/min) was receiving methotrexate, 5 mg 
weekly. A recurrent cystitis was treated with trimethoprim-sulfamethoxazole. Shortly 
after beginning trimethoprim-sulfamethoxazole, bone marrow suppression developed 
(hemoglobin, 5.6 mmol/1; leukocytes, 1.6 χ 10'/1; platelets, 23 χ 10'/1). A bone marrow 
biopsy specimen showed hypocellularity. Both drugs were discontinued, and therapy with 
leucovorin was begun; she recovered in several weeks. 
These two patients were not treated with the combination of sulfasalazine and metho­
trexate; however, other antifolate drugs were used in conjunction with methotrexate. 
Additive folate antagonism, independent of which antifolate drug was used simultaneously 
with methotrexate, seemed to play a central role in inducing bone marrow suppression in 
these patients. We do not recommend prescribing other drugs with antifolate action 
simultaneously with methotrexate. The toxicity of and the possibility of adverse drug 
interactions with methotrexate are increased in the presence of other risk factors such as 
old age, hypalbuminemia, impaired renal function, and decreased bone marrow reserve 
(5). 
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Figure 1. Vasculitic lesions on the big toe (A). Subcutaneous nodules (arrows) on 
the thoracolumbai spine (B). 
To the Editor: 
Recently, the development of new subcutaneous nodules in three patients with 
rheumatoid arthritis (RA), treated with methotrexate (MTX) was described (1). This 
adverse reaction of MTX has also been reported in two other studies (2,3). In our clinic 
we also observed extensive and severe eruption of new nodules with an extraordinary 
localization, i.e the spinal column and the soles of the feet. Moreover, vasculitis lesions 
appeared on the feet. The patient concerned, a 51-year-old man with seropositive RA, 
was treated weekly with MTX 7.5 mg orally. Previous therapy with hydroxychloroquine 
and parenteral gold was ineffective. At the start of MTX therapy he had some nodules on 
his elbows, left-sided pleural effusion, but no vasculitis skin lesions. Laboratory 
investigation revealed an erythrocyte sedimentation rate (ESR) of 100 mm/hr, С reactive 
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protein (CRP) 81.0 mg/1 (normal <6.0 mg/1) and hemoglobin of 5.7 mmol/1. Other 
laboratory values (C3 and C4 included) were normal, except elevation of all immuno­
globulin (Igg) levels. Antinuclear antibody was strongly positive and the HLA typing 
revealed the DR4 phenotype. 
Two months after starting MTX therapy, new nodules developed on his forearms, 
metacarpophalangeal joints and eyebrows. One month later nodules appeared on his 
knees, buttocks and dorsum of his feet. When inflamed nodules developed along his 
spinal column and on the soles of his feet together with vasculitic lesions (Fig. 1), he 
was unable to lay down on his back or to walk. Hospital admission followed and MTX 
was discontinued. After discontinuation of MTX, the nodules gradually regressed in 
about one month. However, the RA relapsed and therapy with azathioprine was started. 
In contrast with the observation of Segal et al. (1), the CRP level remained high (81.0 
mg/1) during MTX therapy. The levels of Igg's did not change during MTX therapy 
despite the good clinical response of his arthritis to MTX. In other RA patients with a 
good clinical response to MTX, we found a significant decrease of Igg levels (4). 
In summary, we have reported on severe eruption of new nodules and vasculitic 
lesions, localized on extraordinary sites in a RA patient treated with low-dose MTX 
therapy. Diametrically opposed to the induction of new nodules and vasculitis (5) by 
MTX, is the beneficial clinical effect of MTX in some patients with rheumatoid 
(vasculitic) ulcers (6,7) and in patients with systemic vasculitis like polyarteritis nodosa 
(8,9). Whether there are (immunohistological) differences between nodules and/or 
vasculitis (skin) lesions developed in the course of RA and those induced by MTX, has 
to be evaluated. 
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Chapter 10 
SUMMARY AND CONCLUSIONS 

The main objective of this thesis was to elucidate the place of low-dose methotrexate 
(MTX) in the treatment of rheumatoid arthritis (RA) patients with emphasis on clinical 
aspects. To this purpose a comparison was made with azathioprine (AZA), the other 
cytotoxic drug frequently used in the treatment of RA. The results of a double-blind trial 
of AZA versus MTX in RA are presented and discussed. The clinical results (Chapter 6), 
the influence on radiologic progression (Chapter 7) and the results of pulmonary function 
tests (Chapter 8) will be reviewed successively. 
In Chapter 1 the pathogenesis of RA, indications for the use of azathioprine and 
methotrexate in RA, and the mechanisms of action of these drugs are summarized. 
Rheumatoid Arthritis is a chronic systemic and articular disorder of unknown origin. The 
main feature of RA is symmetric polyarthritis of hands and feet. The course of the 
disease is variable and often unpredictable. In about 10% of patients the disease runs a 
progressive course, characterized by destructive polyarthritis and frequently by extra-
articular manifestations. 
The sequence of pathological processes in RA, divided into five stages, starts with 
presentation of the unknown antigen to T-cells and ends with invasion and destruction of 
cartilage, intra-articular ligaments and subchondral bone. T-lymphocytes play an impor-
tant part in the complex process of immune and inflammatory events in RA. 
Indications for use of cytotoxic, immunoregulatory drugs such as AZA and MTX are 
presence of active polyarthritis despite combined treatment with first-line antirheumatic 
drugs (non-steroidal anti-inflammatory dmgs = NSAIDs) and second-line antirheumatic 
drugs (hydroxychloroquine, parenteral gold, salazopyrinc or D-penicillamine). Other indi-
cations are development of severe radiologic progression and presence of extra-articular 
manifestations such as vasculitis. 
Despite extensive research the exact mechanism of action of AZA and MTX is still 
unclear. Interesting findings from in vivo and in vitro animal- and human studies have 
shed some light upon possible mechanisms of action of, especially, low-dose MTX in 
RA. Anti-inflammatory, subtle immunomodulating and antiproliferative effects may play 
a part (Chapter 1). 
Chapter 2 and 3 provide general information on azathioprine and methotrexate. 
Azathioprine is quickly metabolized to 6-Mercaptopurine (6-MP). Both drugs are purine 
analogues and inhibit DNA and RNA synthesis after conversion to their ribonucleotides. 
The metabolism of AZA (and 6-MP) follows three important enzymatic routes of which 
the conversion by hypoxanthine guanine phosphoribosyl transferase (HGPRT) is the 
major one. Inherited low thiopurine methyl transferase (TPMT) activity constitutes a 
major risk for development of AZA induced myelosuppression. Concurrent use of AZA 
and allopurinol, a known xanthine oxidase inhibitor, may also led to myelo-suppression. 
The usual dosage of AZA in the treatment of RA ranges from 1.5 mg/kg to 2.5 mg/kg 
daily. Adequate contraception is recommended when the drug is prescribed. Whether 
AZA causes an excess of malignancies in RA is still unclear. 
Double-blind studies of AZA versus other second-line antirheumatic drugs have not 
revealed significant intergroup differences regarding clinical effect or adverse reactions. 
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Gastrointestinal side effects and leucopenia are the most frequent adverse reactions to 
AZA. Less frequent side effects are hepatotoxicity, hypersensitivity reactions, thrombo-
cytopenia, and pancytopenia. 
Methotrexate is an antagonist of folate dependent enzymes of which dihydrofolate 
reductase (DHFR) is the most important target enzyme. Folate dependent enzymes are 
involved in DNA and RNA synthesis. MTX is converted mainly to MTX-polyglutamates. 
Low-dose MTX therapy (7.5-15 mg/week) in RA patients does not cause progressive 
accumulation of MTX-polyglutamates in the liver. Renal excretion is the major route of 
MTX elimination. Patients with decreased renal function (renal clearance <50 ml/min) 
have an increased risk of adverse reactions to MTX. MTX synovial fluid levels are equal 
or higher than MTX serum levels. Concurrent use of nonsteroidal anti-inflammatory 
drugs and low-dose MTX in RA, rarely causes serious drug interactions. Severe 
myelosuppression is possible when MTX and other antifolate drugs such as trimethoprim 
and trimethoprim-sulfamethoxazole (co-trimoxazole) are used concurrently. 
Leucovorin is used as a 'rescue therapy' in patients with (severe) toxicity of MTX. 
Folic acid (1 mg/day) can significantly lower MTX toxicity without affecting the clinical 
efficacy of MTX in RA. Since MTX has teratogenic properties, adequate contraception 
during treatment with the drug is absolutely indicated. There is no evidence to assume 
that MTX is a carcinogenic drug. 
In a double-blind trial MTX was more effective and less toxic than oral gold. In other 
trials no significant differences were demonstrated between MTX and parenteral gold and 
between MTX and AZA. 
The most frequent adverse reactions of MTX are elevated liver enzymes and gastro-
intestinal side effects. Less frequent adverse reactions are stomatitis, hematological- and 
pulmonary (pneumonitis) side effects. Since there is no relevant hepatotoxicity after a 
cumulative dosage of 1.5-2.0 g MTX in RA patients, there is much debate about the 
need for post MTX liver biopsies, especially in low risk patients. The percentage of 
patients who were still on MTX therapy after 5 to 6 years (±50%), is much higher than 
the percentage found for other second-line antirheumatic drugs (less than 20%). 
Chapter 4 reviews the clinical use of MTX therapy in connective tissue diseases. 
Additional data on pharmacology of MTX, its adverse reactions, risk factors, drug 
interactions and recommendations for drug monitoring are presented. 
Four placebo controlled trials of MTX in RA have demonstrated that MTX had a 
superior clinical effect. The clinical experience with MTX in polymyositis, dermato-
myositis, systemic lupus erythematosus, scleroderma, and vasculitis, suggest that MTX is 
an effective drug in these connective tissue diseases. Mechanisms by which other drugs 
can increase the toxicity of MTX are mainly through competition with renal tubular 
secretion, displacement of albumin binding sites and additive folate antagonism. Alcohol 
abuse is the major risk factor for MTX-induced hepatotoxicity. Impaired renal function, 
decreased serum albumin and concurrent use of other antifolate drugs are risk factors for 
the development of hematological adverse reactions to MTX. 
The following scheme for drug monitoring during MTX treatment is proposed: the first 
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4 weeks hemoglobin, leucocytes (with differential count), and platelets weekly, renal and 
liver function tests biweekly; thereafter all aforementioned blood tests monthly until six 
months after start of therapy; after 6 months blood tests every 1-2 months. When an 
increased dosage of MTX is prescribed, drug monitoring should be intensified for several 
months. Baseline chest radiographs and pulmonary function tests (spirometry and CO 
diffusion) should be considered seriously. 
Chapter 5 describes the results of an open 12 month study of 16 patients with active 
RA refractory to hydroxychloroquine, gold thioglucose, D-penicillamine and azathio-
prine. Patients received 7.5 mg MTX weekly and depending on their clinical effect after 
8 weeks, 15 mg MTX weekly. AU patients had used NSAIDs and 8 patients also used 
prednisone (< 10 mg daily) before the study. 
Clinical and laboratory assessments were made monthly during the first 6 months and 
thereafter every 2 months. Two of the 16 patients were excluded from analysis because 
of side effects (one patient severe diarrhoea, one patient depression). Fourteen patients 
completed 6 months and 12 patients completed 12 months of therapy. Two of 14 patients 
discontinued MTX after 6 months because of inefficacy. After 6 months there was 
significant (P<0.05) improvement of 5 clinical variables: morning stiffness, tender 
joints, Ritchie index, swollen joints, and pain score. Furthermore ESR, C-reactive pro-
tein, and IgA, IgG, IgM improved significantly. No significant change in mean rheuma-
toid factor was found. The clinical improvement started as early as after 1 month and 
increased up to 6 months. Between 6 and 12 months clinical and laboratory variables 
only changed minimally (plateau phase). At 12 months all articular indices had improved 
by 50% compared with baseline values. Gastrointestinal side effects (31%) and elevated 
liver enzymes (25%) were the commonest adverse reactions to MTX in this study. All 
these side effects disappeared after reduction of the dose of MTX. 
The general conclusion from this study was that MTX was an effective second-line 
drug in refractory RA. 
In Chapter 6 the results of a double-blind randomized 48 week trial are described and 
discussed. In this trial azathioprine was compared with methotrexate in 64 patients with 
active RA refractory to at least parenteral gold, D-penicillamine or both drugs. Patients 
were randomly assigned to receive 7.5 mg MTX weekly or 100 mg AZA daily (double 
dummy). Depending on the clinical effect after 8 weeks, the dosage was increased to 15 
mg MTX or 150 mg AZA. The dosages of NSAIDs and prednisone (< 10 mg daily) 
were held stable for at least 4 weeks before study entry and throughout the study. 
Clinical results were analyzed for patients who continued on the same drug for 24 and 
48 weeks and also for an intention-to-treat approach, that is, independently of whether 
patients switched to other second-line drugs. Baseline values compared with 24 and 48 
weeks values were calculated. For the period 0-24 weeks, 4 weekly data were utilized in 
an area under the curve (AUC) analysis. Apart from the change in separate clinical and 
laboratory variables, the change in a validated composed index of 4 variables (disease 
activity score =DAS) was calculated. 
Except for gender (P=0.01) patients on AZA (n=33) and MTX (n=31) showed no 
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significant differences in demographic and clinical variables at the start of the study. 
Comparison of 24-week values with baseline values revealed significant (P<0.05) impro­
vement in 12 of 13 clinical and laboratory variables in the MTX group and 6 of 13 in 
the AZA group. Comparison between the two same drug groups at 24 weeks showed sig­
nificant improvement of swollen joints, pain score, ESR, CRP, hemoglobin, platelets and 
DAS in favor of the MTX treated patients (AUG analysis, Ρ < 0.04). An intention-to-treat 
analysis at 24 weeks showed equal clinical results as shown in the same drug groups, 
except for swollen joints. After 48 weeks no significant differences in clinical and labo­
ratory variables were found between the two groups. However, statistically significant 
results in the same drug groups at 48 weeks could be missed because of the small 
number of AZA patients (12 AZA vs 24 MTX patients). 
In the period between 8 and 24 weeks, two to three times more MTX than AZA 
patients had significant improvement of the DAS. After 48 weeks half of the AZA and 
three-quarters of the MTX patients had significant improvement of the DAS. Signifi­
cantly more patients on AZA withdrew from the study due to severe side effects (13 
AZA vs 2 MTX). Severe adverse reactions to AZA comprised gastrointestinal complaints 
(5), cholestatic liver dysfunction (2), hypersensitivity (3), and hematological (2) side 
effects. Dermatitis and severe nodulosis necessitated discontinuation of MTX therapy in 
two patients. 
In conclusion, this double-blind trial demonstrated clinical superiority of MTX to AZA 
in RA patients. The earlier, more pronounced, and more sustained clinical improvement 
after one year of MTX therapy was accompanied by a lower rate of serious adverse 
reactions. 
Chapter 7 describes the influence of methotrexate and azathioprine on the radiologic 
progression in RA. This influence was investigated in the same patient groups as mentio­
ned in Chapter 6. Radiographs of hands, wrists and feet were taken at baseline and after 
24 and 48 weeks. Radiographs of the hands and wrists were scored according to the 
modified method of Sharp. Since there was hardly any variation (R=0.98) in either the 
intra- or the interobserver measurements for erosions and joint space narrowing, all 
radiographs of the trial were scored by one experienced rheumatologist, who was 
unaware of the clinical findings and drugs the patients used. Results of radiologic scores 
were analyzed for patients who completed 24 and 48 weeks of the same therapy and also 
in an intention-to-treat approach. Initial radiologic scores (erosion score and total joint 
score, i.e. score for erosion plus score for joint space narrowing) were comparable in the 
two treatment groups. After including possible confounders (gender, disease duration etc) 
all radio-graphic scores changed at most 0.2 (multiple regression analysis). Therefore 
unadjusted estimates were presented. 
Patients who completed 24 and 48 weeks of the same drug, showed more new erosions 
when treated with AZA than with MTX. This difference was significant after 48 weeks. 
The total radiologic score at 24 and 48 weeks also showed less progression in the MTX 
group, but the difference was not significant. The small number of patients who com­
pleted 48 weeks of AZA therapy, however, limited the statistical power. After an 
intention-to-treat analysis at 24 and 48 weeks, significantly fewer new erosions and less 
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change in total radiologie score were found in favor of the patients initially treated with 
MTX. Radiologic stabilization after 48 weeks was present in 10% of the AZA group and 
in 29% of the MTX group. 
In summary, this study shows significantly less radiologic progression in RA patients 
who started on MTX compared with patients who started on AZA. The favorable radio-
logic results of MTX probably reflect the earlier response and more pronounced clinical 
effect of MTX. These data indicate also that even in longstanding erosive RA, further 
radiologic progression may be influenced by antirheumatic second-line drugs. 
In Chapter 8 the question was investigated whether periodic pulmonary function tests 
and chest radiographs were useful for detecting MTX-induced pulmonary toxicity in RA. 
It was also investigated whether pre-existent pulmonary abnormalities were a risk factor 
for development of MTX pneumonitis. The patients on AZA therapy served as a control 
group. A question of secondary importance was whether there was an association be-
tween the presence of keratoconjunctivitis in RA and the presence of small airways 
disease, detected by flow volume curves. 
Clinical findings in the two patient groups were identical to the data mentioned in 
Chapter 6. Pulmonary function tests (spirometry, flow volume curves, CO diffusion, lung 
compliance) and chest X-rays were performed at study entry, after 24 weeks and after 2 
years. 
Baseline pulmonary function tests, performed in 52 patients (27 AZA; 25 MTX 
patients) were not significantly different between the two groups and showed abnormal 
results of one or more function tests in 15 to 50% of all patients. Thirty-seven percent of 
patients had decreased CO diffusion. Five patients had radiographic signs of lung fibro-
sis, one patient had pleural effusion and one patient had pulmonary nodules. At the time 
of data collection, 35 patients (18 on AZA; 17 on MTX) had completed 2 years of 
follow-up. After 24 weeks and 2 years there were no significant changes in mean results 
of pulmonary function tests within the two groups nor differences between both groups. 
When patients were divided into those with and without decreased (comparison with 
predicted values) pulmonary function tests, no differences at 24 weeks were found, 
either, between patients treated with AZA or MTX. 
Patients with pre-existent lung abnormality did not develop MTX-induced pneumonitis. 
Nine patients (6 AZA; 3 MTX patients) had keratoconjunctivitis sicca (KCS). An asso-
ciation between KCS and presence of small airways disease and HLA DR4 was confir-
med. All but one patient in this subgroup of RA had subcutaneous nodules. Small air-
ways disease is considered to be one of the extra-articular features of RA and part of a 
generalized exocrinopathy. 
In conclusion, this study has demonstrated that pulmonary function tests and chest X-
rays do not change after 24 weeks and 2 years of therapy with AZA or MTX in RA. 
Patients with pre-existent lung abnormalities did not develop MTX-induced pneumonitis. 
In view of the prevalence of MTX-induced pulmonary toxicity, baseline pulmonary 
function tests (spirometry, CO diffusion) is advisable. However, the results of this study 
suggest no need for periodic pulmonary function tests and chest radiographs during MTX 
therapy in RA. Long-term prospective studies of more patients are necessary for definite 
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conclusions. 
In Chapter 9 four rare, but potentially dangerous side effects of AZA and MTX are 
described. Pancytopenia induced by AZA occurred in one patient within three weeks 
after starting the trial. Rapid fall of all blood cells, mainly platelets, necessitated hospita­
lization. A bone marrow biopsy showed hypoccllularity and absent megakaryocytes. 
Because platelet counts fell further (4 χ 109/1), transfusion with platelets was necessary. 
In another patient (not a trial patient) pancytopenia developed due to the simultaneous use 
of allopurinol and AZA. 
In a second article the case studies of three trial patients were described in whom the 
following adverse reactions to AZA developed within two weeks after starting AZA: 
patient one showed fever with chills, rash, and severe cholestatic liver dysfunction; the 
second patient showed fever, nausea, diarrhoea, and liver dysfunction; the third patient 
had very high fever and severe chills. In the first patient raised liver enzymes persisted 
until seven months after discontinuation of AZA. 
In a third article eruption of subcutaneous nodules and vasculitis during MTX therapy 
were described. Before MTX therapy, the patient concerned had only nodules at his 
elbows. MTX therapy was effective for his polyarthritis. However, from the third month 
of MTX therapy, multiple new nodules developed on extraordinary sites such as knees, 
along the spinal column, eyebrows etc. Later on inflamed nodules developed and vascu-
litic lesions were found on the soles of his feet, necessitating hospital admission. After 
discontinuation of MTX, the nodules regressed within 4 weeks. Pancytopenia due to the 
combined use of methotrexate and trimethoprim-sulfamethoxazole is reported in a fourth 
article. 
General conclusions from this thesis are: 
-Methotrexate is effective in refractory RA, i.e. in RA patients with unresponsiveness 
to four other second-line drugs: hydroxychloroquine, parenteral gold, D-penicillami-
ne, and azathioprine 
- Methotrexate has a superior clinical effect compared with azathioprine in RA patients 
refractory to parenteral gold, D-penicillamine or both drugs 
- The clinical effect of methotrexate starts earlier than that of azathioprine 
- Methotrexate causes fewer severe adverse reactions than azathioprine 
-RA patients who start on methotrexate therapy show significantly less radiologic pro­
gression than patients who start on azathioprine therapy 
-Pulmonary function tests did not change during therapy with either methotrexate or 
azathioprine in RA 
- Pre-existent lung abnormalities are no contraindication to MTX therapy in RA 
-In view of its superior clinical effect and its disease modifying effect methotrexate is 
preferable to azathioprine in rheumatoid arthritis. 
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Chapter 11 
SAMENVATTING 

De voornaamste doelstelling van dit proefschrift was onderzoek naar de plaats van lage 
dosis methotrexaat (MTX) bij de behandeling van ernstige Reumatoide Artritis (RA). Om 
dit te onderzoeken werd een studie opgezet, waarin MTX vergeleken werd met azathio-
prine (AZA), een ander cytotoxisch medicament, dat regelmatig gebruikt wordt bij de 
behandeling van RA. 
In de Hoofdstukken 6, 7, en 8 komen achtereenvolgens de klinische resultaten van dit 
onderzoek, de röntgenologische gegevens, en de bevindingen van longfunctie-onderzoek 
tijdens die studie aan bod. 
In Hoofdstuk 1 worden de criteria en de ontstaanswijze van RA beschreven om ver-
volgens in te gaan op de indicaties voor het gebruik van cytotoxische geneesmiddelen bij 
RA en het werkingsmechanisme te bespreken van AZA en MTX. De Hoofdstukken 2 en 
3 bevatten algemene en meer gedetailleerde informatie over respectievelijk AZA en 
MTX. Beschreven en belicht worden o.a de farmacologie en -kinetiek, de wisselwerking 
met andere medicamenten, de toepassing in gecontroleerde studies bij patiënten met RA 
op korte- en lange termijn, bijwerkingen enzovoorts. In Hoofdstuk 4 wordt de klinische 
toepassing van MTX bij collageenziekten samengevat, naast aanvullende gegevens over 
farmacologie, mechanismen van geneesmiddeleninteracties (tussen MTX en andere medi-
camenten) en bijwerkingen van MTX. In Hoofdstuk 5 worden de resultaten van een 
open studie van MTX bij RA belicht. 
Terugkerend naar Hoofdstuk 1 wordt beschreven dat Reumatoide Artritis een chro-
nische ziekte is met onbekende oorzaak, gekenmerkt door symmetrische gewrichtsont-
stekingen (=polyartritis) in vooral handen, polsen en voeten, en minder frequent in 
ellebogen, knieën en schouders. In 1987 zijn de criteria voor de classificatie van RA 
herzien. Een patiënt voldoet aan de diagnose RA, indien tenminste 4 van 7 criteria 
gedurende tenminste 6 weken aanwezig zijn. Deze criteria omvatten: ochtendstijfheid 
langer dan 1 uur, artritis in 3 of meer gewrichten, artritis in handen, symmetrische 
artritis, aanwezigheid van reumanoduli, aanwezigheid van reumafactoren in het serum, 
karakteristieke röntgenologische afwijkingen (o.a erosies). 
RA komt 2 à 3 maal vaker voor bij vrouwen dan bij mannen en treft ongeveer 1 à 2 % 
van de bevolking. Het verloop van de ziekte is veelal onvoorspelbaar en wisselend, 
waarbij opvlammingen van de ziekte worden afgewisseld door rustige perioden. Bij een 
klein percentage van de patiënten (± 10%) verloopt de ziekte ernstig progressief. Een 
dergelijk progressief ziektebeeld wordt gekenmerkt door een ernstige, deformerende en 
destructieve polyartritis vaak in combinatie met extra-articulaire verschijnselen zoals 
vasculitis. Vooral voor deze laatste groep patiënten is adequate en krachtige (medica-
menteuze) therapie aangewezen. 
Het pathologisch proces van RA, grofweg ingedeeld in 5 stadia, begint met de "presen-
tatie" van een onbekend antigeen aan de T-lymfocyt en eindigt met invasie en destructie 
van kraakbeen, intra-articulaire ligamenten en subchondraal bot. De T-cellen spelen een 
belangrijke rol in het complexe ontstekingsproces van RA. 
Eén van de indicaties voor het gebruik van cytotoxische medicamenten als AZA en 
MTX, is de aanwezigheid van persisterende polyartritis ondanks behandeling met 
eerstelijns antireumatica [=niet steroidale anti-inflammatoire middelen (NSAIDs)] in 
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combinatie met tweedelijns antireumatica als hydroxychloroquine, oraal goud, salazo-
pyrine, parenteraal goud of D-penicillamine. Andere indicaties zijn ernstige radiologische 
progressie en de aanwezigheid van extra-articulaire manifestaties. 
Hoofdstuk 2 bevat gegevens over azathioprine. De eerste stap in het metaboliserings-
proces van AZA, is de snelle omzetting naar 6-Mercaptopurine (6-MP). Beide genees-
middelen zijn purine analoga en remmen de DNA en RNA synthese. De precieze wer-
king van AZA bij RA is onbekend. Vergeleken met placebo is er een bewezen klinisch 
antireumatisch effect. Studies waarin AZA vergeleken is met andere tweede-lijns anti-
reumatica, laten geen verschillen zien noch wat betreft het klinisch effect bij RA noch 
wat betreft het optreden van bijwerkingen. 
Na de snelle thiolysis (in lever en erythrocyten) van AZA naar 6-MP, vindt verdere 
omzetting van AZA via drie enzymatische wegen plaats. De route via het enzym hypo-
xanthine guanine phosphoribosyl transferase (HGPRT) is hiervan de belangrijkste. 
Patiënten met een (genetisch bepaald) laag gehalte aan het enzym thiopurine methyl-
transferase (TPMT) en die behandeld worden met AZA, hebben een potentieel verhoogde 
kans op beenmergschade. De gelijktijdige toepassing van allopurinol en AZA, zonder de 
dosis van AZA met 75% te verlagen, is gevaarlijk eveneens met het oog op beenmerg-
schade. 
De dosis azathioprine die aan RA patiënten wordt gegeven, varieert tussen de 1.5 en 2.5 
mg/kg lichaams-gewicht/dag. De meest frequent voorkomende bijwerkingen van AZA 
zijn gastro-intestinale complicaties en leucopenie. Bijwerkingen die minder frequent 
voorkomen zijn hepatotoxiciteit, allergische reacties en hcmatologische complicaties zoals 
anemie, trombopenie of pancytopenie. 
In Hoofdstuk 3 passeert methotrexaat de revue. MTX is een antagonist van foliumzuur 
afhankelijke enzymen, waarvan dihydrofolaat reductase (DHFR) de belangrijkste is. 
Foliumzuur afhankelijke enzymen zijn betrokken in de DNA en RNA synthese. De 
werking van MTX bij RA is, ondanks veel onderzoek, nog slechts ten dele bekend. De 
aanbevolen dosis MTX bij RA varieert tussen de 7,5 en 15 mg per week in één dosis, of 
verdeeld in drie doses om de 12 uur. In-vivo en in-vitro gegevens bij mens en dier doen 
vooral anti-inflammatoire maar ook immuunmodulerende en antiproliferatieve eigen-
schappen van MTX vermoeden. MTX wordt omgezet in MTX-polyglutamaten, welke 
vooral in de lever worden aangetroffen. Onderzoek heeft aangetoond, dat er geen cumu-
latie ontstaat van MTX-polyglutamaten in de lever bij RA patiënten, die behandeld wor-
den met een lage dosis methotrexaat. 
MTX wordt voornamelijk via de nier uitgescheiden. Een verminderde nierfunctie 
(klaring <50 ml/min) geeft meer kans op bijwerkingen. De concentratie van MTX in de 
synoviale vloeistof komt vrijwel overeen met die in het serum. Het gelijktijdig toepassen 
van NSAIDs en een lage dosis MTX veroorzaakt zelden bijwerkingen bij RA patiënten. 
Er bestaat een verhoogde kans op beenmergschade, indien gelijktijdig met MTX, andere 
foliumzuur antagonisten zoals trimethoprim-sulfamethoxazol (co-trimoxazol) worden 
voorgeschreven. Aangezien MTX teratogene eigenschappen heeft, is adequate contra-
ceptie tijdens toepassing van dit middel absoluut vereist. 
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MTX blijkt bij RA patiënten significant effectiever te zijn dan placebo. Uit verge-
lijkingsstudies blijkt verder, dat MTX ten opzichte van andere tweedelijns antireumatica 
op zijn minst even effectief is. In vergelijking met oraal goud (ridaura) heeft MTX 
klinisch meer effect en is minder toxisch. Het percentage patiënten dat na 5 jaar nog 
MTX gebruikt (±50%) is veel hoger dan het percentage dat gevonden wordt voor andere 
tweedelijns antireumatica (±20%). 
De meest frequent voorkomende bijwerkingen van MTX zijn verhoogde waarden van 
leverenzymen en gastro-intestinale bijwerkingen. Minder frequent voorkomende bijwer-
kingen zijn ulcera in de mond en hematologische en pulmonale complicaties (pneumoni-
tis). Uit onderzoek is gebleken, dat de toevoeging van een lage dosis foliumzuur (1 mg 
/dag) minder bijwerkingen veroorzaakt, zonder het klinisch effect van MTX bij RA te 
beïnvloeden. 
Ervaring met ruim 800 RA patiënten heeft aangetoond, dat ernstige, histologisch 
bevestigde hepatotoxiciteit (cirrose) zeer zelden voorkomt na een cumulatieve dosis van 
1.5-2.0 gram MTX. In de reumatologische literatuur bestaat er communis opinio om 
geen leverbiopsieën meer te doen vóór het starten van MTX bij RA, tenzij er risicofac-
toren zijn. Er bestaat veel discussie omtrent de noodzaak tot het doen van "post-MTX" 
leverbiopsieën na een cumulatieve dosis van 1.5-2.0 gram, met name in de groep van 
patiënten die geen risicofactoren bezitten (zoals geen of nauwelijks alcohol gebruik en 
geen pre-existente leverziekte). De ervaring met MTX bij RA patiënten op langere ter-
mijn is echter nog te gering om definitief leverbiopsieën uit het controle schema te 
schrappen. 
In Hoofdstuk 4 komt het gebruik van MTX bij de verschillende collageenziekten aan 
de orde. Na gegevens over de historie van MTX en diermodel studies bij MTX, volgt 
aanvullende informatie op hoofdstuk 3 over de farmacologie en farmacokinetiek van 
MTX, naast hypothesen over het werkingsmechanisme van MTX bij RA. Wat betreft de 
klinische toepassing van MTX bij collageenziekten, is de ervaring bij poly- en dermato-
myositis het grootst, en veelal gunstig. De ervaring met MTX bij vasculitis, scleroder-
mie, en systemische lupus erythematosus (SLE) is beperkt, maar biedt perspectieven. In 
dit hoofdstuk komen tevens de belangrijkste risicofactoren voor het gebruik van MTX 
(met name alcohol gebruik) alsmede mechanismen van geneesmiddelen interacties met 
MTX (competitie met tubulaire secretie, verdringing van eiwitbinding, additief folium-
zuurantagonisme) aan de orde. Verder worden aanvullende gegevens vermeld ten aanzien 
van de bijwerkingen van MTX. Tenslotte worden nog aanbevelingen gedaan voor een 
controleschema, welke gehanteerd kan worden bij de toepassing van MTX. 
Hoofdstuk 5 bevat de klinische resultaten van een 1-jarige open studie, waarbij 16 
patiënten met actieve, therapieresistente RA behandeld werden met een lage dosis MTX 
(7,5-15 mg/week). Eerdere therapie met 4 andere antireumatische middelen, te weten 
hydroxychloroquine, parenteraal goud, D-penicillamine en azathioprine, had bij deze 
patiënten gefaald. Alle patiënten gebruikten voor en tijdens de studie NSAIDs. Acht van 
hen waren reeds voor de start van de studie ingesteld op prednison (^10 mg/dag). Het 
eerste half jaar vonden maandelijks klinische metingen en laboratoriumcontroles plaats; in 
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het tweede halfjaar vonden de controles elke 2 maanden plaats. 
Twee patiënten werden van analyse uitgesloten in verband met het vroege ontstaan van 
bijwerkingen (respectievelijk diarree na 2 weken en depressie na 2 maanden). Bij 12 van 
de 14 resterende patiënten bleek er na 2 maanden een significante verbetering te zijn 
ontstaan in 5 klinische graadmeters [ochtendstijfheid, het aantal pijnlijke en gezwollen 
gewrichten, de score voor pijn en algemeen welbevinden (0-10 cm schaal)], naast ver-
betering van een aantal laboratorium graadmeters [bezinking, C-reactieve proteine (CRP), 
en de Immunoglobulines A, M, en G]. De klinische verbetering nam in de periode tussen 
de Τ en 6' maand toe, maar bereikte hierna een plateau fase. Dit betekende dat er vanaf 
de 6' tot de 12e maand nauwelijks verdere verbetering optrad. De helft van de patiënten 
kreeg te maken met bijwerkingen, meestal van gastro-intestinale aard ofwel in de vorm 
van verhoogde waarden van leverenzymen. Deze bijwerkingen waren vrijwel altijd van 
milde aard en verdwenen na tijdelijk stoppen of verlagen van de dosis MTX. 
Samenvattend bleek uit deze studie, dat MTX bij patiënten met therapieresistente RA 
een effectief geneesmiddel was. 
In Hoofdstuk 6 worden de klinische resultaten van een dubbelblinde studie tussen 
MTX en AZA bij RA uitvoerig beschreven. Het betrof 64 patiënten (33 AZA;- 31 MTX) 
met actieve RA, die onvoldoende gereageerd hadden op, of bijwerkingen kregen van 
behandeling met parenteraal goud. Driekwart van hen was ook zonder succes behandeld 
met hydroxychloroquine en driekwart tevens met D-penicillamine. Alle patiënten vol-
deden aan een 4-tal insluitcriteria voor actieve RA. Patiënten kregen óf 7,5 mg MTX per 
week óf 100 mg AZA per dag. Afhankelijk van het klinisch resultaat na 8 weken, werd 
de dosis verhoogd naar respectievelijk 15 mg MTX en 150 mg AZA. De doses prednison 
en NSAIDs werden tijdens de studie en 4 weken voor de start van de studie stabiel 
gehouden. 
De klinische resultaten werden beoordeeld zowel voor de patiëntengroepen die na 24 
en 48 weken nog steeds hetzelfde medicament (dwz of AZA of MTX) gebruikten, als 
ook volgens een "intention-to-treat methode", dwz onafhankelijk van het feit of patiënten 
een ander tweedelijns middel dan AZA of MTX kregen. Naast vergelijking van uitslagen 
na 24 en 48 weken met de gegevens aan het begin van de studie, werd voor de periode 
tussen 0 en 24 weken ook de oppervlakte onder de curve van de belangrijkste graad-
meters van ziekteactiviteit berekend. Tenslotte werd nog de procentuele verbetering van 
deze graadmeters en een samengestelde, gevalideerde ziekte-index [de zogenaamde DAS 
(=disease activity score)] van 4 graadmeters berekend. 
Uit het onderzoek kwam naar voren, dat er geen significante verschillen in demogra-
fische en klinische gegevens waren tussen beide patiëntengroepen. Verdere berekening 
toonde aan, dat 12 van 13 klinische- en laboratoriumgraadmeters in de MTX groep 
significant na 24 weken verbeterden. In de AZA groep verbeterden 6 van 13 graad-
meters. Uit analyse (oppervlakte onder de curve) bleek tevens, dat patiënten uit de MTX 
groep significant meer verbetering lieten zien in de volgende 7 graadmeters: pijnscore (Ο­
ΙΟ cm schaal), aantal gezwollen gewrichten, bezinking (BSE), CRP, hemoglobine, trom-
bocyten en de DAS. Een intention-to-treat analyse na 24 weken leverde een gelijksoortig 
resultaat op met uitzondering van het aantal gezwollen gewrichten. Na 48 weken waren 
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er geen significante verschillen tussen beide groepen meer aantoonbaar. Het aantal 
patiënten met een significant verbeterde DAS in de periode tussen 0 en 24 weken, was 
driemaal hoger in de MTX dan de AZA groep. Het aantal patiënten dat moest stoppen 
vanwege bijwerkingen, was significant hoger in de AZA groep. Ernstige bijwerkingen 
door behandeling met AZA bestonden uit gastro-intestinale (5x), cholestatische lever-
functiestoomissen (2x), overgevoeligheidsreacties (3x) en hematologische complicaties 
(2x). 
De conclusie van deze studie was, dat MTX bij RA patiënten klinisch superieur was 
ten opzichte van AZA. Naast een sneller intredend effect, was het klinisch effect van 
MTX ook meer uitgesproken en ging gepaard met minder ernstige bijwerkingen dan 
AZA. 
In Hoofdstuk 7 wordt de invloed van AZA en MTX op de radiologische progressie bij 
RA onderzocht. Het betrof dezelfde patiëntengroepen zoals beschreven in de dubbelblinde 
studie van hoofdstuk 6. Röntgenfoto's van handen, polsen en voon/oeten werden aan het 
begin van de studie en vervolgens na 24 en 48 weken gemaakt. Deze röntgenfoto's 
werden gescoord volgens de gemodificeerde methode van Sharp door een ervaren reuma-
toloog, die niet op de hoogte was van de klinische gegevens dan wel de medicatie die de 
betreffende patiënten gebruikten. Vóór de studie werd het verschil bij het scoren van 
röntgenfoto's zowel tussen de onderzoekers als "binnen" de onderzoekers beoordeeld. 
Hierbij werd nauwelijks enig verschil (R=0.98) gevonden. 
Radiologische scores werden zowel voor patiëntengroepen die gedurende 24 en 48 
weken hetzelfde medicament (dwz of AZA of MTX) gebruikten, als ook volgens een 
intention-to-treat methode berekend. De initiële radiologische scores tussen beide groepen 
verschilden nauwelijks van elkaar. 
Na 24 en 48 weken bleek, dat in de patiënten die steeds MTX hadden gebruikt, er 
minder nieuwe erosies waren ontstaan. Dit verschil in nieuwe erosies was ten opzichte 
van de AZA groep na 48 weken significant. Wat betreft de totale score (=erosies + 
gewnchtsspleetversmalling) bleek er eveneens minder progressie in de MTX groep te 
zijn. Een intention-to-treat analyse liet zien, dat er significant minder nieuwe erosies en 
minder verandering in de totale score na 24 en 48 weken waren in de patiënten die ge-
start waren met MTX. Na 48 weken bleek er bij 10% van de AZA en 29% van de MTX 
patiënten geen veranderingen te zijn ontstaan in reeds aanwezige afwijkingen op röntgen-
foto's van handen en voeten (=radiologische stabilisatie). 
De conclusie van deze studie was, dat er bij RA patiënten die gestart waren met MTX, 
na 1 jaar significant minder radiologische progressie was in vergelijking met patiënten die 
gestart waren met AZA. Deze gunstige radiologische resultaten voor MTX hebben 
mogelijk te maken met het sneller intredend en krachtiger klinisch effect van MTX zoals 
beschreven in hoofdstuk 6. 
In Hoofdstuk 8 komen de resultaten van longfunctie-onderzoek en thoraxfoto's bij de 
eerder beschreven 2 patiëntengroepen aan de orde. De voornaamste vraag die we ons 
stelden was, of periodieke thoraxfoto's en meting van longfuncties zinvol waren voor de 
(vroege) detectie van eventuele MTX pneumonitis. Bovendien werd onderzocht of RA 
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patiënten met reeds bestaande longafwijkingen een risicogroep vormden voor het ont-
wikkelen van een mogelijke MTX pneumonitis. Tenslotte was nog een bijkomende vraag 
of er een associatie was tussen de aanwezigheid van keratoconjunctivitis bij RA en de 
aanwezigheid van aandoeningen van de kleine luchtwegen (zogenaamde "small airways 
disease"). 
Thoraxfoto's en longfunctie-onderzoek bestaande uit spirometrie, flow volume curves, 
CO diffusie en compliance werden uitgevoerd aan het begin van de studie, na 6 maanden 
en na 2 jaar. 
Longfunctietesten aan het begin van de studie, uitgevoerd bij 52 patiënten (27 AZA; 25 
MTX), lieten geen significante verschillen zien tussen de twee groepen. Verder bleek dat 
in beide groepen, 15 tot 50% van de patiënten, een of meerdere afwijkende longfunctie-
testen had. Op het tijdstip van de analyse waren 35 patiënten 2 jaar vervolgd. 
Na 24 weken en 2 jaar bleken er in vergelijking met beginwaarden, geen significante 
verschillen in longfunctietesten te zijn noch tussen beide groepen noch binnen de twee 
groepen. Indien patiënten werden verdeeld in groepen met en zonder verlaagde waarden 
van longfunctietesten was er ook na 24 weken geen verschil aanwezig. Vergelijking 
tussen thoraxfoto's aan het begin van de studie met die na 2 jaar leverden geen verschil-
len op in beide groepen. 
Patiënten met bestaande longafwijkingen (o.a longfibrose) ontwikkelden geen MTX 
pneumonitis. Negen patiënten (6 AZA; 3 MTX) hadden keratoconjunctivitis sicca (KCS). 
Een associatie tussen KCS en aandoeningen van de kleine luchtwegen, zoals beschreven 
in de literatuur, kon worden bevestigd. Vrijwel al deze patiënten waren positief voor het 
humaan leucocyte antigeen (HLADR4) en hadden subcutane noduli. 
Concluderend bleek dat longfunctietesten en thoraxfoto's van RA patiënten niet ver-
anderden na 24 weken en 2 jaar behandeling met AZA of MTX. Bij patiënten met reeds 
bestaande longafwijkingen werd geen MTX pneumonitis gevonden. Met het oog op het 
voorkomen van MTX pneumonitis (±3-5%) is het aanbevelenswaardig om (beperkt) 
longfunctie onderzoek te doen (spirometrie en CO diffusie) en een thoraxfoto te maken 
voor het starten van behandeling met MTX. Herhaald onderzoek van longfunctie en 
thoraxfoto lijkt op grond van deze studie alleen nodig indien het klinisch beeld daartoe 
aanleiding geeft. Studies met een langere vervolgduur en een groter aantal patiënten zijn 
echter nodig om tot een definitiever advies te komen. 
In Hoofdstuk 9 worden in drie publicaties een drietal zeldzame, maar potentieel ge-
vaarlijke bijwerkingen van AZA en MTX, die tijdens deze studie ontstonden, in detail 
besproken en bediscussieerd. 
In het eerste artikel wordt beschreven, hoe binnen 3 weken pancytopenie ontstond 
tijdens behandeling met AZA. In verband met een ernstige trombopenie werd de betref-
fende patiënt opgenomen en kreeg trombocytenconcentraat toegediend. Bij een tweede 
patiënt (geen trial patiënt) ontstond pancytopenie tijdens gecombineerde behandeling van 
AZA en allopurinol. 
In het tweede artikel worden drie patiënten beschreven bij wie de volgende bijwerkin-
gen ontstonden binnen 2 weken na starten van AZA: bij de eerste patiënt koorts met 
koude rillingen en cholestatische leverafwijkingen, bij de tweede, koorts, huiduitslag, 
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diarree en leverfunctiestoomìssen en bij de derde patiënt zeer hoge koorts en heftige 
koude rillingen. Bij de eerste patiënt waren de leverfuncties pas na 7 maanden genormali-
seerd. 
In een derde artikel wordt een patiënt gedemonstreerd, bij wie plotseling vele reuma-
noduli ontstonden tijdens behandeling met MTX. Na 3 maanden behandeling met MTX 
kreeg deze patiënt noduli op vele, vaak ongebruikelijke plaatsen zoals knieën, wervel-
kolom en wenkbrauwen. Er volgde opname toen deze noduli ontstoken raakten en er 
vasculitis verschijnselen op de voeten waren verschenen. Na het staken van de MTX 
verdwenen de noduli en vasculitis binnen vier weken. 
Pancytopenie bij 2 patiënten (beiden niet afkomstig uit de trial) wordt tenslotte be-
schreven in een vierde artikel van dit hoofdstuk. De pancytopenie ontstond door de 
gelijktijdige toepassing van MTX en andere foliumzuurantagonisten (trimethoprim en 
trimethoprim-sulfamethoxazole). 
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DANKWOORD 
Meer dan ik ooit voor mogelijk heb gehouden, zijn veel mensen bij de uiteindelijke 
totstandkoming van dit proefschrift betrokken geweest. Ik wil daarom al degenen die mij 
op enigerwijze geholpen hebben, langs deze weg nog eens hartelijk bedanken. In de 
eerste plaats ben ik alle patiënten, die aan het onderzoek hebben meegewerkt, zeer 
erkentelijk. Zonder in cliché's te vervallen is het zeker zo, dat zonder uw medewerking, 
inzet en trouwe bezoek aan de poliklinieken, dit onderzoek volstrekt onmogelijk was 
geweest. Verder wil ik, in willekeurige volgorde, alle mensen van de deelnemende 
klinieken [secretaresses, personeel van diverse laboratoria (inclusief longfunctie)] be-
danken voor hun gastvrijheid en hulp. Jullie stonden steeds klaar om, indien nodig, 
onderzoek met voorrang te verrichten, statussen te zoeken etc. Ook telefoontjes of vragen 
over (achtergebleven) uitslagen waren nooit teveel. De verwerking en bepaling van de 
vele serummonsters, met name die van Complement C3, C4, Clq en de APF waren in 
goede handen van Gertie Vierwinden en Ans van Ε φ . 
Een woord van dank gaat zeker uit naar de collega's J. Rasker en M. Kruijsen uit 
Enschede, H. van Beusekom en W. Hissink Muller uit Tilburg, J. Haverman uit Den 
Bosch, M. Franssen en DJ. de Rooy uit Nijmegen (St Maartenskliniek) en alle collega's 
van de afdeling reumatologie van het St Radboudziekenhuis, die de tijd en ruimte vonden 
om eventuele geschikte trialpatiënten aan mij voor te dragen. Toon Westgeest maakte al 
een aanvang met het eerste ontwerp van de trial- en laboiatoriumformulieren en 
organiseerde de opslag van de serummonsters. 
Voor de statistische ondersteuning stonden J. Mulder en W. Doesburg altijd klaar. 
Beste Jan, uit de enorme vracht aan gegevens wist je met mijn vele vragen uiteindelijk 
steeds de juiste zaken uit de computer te halen. De vele kilo's computervellen getuigen 
van je inzet. Beste Wim, het was mij een genoegen om met je te discussiëren over de 
resultaten van het onderzoek. Elk moment van de dag kon ik even overleggen. Je hebt 
constructief meegedacht en veel tijd besteed aan de statistische analyse van de belang-
rijkste artikelen. 
Het vele typewerk werd aanvankelijk door Marion Janssen gedaan. Beste Marion, 
bedankt voor de zorg en de tijd die je eraan besteedde. Het was vaak "passen en meten" 
om tussendoor iets te typen. Toen het teveel tijd ging vergen, nam Bianca Schippers het 
"roer" over. Beste Bianca, bedankt voor het vele typewerk, je inzet en je geduld. Ik kon 
altijd langskomen voor veranderingen van teksten, zelfs toen je hand in het gips zat. 
De vriendschap en collegialiteit op de afdeling reumatologie in Nijmegen heeft mij altijd 
zeer getroffen. Het is de basis geweest voor een uiterst plezierig werkklimaat. Beste 
Agnes, Leo, Alphons, Desiree, Frank, Ike, Marcel, Piet, Pit, en Roland, bedankt 
hiervoor. Roland, ik heb je spontane aanbod om diverse tabellen te vervolmaken zeer 
gewaardeerd. 
Uiteraard wil ik ook mijn promotores Prof. Dr. L.B.A. van de Putte en Prof. Dr. 
F.W.J. Gribnau niet vergeten. Beste Leo, bedankt voor het vertrouwen dat je in mij 
stelde om dit onderzoek te verrichten. Je wist steeds snel en haarscherp de juiste posi-
tieve kritiek te leveren. Beste Frank, met name de hoofdstukken 2 en 3 heb je van 
kritisch commentaar voorzien. Je hebt mij daarbij vele nuttige suggesties aan de hand 
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gedaan. 
Last but not least, wil ik Dr. A.M.Th. Boerbooms bedanken. Beste Agnes, woorden 
schieten tekort voor de manier waarop je mij hebt begeleid. Jouw bezielende leiding, je 
enthousiasme en stuwende kracht waren voor mij een enorme stimulans. Bedankt voor 
alles wat je hebt gedaan! 
De kinderen, familie, en vrienden wil ik bedanken voor hun geduld. Vaak moest ik 
noodgedwongen verstek laten gaan bij verjaardagen en andere feestelijke gebeurtenissen. 
Vooral Astrid en Linda hebben heel wat begrip moeten opbrengen. Marianne en Victor 
bied ik nog een glaasje "Spatie rood" aan voor hun geweldige hulp aan het eind van de 
rit. 
Ik zou niet willen eindigen zonder mijn vrouw Wanda in de bloemetjes te zetten. 
Meisje, zonder jouw steun was het me nooit gelukt om zo ver te komen. Zonder enig 
woord van protest heb je vele, vele avonden en dagen alleen moeten doorbrengen. Vaak 
bood je mij aan om te helpen of iets uit te zoeken. Je typte ook daadwerkelijk menig 
"A4tje" en verrichtte veel noodzakelijk controlewerk. Tot het laatste toe stimuleerde je 
mij om door te gaan. Ook die vaak onzichtbare steun is mij meer dan dierbaar geweest! 
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CURRICULUM VITAE 
De schrijver van dit proefschrift, Maurice Jeurissen, werd op 31 augustus 1953 te 
Eindhoven geboren. Van 1965-1971 was hij leerling aan het Bemardinus College te 
Heerlen, waar hij in mei 1971 zijn diploma gymnasium-B behaalde. 
Van september 1971 tot november 1972 studeerde hij Tandheelkunde aan de Katholieke 
Universiteit te Nijmegen. Aan dezelfde Universiteit begon hij in januari 1973 met de 
studie Geneeskunde. Op 18 mei 1979 werd het artsexamen behaald. 
Van juli 1979 tot oktober 1980 was hij, in verband met zijn dienstplicht, als controle-
en kazemearts werkzaam in de Brederode kazerne te Vught. Op 1 november 1980 startte 
hij de opleiding Interne Geneeskunde in het Grootziekengasthuis te 's Hertogenbosch 
(opleiders Dr. J. Lips en Dr. J. Jansen). Hij werd op 1 januari 1986 ingeschreven als 
internist. 
Vervolgens maakte hij op 1 maart 1986 een aanvang met de opleiding tot reumatoloog 
in het St Radboudziekenhuis te Nijmegen (opleider Prof. Dr. L.B.A van de Putte). In 
april 1987 begon hij met zijn promotie-onderzoek, afgewisseld door klinische- en 
poliklinische werkzaamheden. In september 1990 volgde zijn registratie als reumatoloog. 
Vanaf 1 oktober 1990 is hij als reumatoloog werkzaam in het ziekenhuis de Gelderse 
Vallei (locaties Wageningen, Veenendaal, Bennekom, Ede) en in het ziekenhuis Rijnstate 
te Arnhem, in associatie met twee collegae reumatologen. 
Maurice Jeurissen is gehuwd met Wanda Simons. Zij hebben twee dochters, Linda en 
Astrid. 
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STELLINGEN 
behorende bij het proefschrift 
METHOTREXATE VERSUS AZATHIOPRINE 
IN RHEUMATOID ARTHRITIS 
Maurice Jeurissen 
Nijmegen, 2 december 1991 
1. Methotrexaat in een dosis van 7. S-15 mg per week is bij veel patiënten met 
reumatoide artritis eerder werkzaam, effectiever, en leidt tot minder ernstige 
bijwerkingen dan behandeling met azathioprine. 
(Dit proefschrift) 
2. Methotrexaat is, vergeleken met azathioprine, meer in staat om het proces van 
radiologische progressie bij reumatoide artritis af te remmen. 
Lage dosis methotrexaat kan dan ook met recht gerekend worden tot de 
DMARD's = disease modifying antirheumatic drugs. 
(Dit proefschrift) 
3. Het voorschrijven van allopurinol in combinatie met azathioprine, zonder de dosis 
van azathioprine drastisch aan te passen, kan ernstige gevolgen hebben. 
(Dit proefschrift) 
4. De kans dat een cumulatieve dosis van 1.5-2 gram methotrexaat bij reumatoide 
artritis, met name bij patiënten zonder risicofactoren, irreversibele leverschade 
veroorzaakt, is erg klein. In hoeverre dit ook geldt voor hogere doses methotre-
xaat is nog onvoldoende bekend. 
(Dit proefschrift) 
5. "You can not teach an old dog new tricks", gaat niet op voor het al uit 1947 
stammende medicijn methotrexaat. Voor de dosis gebruikt bij reumatoide artritis 
zou kunnen gelden: "You can teach an old drug superior tricks". 
6. Preëxistente longafwijkingen bij patiënten met reumatoide artritis zijn geen 
contraindicatie voor behandeling met methotrexaat. 
(Dit proefschrift) 
7. Het gelijktijdig voorschrijven van methotrexaat en andere foliumzuur antagonisten 
zoals sulfapreparaten, kan de kans op beenmerg depressie aanzienlijk verhogen. 
(Dit proefschrift) 
8. Het nog steeds gebruiken, anno 1991, van woorden als malaria (mal, slecht; aer, 
lucht) en arteria (aer, lucht; terrere, dragen) getuigt van weinig modem inzicht in 
de ontstaanswijze van malaria of fysiologie van de bloedcirculatie. Reeds Galenus 
(200 n. Chr.) ontzenuwde de mening dat slagaders bij het leven lucht zouden 
bevatten en na de dood leeg zouden zijn! 
9. Men weet eigenlijk slechts zolang men nog weinig weet; hoe meer men weten 
gaat, hoe meer men gaat twijfelen. 
(Goethe) 
10. Bij leucocytose in combinatie met een verhoogde bezinking en een in korte tijd 
ontstane plankharde zwelling in het bovenbeen, dient in de eerste plaats aan 
pyomyositis gedacht te worden. 
(Eigen waarneming) 
11. Wie tevreden is over zijn arbeid, heeft reden tot ontevredenheid over zijn 
tevredenheid 
(Multatuli) 
12. De verspreking "methotractatie", gehoord uit de mond van een reumapatiënt, wekt 
de verkeerde indruk dat methotrexaat het "snoepje van de week" zou zijn. 



